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ABSTRACT 
Biosystematic Studies of the genus DgtW,, _ in North-west 
Europe. 
M. D. Atkinson 
Usi. ng canonical discriminant analysis, a discriminant 
function was derived which enabled 97.1% of trees to be 
correctly classified as eithera, pPndpJp or By pybggg&p§, 
the criterion used against which to test the classification 
being chromosome number. This function used three leaf 
measurements: leaf apical segment width, leaf tooth factor 
and distance to the first tooth on the'leaf base. Another 
discriminant function was developed which, using nine leaf 
measurements, allowed 98.1% correct classification. 
Stomatal guard cell length was found to be very useful as a 
supplementary character in distinguishing between the 
diploid (f,. L)andplg) and the tetraploid Q. 
A pair of discriminant functions was derived which 
could be used to distinguish interspecific hybrids from 
both f,, pgpdyln and Pý, ppýgpýpý. The overall correct 
classification by these functions was 94.7%. Hybrids were 
shown to be morphologically more similar to ]},, ppbg§. qgDp 
than to B. pgpd1j1D but on stomatal guard cell length, they 
were closer to 5,, pgpdplg. 
Comparative studies were made of mixed and single 
species birch populations from Great Britain and Europe. 
Each population was scored for nine leaf characters and, 
together with data from two reference populations chosen as 
a result of their single species status, were subjected to 
principal components analysis and cluster analysis. By 
this means (i) A group of plants equivalent to D. ppbg§ggng 
subsp. 1g, CDugga could be distinguished; these were 
morphologically similar to certain hybrids between f, 
, ppbsppgn§ and f,, pppg. 
(ii) A large-leaved variant of ýs 
pgpaplp could be distinguished which was similar to fl 
ppngvJB var. I_appg1)15a Lindq. 
A preliminary study of isoenzymes was made at the 
species level. Extracts were made from leaves, pollen and 
wood cambium. These were run on polyacrylamide tube gels 
and vertical slab gels and were stained for a-na, phthyl 
esterase, peroxidase and malate dehydrogenase. Cambial 
peroxidases showed population specific rather than species 
specific, banding patterns. It was suggested that this may 
be linked to their involvement in 1ignification and 
regulation of plant growth substances. Pollen esterases 
and peroxidases showed consi, deraable variation between 
individual trees but no population or species specificity. 
Malate dehydrogenase extracted from leaves showed a species 
specific differentiation with @, 1? g13OUJg having a greater 
activity and number of bands than J3, ß Leaf 
peroxidases showed a similar differentiation in some 
populations but this pattern was obscured in other 
populations by physiological effects. 
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DEVELOPMENT OF POTENTIAL ANTITUMOUR AGENTS BASED 
ON A CONSIDERATION OF THE MODE OF ACTION AND 
PHARMACORINETICS OF DAUNOMYCIN AND ADRIAMYCIN. 
Bijukumar Mohanlal GANDECHA. 
ABSTRACT 
Cancer is a major cause of death in Western countries. 
Although chemotherapy is widely used in the treatment 
of cancer, complete cure for the majority of tumours 
has not been achieved. The anthracyclines daunorubicin 
(Daunomycin) and doxorubicin (Adriamycin) have played a 
significant role in the treatment of cancer. 
Doxorubicin has a broad spectrum of antitumour 
activity; however its use is limited by its cumulative 
cardiotoxicity. One of the modes of antitumour action 
of doxorubicin and other anthracyclines, is 
intercalation (insertion) of the anthraquinone 
chromophore between successive base-pairs of DNA 
thereby inhibiting nucleic acid synthesis. 
Three series of anthraquinones were prepared. The first 
and the second series consisted of 1-; 1,5-; 1,8-; and 
1,4-; 2'-(diethylamino)ethylamino and 2'-(hydroxy- 
ethylamino)ethylamino-substituted anthraquinones 
respectively. The third series consisted of 
azoanthraquinones and their possible aminoanthraquinone 
metabolites. All compounds prepared were examined for 
their DNA binding properties. The methods included 
effect of DNA on spectral properties of drug, 
spectrophotometric titration, stopped-flow kinetics, 
competitive fluorescence polarisation, the effect of 
drug on thermal denaturation of DNA, and on the 
unwinding of cccDNA. It was shown conclusively that the 
anthraquinones bind to DNA by intercalation. The data 
obtained from this work were correlated with computer 
graphics modelling studies. The in vitro metabolism of 
azoanthraquinones by rat liver was also examined. 
Furthermore all anthraquinones were tested for their 
antiproliferative activity against HeLa cells, and CCRF 
human leukaemia cells. 
The affinity for DNA, in both series was in the order 
1,5-, > 1,4-, > 1,8-, > 1- substituted anthraquinones. 
The 21-(diethylamino)ethylamino series had greater 
affinity for DNA than the corresponding 
2'-(hydroxyethylamino)ethylamino anthraquinones. It was 
also shown that the azoanthraquinones did not 
intercalate into DNA; but the ' corresponding 
aminoanthraquinones to which they were metabolised by 
rat liver azoreductase did intercalate into DNA. These 
results are of use in the design of new effective 
antitumour agents. 
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1. INTRODUCTION 
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1.1 GENERAL INTRODUCTION. 
Cancer is a leading cause of death in Western 
countries. To date, complete cure for the majority of 
tumours using chemotherapeutic agents has not been 
achieved, despite an international effort. 
Nevertheless, since the late 1940's, many antitumour 
agents have been discovered, mainly by large scale 
empirical screening programmes. An alternative approach 
to discover more effective antitumour agents is to 
study the mechanisms by which the existing drugs act 
and to try and improve their activity by modification 
of the structure, or by selectively targetting the 
drugs to the tumour site. 
This project is one such attempt.. to design 
antitumour agents based on the present understanding of 
the mode of action of doxorubicin (1) and 
daunorubicin (2), (Fig. 1) (Arcamone et al., 1969; 
DiMarco et al., 1969). Doxorubicin and daunorubicin 
are members of the anthracycline group of antibiotics 
and both are potent antileukaemic agents. Doxorubicin 
also shows cytotoxicity against arbroad spectrum of 
solid tumours (Blum and Carter, 119,74; Bonnadonna 
et al., 1975). A major drawback of both these drugs is 
that they are cardiotoxic above a cumulative dose of 
about 550 mgM-2 (Carter, 1975; Wiernik, 1980). - 
* The names doxorubicin and daunorubicin are 
international non-proprietary names; these drugs are 
also known by their trivial names adriamycin and 
daunomycin respectively. 
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2 
3 
H 
41 
HI 
H 13 14 
COCHZR 
OH 
R=OH Doxorubicin (1) 
R=H Daunorubicin (2) 
Figure 1: Doxorubicin (1) and daunorubicin (2). 
L 
One of the modes of antitumour action of 
doxorubicin and other anthracyclines is by 
intercalation (insertion) between successive base-pairs 
of DNA thereby inhibiting the synthesis of DNA and RNA 
(DiMarco, 1975; Brown, ' 1978; Arcamone, 1981). The 
majority of antitumour agents used clinically are 
thought to exert their action by inhibition of 
synthesis of nucleic acids. Conversely, the cardiotoxic 
properties of doxorubicin (and daunorubicin) are 
thought to be mediated by formation of semiquinone free 
radicals, resulting in lipid pe roxida tion and 
disruption of cellular membranes (Bachur et al., 1977; 
Mimnaugh et al., 1979). Doxorubicin is thus a good 
candidate as a lead for the design of antitumour drugs 
based on its mode of action because from our present 
understanding there appears to be at least two distinct 
mechanisms of action, one related to the antitumour 
activity and the other to the cardiotoxic action. 
The anthraquinone moiety of the anthracyclines 
can intercalate into DNA, and therefore several 
aminoalkyl-substituted anthraquinones have been 
synthesised to exploit this property (M(Iller, et al., 
1971; Double and Brown, 1975; Zee-Cheng and Cheng, 
1978; Murdock, et al., 1979). However only a limited 
range of structural variation has been investigated in 
these studies. Furthermore there is a lack of 
systematic -study of the nature of interaction of 
anthraquinones with DNA. 
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In this project 1-; 1,4-; 1,5-; and 1,8- 
aminoalkyl-substituted anthraquinones will be 
synthesised and their binding to DNA, in solution, 
examined. The data obtained from this work will be 
correlated with computer graphics modelling studies 
(performed by S. A. Islam and S. Neidle) of the 
interaction of the, synthesised anthraquinones, with 
DNA. Furthermore prodrugs of these aminoalkyl 
substituted anthraquinones will be prepared in an 
attempt to target these drugs to- the liver. The 
metabolism of these prodrugs will also be examined. 
s 
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1.2 CANCER. 
Cancer is a term which describes a group of 
diseases embracing a multitude of unique conditions 
which are classified according to the tissue affected. 
These conditions are characterised by an uncontrolled 
cell division with invasion of normal non-dividing 
tissue; it can occur in any tissue capable of cell 
division. Cancer may arise in any organ of the body, in 
tissues of ectodermal, mesodermal, or endodermal 
origin. The host mounts a variable immune response to 
this uncontrolled cell division. Each case of cancer is 
thus unique, and the response to drugs and other 
treatment will vary and may be modified due to the 
variability of the health of the patient (Carter and 
Math4,1980). 
Cancers can be classified into two major 
categories; solid tumours and haematological 
malignancies. Solid tumours are ipitially confined to a 
specific tissue or organ site. In time, however 
cancerous cells detatch from the original tumour mass, 
enter the circulatory system and start secondary 
growths, termed metastases. When this occurs the 
disease is said to be in a disseminated state. 
Conversely the haematological malignancies involve both 
blood and lymph systems, and are therefore frequently 
disseminated at the time of initial presentation 
(Carter and Math4,1980). 
Cancer is currently the second most common cause 
of death in the United States (Cairns, 1978). It occurs 
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in all parts of the world and in all races. However 
different cancers develop in differing populations, for 
example Great Britain has the highest incidence of lung 
cancer in the world, whilst Japan has the highest 
incidence of stomach cancer (Doll, 1977a). It is 
notable that in general lowest incidence of most types 
cancer occur in Africa, Nigeria has the lowest 
incidence of oesophagus, lung, colon, and rectal 
cancers. 
There are several probable causes of cancer. In 
general, they are caused by agents external to the 
body, though it is generally difficult to determine the 
exact nature of the agent. This is because there is a 
large variety of carcinogens in the environment. These 
include chemicals, radiation, and viruses. In addition 
there can be a genetic tendency toward cancer, although 
this is rare (Cairns, 1978; Doll, 1977b). 
The malignant tumour cell has one or more 
phenotypic derangements, which may be expressed as 
alterations in cellular membranes, or in levels of 
certain cellular enzymes (e. g. enzymes involved in 
nucleic acid synthesis and metabolism), or in the 
appearance of inappropriate gene products (e. g., the 
synthesis of placental hormones and of foetal antigens 
not normally seen in adult cells). 
The biochemical mechanisms involved in this 
phenotypic derangement of the malignant cell is not yet 
fully understood. It could be genetic mutation induced 
by chemicals or irradiation or both, or expression of 
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abnormal genetic information induced by viral 
"oncogenes", or gain or loss of chromosomal material by 
neoplastic cells, or derepression of oncogenes, such as 
"oncofoetal" genes that are present but normally silent 
in adult cells, or alterations in post-transcriptional 
processing of critical cellular macromolecules (Pratt 
and Ruddon, 1979). 
Until recently, the vast size of the mammalian 
genome effectively prevented any direct search for the 
cellular genes involved in cancer. The genes were 
discovered, however, because they confer 
tumourigenicity when they are picked up by certain 
retroviruses (Dulbeco, 1982). The genes have come to be 
called "oncogenes" as if their primary role were to 
cause cancer. However typically they are cellular genes 
("proto-oncogenes"), the function of which is 
sufficiently important for them to have been highly 
conserved through the evolutionary process. It has been 
shown that the certain types of bladder cancer may 
arise due to alteration of the cellular proto-oncogene 
which affects the structure of the oncogene-encoded 
protein (Tabin et al., 1982; Reddy et al., 1982). 
Recently it has been shown that amino acid sequences of 
certain oncogene-encoded proteins are closely related 
to growth factors (Downward et al., 1984; Waterfield 
et al., 1983). The binding of growth factors to their 
specific receptors can induce a number of biochemical 
events including changes in ion movements and in 
intracellular pH, stimulation of tyrosine-specific 
protein kinases and several other changes which can 
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culminate in DNA synthesis and cell proliferation. 
Whatever the cause of cancer the phenotypic 
alteration gives the cancer cell some selective 
advantage for growth over normal cells. The critical 
change in the malignant cell is that it does not 
differentiate normally. The genes coding for 
differentiation appear to be shut off or inadequately 
expressed, while the genes coding for cell 
proliferation are expressed when they should be 
repressed. 
1.3. TREATMENT OF CANCER. 
The aim in treatment of cancer is to eradicate 
or remove all neoplastic cells whilst causing minimal 
effect to the host. This is essential because the 
immune response to cancer cells is weak, so that even 
if only a few cells survive, these will divide to form 
a new tumour. There are four possible forms of 
treatment namely surgery, radiotherapy, chemotherapy, 
and immunotherapy (Cohen et al., 1971). Surgery is the 
most frequently used method of treatment for solid 
tumours. Radiotherapy is also used for treatment of 
solid tumours either in combination with surgery or 
with cytotoxic agents. Chemotherapy can be used against 
all forms of cancer and is defined as the utilisation 
of cytotoxic drugs to treat cancer (Carter and Mathe, 
1980); this defination also includes hormonal additive 
therapy. Immunotherapy, or stimulation of immune 
response with e. g. Corynebactrium parvum, or treatment 
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involving the use of antibodies to tumour cells, is 
useful in treating both localised and, in combination 
with other therapy, disseminated disease; but in terms 
of practical results it is still in its early phase of 
development, (Gutterman, 1978; Morton and Goodnight, 
1978; and Carter and Mathe, 1980). 
1.3.1.. Factors which determine the response of tumour 
cells to anticancer drugs. 
1.3.1.1 Growth Fraction and Mass Doubling Time. 
Malignant tumours arise from the induction of a 
mutagenic change in a cell, resulting in daughter cells 
which unlike normal adult tissues are not subject to 
growth regulation. Once a cell is thus transformed, it 
may continue to divide unabated, limited only by the 
availability of nutrients, and by the host's ability to 
mount an immunological response. The time taken for the 
initial transformed cell to produce a clinically 
detectable tumour may be months or years, depending 
upon the type of cancer (Weisberger, 1973). Some human 
tumours grow more rapidly than others. The 
mass-doubling time of Burkitt's lymphoma, is about one 
day whilst that of a typical breast cancer is about 100 
days, (Zubrod, 1972). 
This tumour mass doubling time is determined by 
the proportion of the dividing cells, called the 
"growth fraction". Thus a tumour with a high growth 
fraction will have a shorter doubling time. Dividing 
cells are more sensitive to cytotoxic agents and 
therefore tumours with a high growth fraction are more 
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responsive to drug treatment. Normal tissues with a 
high growth fraction, for example bone marrow, are 
similarly susceptable to damage by cancer 
chemotherapeutic agents (Steel, 1973). Thus during 
treatment with anticancer drugs, bone marrow cells will 
be damaged by those drug levels which are necessary to 
kill cancer cells. Due to the type of cells that arise 
from the marrow, (eg. granulocytes, platelets), 
mylesuppression and leucopenia are two of the limiting 
complications of cancer chemotherapy. 
1.3.1.2. Total Tumour Burden. 
Tumour size is another factor which limits 
succesful chemotherapy in malignant diseases; large 
bulky tumours are not usually curable by chemotherapy. 
A high percentage 'of cells in a bulky tumour may be in 
a non-proliferative stage at the time of treatment and 
thus survive to re-establish the tumour mass. Drugs may 
not be able to penetrate into a solid tumour in 
sufficient concentration to effect a cell kill, due to 
poor vascularisation of tumour mass (Pratt and Ruddon, 
1979). The killing of tumour cells by drugs appears to 
follow first-order kinetics, hence a given drug regimen 
will eliminate a constant proportion of cells rather 
than a constant number of cells. 
1.3.1.3. The Cell Cycle. 
To understand the observation that only certain 
cells in a tumour are susceptible to drugs, and also 
the mode of action of cytotoxic drugs, the phases of 
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Gl : Begning of duplication of all the cell organelles, 
preparation for the replication of DNA within the 
nucleus. 
S: Synthesis or replication of cellular DNA. 
G2- : Preparation for mitosis, end of duplication of the 
cell organelles. 
M: Mitosis. 
G0 : "Resting" phase containing temporarly dormant 
cells. 
Figure 2: The cell cycle. 
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the cell cycle must be considered. It is generally 
considered that all proliferating cells which are 
synthesising DNA progress cyclically through a series 
of phases known as the cell cycle, as shown in figure 
2, (Carter and Mathd, 1980). 
The cell cycle is divided into a G1 or 
intermitotic phase, an S or DNA synthesis phase, a G2 
or premitotic phase and an M or mitotic phase (Carter 
and Math4,1980). In all normal differentiated adult 
tissues and in most tumours, there is a population of 
viable cells that is not proliferating. These cells are 
sometimes said to be in the G0 phase. If the majority 
of the tumour cells are in G0 phase then these cells 
are less readily killed by cytotoxic agents and thus 
the tumour will not readily respond to chemotherapeutic 
agents. In the S phase, nucleic acid synthesis is 
taking place. This nucleic acid synthesis is inhibited 
by several drugs used in the treatment of cancer, 
including purine and pyrimidine antimetabolites, 
methotrexate, alkylating agents and drugs which bind to 
DNA such as doxorubicin. In the M, or mitotic phase the 
cells divide, and antitumour agents which are effective 
in this phase include vincristine and vinblastine. 
1.3.1.4. Drug Resistance In Tumour Cell Populations. 
A drug that initially is capable of killing 
cancer cells later becomes ineffective due to altered 
metabolic properties of the surviving cancer cells. 
Drug-resistant cells in a tumour cell population may 
re-establish the tumour mass after drug-sensitive cells 
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have been killed. Thus subsequent therapy with the 
initially effective drug may fail. Therefore it is 
common practice to use more than one chemotherapeutic 
agent, each having a different mode of action to reduce 
the problem of drug resistance. 
1.3.1.5. General Condition Of The Patient. 
A number of factors which determine the 
chemotherapeutic response are intrinsic to the host 
rather than the tumour cell. One important factor to 
consider is the general status of the patient and his/ 
her ability to tolerate the cytotoxic effects of the 
drugs. Cancer chemotherapy is only worthwhile if the 
treatment will prolong the life of, or reduce the pain 
in a cancer sufferer. 
All currently used cancer chemotherapeutic 
agents have side effects that must be considered when 
planning the treatment regimen. During drug treatment, 
the patient may become nauseated and with some drugs 
vomiting is common. With an aggressive, highly toxic 
regimen, the patient's mouth may become ulcerated, or 
alopecia, or infections may occur and tendency to bleed 
may develop. Although many side effects may be 
minimised with carefully conducted drug regimens, toxic 
effects like these clearly impose limitations on the 
use of some drugs, particularly in debilitated patients 
who tend to have a lower response rate and who tolerate 
such drugs poorly (Kennealey and Mitchell, 1977; Carter 
and Maths, 1980; and Pratt and Ruddon, 1980). 
- 17 - 
In order to understand why a particular 
chemotherapeutic regimen is used in the clinic it is 
essential to appreciate the modes of action of these 
drugs. 
1.4. THE STRUCTURE OF DNA. 
This project is concerned with development of 
potential antitumour agents. Most of the currently 
available chemotherapeutic agents inhibit replication 
of the genetic material. Before discussing the 
mechanisms involved in the inhibition, it is necessary 
to review the composition and the structure of DNA. 
1.4.1. Chemical composition of DNA. 
DNA contains two types of heterocyclic bases, 
those containing a purine ring system and those 
containing a pyrimidine ring system. The purine bases 
in DNA are adenine and guanine and the pyrimidine bases 
are thymine and cytosine (Adams et al., 1976), although 
other bases may be found in small amounts, eg. 
N-methyladenine. The ratio of adenine to cytosine (and 
hence thymine to guanine) is dependent on the source of 
DNA but for most DNA the ratio of adenine to thymine 
and guanine to cytosine equals unity (Chargraff, 1950). 
The bases are attached to the 1'-carbon atom of 
D-2-deoxyribose, (in the case of DNA), through an 
N-glycosidic bond. A purine or pyrimidine base attached 
to a sugar (ribose or deoxyribose) is termed a 
nucleoside, the addition of a phosphate group to the 
nucleoside results in a nucleotide. The construction of 
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all nucleic acids is based on the nucleotide. 
The primary structure of DNA consists of the 
sugar units of DNA linked through the 3'-phosphate 
group of one pentose and the 5'-hydroxyl group of a 
second molecule by a phosphodiester bond, producing a 
sugar phosphate chain. 
1.4.2. Secondary and tertiary structure of DNA. 
The currently accepted structure of DNA was 
postulated by Watson and Crick (1953) using data from 
the X-ray diffraction studies of Wilkins et al. (1953). 
It was suggested that DNA is in the form of a 
right-handed double-stranded helix consisting of two 
antiparallel chains, the nucleotide linkage on one 
chain being 3'-5'; whilst the other chain is 5'-3'. The 
adenine residues of one strand are hydrogen bonded with 
thymine residues of the other strand and similarly 
guanine residues are hydrogen bonded to cytosine 
residues (figure 3). This base pairing is now generally 
accepted (Adams et al., 1976) since AT and GC base 
pairs are of equal dimensions and therefore allow 
uniform spacing between the two sugar-phosphate 
backbones of the double helix. The purine and 
pyrimidine bases are orientated towards the centre of 
the helix and are stacked on top of each other; their 
planes being perpendicular to the helix axis. It is 
this stacking which stabilises the DNA helix. 
The exterior of DNA is polyanionic due to the 
presence of outwardly directed phosphate residues, and 
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Figure 3: Hydrogen bonding of base pairs. 
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the interior is hydrophobic due to the arrangement of 
bases. The major and minor grooves run down the outside 
of the helix and afford access to the bases. This 
Watson-Crick model of DNA has gained wide acceptance 
except for minor corrections in the postulated bond 
angles. 
There have however been proposals for 
alternative structures for DNA in the recent years 
(Rodley et al., 1976; Sasisekharen et al., 1977; Pohl 
and Roberts, 1978). The most important of these 
proposed alternative structures for DNA, is the 
side-by-side (SBS) model, of Rodley et al. (1976). This 
model maintains the Watson-Crick base pairing and the 
antiparallel nature of the two chains but disputes the 
gross intertwining of the sugar-phosphate backbone. The 
right and left-handed segments of DNA are proposed to 
alternate, and bends in the sugar-phosphate backbone 
structure are proposed at every five base pairs. This 
model is consistent with X-ray diffraction-patterns of 
DNA and also explains other properties of DNA such as 
the separation of the strands during replication. 
However the existence of the side-by-side model is 
extremely doubtful (Arnott, 1979) since studies using 
gel electrophoresis and supercoiled DNA provide 
evidence which strongly support the Watson-Crick model 
for DNA (Wang and Bauer, 1979; Crick et al., 1979). 
1.4.3. Conformation of DNA. 
Early studies on DNA showed that DNA can adopt 
three conformations, namely At B, and C, which are 
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Figure 4: Schematic representation of the Watson-Crick 
model of DNA. 
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dependent on the ionic strength of the solution 
(Arnott, 1970). The "native" form of DNA is the 
B-conformation which is that proposed by Watson and 
Crick. Figure 4 shows a schematic representation of the 
Watson-Crick model of DNA. 
The B structure of DNA (Watson-Crick model) is 
characterised by an overall helix diameter of 20A with 
base pairs stacked perpendicular to the helix axis and 
slightly twisted relative to one another. The bases 
overlap with the distance from the helix axis being 
0.6311 and are held together by hydrogen bonding 
(Watson and Crick, 1953). The helix is right-handed 
with ten bases per turn and a rise per base pair of 
3.4A. Two grooves of unequal width run around the 
outside of the helix, the larger is 22A in diameter and 
is termed the major groove whilst the minor groove is 
12A in width. They are both 7Ä in depth measured from 
the surface of the enveloping cylinder. The 
conformation of the deoxyribose is C2-endo (Arnott, 
1970). 
The A structure of DNA is found in fibres of 
lower relative humidity (75% compared to 92% for the B 
form) when the counterion for DNA is sodium, potassium 
or caesium. The structure is also in the form of a 
right handed helix, but differs from the B structure in 
that there are 11 base pairs per turn and a rise per 
base pair of 2.81. The bases are also tilted by 20°. 
The C form of DNA is found in fibres of lithium DNA at 
66% relative humidity. The basic structure is similar 
to the B form, but has 9.3 base pairs per turn and a 
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rise per base pair of 3.11. The bases are tilted by 611 
(Adams et al., 1976). 
Previous work on the elucidation of DNA 
structure were based on fibre diffraction studies. 
However following the syntheses of double stranded 
oligonucleotides, X-ray crystallography was used to 
define the structure. The B and A models were shown to 
be averaged structures and also novel DNA structures 
were found, the most significant being the Z form. This 
Z-DNA structure was proposed following studies on the 
3-dimensional structure of crystalline d(C-G)3 
fragments (Wang et al., 1979; Davies and Zimmerman, 
1980; Arnott et al., . 1980). Two of the d(C-G)3 
molecules are combined to form a left-handed double 
helical segment with Watson-Crick base pairing. The 
model maintained the anti-parallel strands but had 
twelve base pairs per turn (compared to ten in the case 
of Watson-Crick model). The base pairs were tilted by 
70 from the helix axis making a distance of 3.7A 
between the base pairs along the axis, although they 
were stacked 3.4A apart. In this model, the cytosine 
bases were in the anti-conformation, as in Watson-Crick 
model, while the guanine bases were in the 
syn-conformation. The puckering of the 2-deoxyribose 
rings also differed, being C3-endo for the two internal 
deoxycytidines. The conformation of the backbone about 
the C4-C5 bond was gauche-trans for the dG residues and 
gauche-gauche for the dC residues. The net result of 
these differences was to produce a staggered zig-zag 
course for the deoxyribose phosphate backbone and hence 
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the term "Z-DNA". In this 
groove all the way along 
groove had a serrated edge 
are 8.5A apart between 
itself is 9A deep since it 
of the 18. E diameter helix. 
case there was only one 
the axis of the molecule. The 
of phosphate groups which 
the two edges and the groove 
extends to the central axis 
Similar structures have been proposed for 
poly(dG-dT) . poly(dA-dC) and poly(dG-dC) . poly(dG-dC) 
(Arnott et al., 1980). The Z-form can exist in 
physiological salt solutions when poly (dC-dG) is fully 
methylated at the cytosine 5 position (Behe and 
Felsenfeld, 1981). It can also coexist with B-DNA at 
low salt concentrations in closed circular plasmid 
DNA's (Peck et al., 1982). The demonstration that 
right- and left-handed segments can coexist in a single 
DNA chain may have profound implications for the role 
of DNA in regulatory processes. For example, Z-DNA 
maintained within a principally right-handed molecule, 
could be a store of negative windings. In appropriate 
conditions these could be used to compensate positive 
windings and produce a region of melted DNA available 
for polynucleotide synthesis. The left-handed segments 
could also be used to titrate out the negative 
supercoils. 
Having'first considered the structure of DNA, it 
is now necessary to examine the mechanisms by which 
currently available chemotherapeutic agents exert their 
effect in order to identify where rational design of 
antineoplastic drugs may be possible. 
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1.5. DRUGS USED IN THE TREATMENT OF CANCER. 
Several classes of drugs have been introduced 
for the treatment of cancer during the past thirty 
years. The majority of these drugs depend for tumour 
cell selectivity on the fact that the tumour cells 
utilise amino acids, purine and pyrimidine bases and an 
energy source to a greater extent than normal cells. 
Cancer chemotherapeutic agents may be divided 
into seven major classes, namely alkylating agents 
(Section 1.5.1), antimetabolites (Section 1.5.2), 
enzymes (Section 1.5.3), hormones (-Section 1.5.4), 
mitotic inhibitors (Section 1.5.5), radio-sensitising 
agents (Section 1.5.6) and drugs which interact with 
DNA (Section 1.5.7, and 1.6). This classification is 
based upon our present understanding of the mode of 
acion of these drugs, (Bender et al., 1978; Chabner 
et al., 1975; Pratt and Ruddon, 1979). Figure 5 shows 
schematically the biochemical sites of action of the 
most common antitumour agents. 
1.5.1. Alkylating agents. 
Alkylating agents contain a substituted alkyl 
group which is capable of covalent reaction with 
cellular constituents (Price, 1975). The alkylating 
agents have a complex action: they alkylate DNA and 
various enzymes which are essential for cell division. 
Alkylating agents may cause cross linking of two 
strands of the DNA double helix, hence preventing 
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Figure 5: Some biochemical sites where antitumour 
agents have been shown to interfere with 
nucleic acid synthesis and function. 
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replication. 
Five major classes of alkylating agents are used 
in cancer chemotherapy: these are nitrogen mustards, 
nitrosoureas, triazenes, methane sulphonic acid esters, 
and ethylenimines (Pratt and Ruddon, 1979; Connors, 
1975; Wilman and Connors 1983). The most commonly used 
alkylating agents include cyclophosphamide, melphalan, 
chlorambucil, dacarbazine (DTIC), busulphan and 
thiotepa. 
1.5.2. The antimetabolites. 
These agents substitute for normal metabolites 
in various biochemical pathways and their cytotoxicity 
is therefore greatly influenced by the level of natural 
metabolites with which they compete. 
The clinically 
antagonists of either 
methotrexate), or 
6-me rcaptopurine), or 
5-fluorouracil). 
important antimetabolites are 
folic acid (for example 
purines (for example 
pyrimidines (for example 
1.5.3. Enzymes. 
The only example in this group is L-asparaginase 
which causes depletion of endogenous plasma asparagine. 
This amino acid is non-essential for normal cells, but 
some malignant cells are unable to synthesise 
asparagine and require an exogenous source for protein 
synthesis (Horwitz et al., 1968). 
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1.5.4. Hormones. 
Those hormones used in cancer chemotherapy 
include oestrogens, progestogens, and androgens. 
Synthetic antioestrogenic compounds and glucocorticoids 
are also used. 
Cancers which originate in organs normally 
sensitive to the suppressant action or maturing effects 
of hormones may be inhibited by hormonal treatment. 
Oestrogens are extensively employed in the treatment of 
prostate carcinoma, whilst antioestrogenic drugs are 
used for the treatment of breast cancer, (Carter and 
Maths, 1980). 
1.5.5. Mitotic spindle inhibitors. 
The two most clinically important drugs in this 
group are vincristine and vinblastine. They are mainly 
used in the treatment of the leukaemias in combination 
with drugs which inhibit DNA replication for example, 
alkylating agents, intercalating agents, and 
antimetabolites. The mitotic inhibitors act by 
interfering with the function of microtubules during 
mitosis. The clinical use of vincristine and 
vinblastine is limited by their neurotoxic side 
effects, (Weiss et al., 1974). 
1.5.6 Radiosensitizing agents. 
Ionising radiation has been extensively utilised 
in the treatment of cancer. The radiosensitivity of 
cells depends in part on the local concentration of 
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oxygen present at the time of irradiation. However, 
within a solid tumour mass a large number of tumour 
cells are hypoxic and thus not sensitive to 
radiotherapy. In an attempt to mimic the free radical 
forming ability of oxygen a number of nitrohetrocyclic 
compounds have been developed. 
1.5.7. Drugs which interact with DNA. 
A number of antitumour, antibacterial, and 
antiparasitic drugs inhibit nucleic acid synthesis; 
furthermore mutagens and carcinogens also exert their 
toxic effects in this manner. There are three levels at 
which nucleic acid inhibitors may exert their effects 
(Waring, 1981). Firstly they may inhibit nucleotide 
synthesis, (eg. the antimetabolites); secondly they may 
inhibit the polymerisation of nucleic acids by imparing 
the capacity of DNA to function as a template (eg. drugs 
which reversibly (or irreversibly) react with DNA). 
Thirdly they may inhibit polymerase or other enzymatic 
processes involved in the replication of DNA. Drugs 
which inhibit polymerisation of nucleic acids interact 
with DNA either irreversibly or reversibly. Replication 
of DNA may thus be inhibited by these interactions. 
Drugs which bind irreversibly with DNA cause 
structural alterations within the DNA molecule, such as 
strand scission or removal of bases, or may crosslink 
the DNA strands. The alkylating agents may be 
classified in this group since bifunctional alkylating 
agents can covalently bind to DNA. Mitomycin C also 
crosslinks the two complementary strands of DNA 
molecule; it is first reduced to the semiquinone form 
which then inserts into and becomes covalently attached 
to DNA (Lin et al., 1976): 
Bleomycin has been extensively used in the 
treatment of neoplastic diseases. The interaction of 
bleomycin involves the formation of three strong 
hydrogen bonds between the drug molecule and DNA, 
insertion of bithiazole rings between the nucleic acid 
base pairs together with electrostatic binding (Povirk 
et al., 1979). 
Drugs may interact reversibly with DNA either by 
binding to the exterior of the helix or by 
intercalation (drug insertion between successive base 
pairs) into the DNA molecule. 
Netropsin and' distamycin are antibiotics which 
have been shown to bind to DNA by reinforced 
electrostatic binding to the exterior of the helix. 
They bind to the minor groove of the B-form of DNA 
(Waring, 1981) and show A-T binding specificity. 
Distamycin has been shown to have antineoplastic 
activity in animals. The aromatic diamidines, berenil, 
and hydroxystilbamidine interact with DNA by a similar 
mechanism to that of distamycin. 
The antibiotics chromomycin, mithramycin and 
olivomycin have been shown to bind externally to the 
DNA helix. The interaction of chromomycin with DNA is 
mediated by an antibiotic-Mg 
2+ 
complex (Waring, 1981). 
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The most characteristic feature of the binding of these 
antibiotics to DNA is the requirement of a 
stoichiometrically equivalent amount of Mg2+ (Ward 
et al., 1965). Chromomycin appears to interact 
specifically with guanine residues of helical DNA. 
In this work, compounds will be synthesised 
based on the mode of action of doxorubicin. One of the 
modes of antitumour activity of doxorubicin is by 
intercalation (see later) it is therefore necessary to 
examine the mechanisms underlying intercalation, and 
also the structural requirements for intercalating 
agents. 
1.6. INTERCALATION. 
The second. mechanism by which drugs interact 
reversibly with DNA is by intercalation of the drug 
molecule between adjacent base pairs of DNA. Several 
anticancer drugs act by intercalation into DNA. These 
agents are uniquely suited for studies concerned with 
molecular basis of drug action since the precise 
structure and conformation of the receptor is well 
documented. Thus drugs which bind to DNA provide a good 
opportunity to examine in detail the nature of 
drug-receptor interactions. The advkntage of designing 
drugs which interfere directly with DNA structure is 
that the binding to DNA can be quantified and the 
structural requirements for drug binding to DNA are 
known, thus allowing a considerable scope for 
structural variation. 
Drug which interfere with the template role of 
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DNA either by causing structural changes such as strand 
scission (eg. bleomycin), removal of bases, or 
formation of covalent cross-links (eg. mitomycin) or by 
reacting with it to form a reversible DNA/drug complex. 
This reversible complex may be formed either by the 
drug binding to the exterior of the helix (for example, 
distamycin) or by a process termed intercalation, in 
which the drug molecule is inserted into the helix 
between succesive base pairs. Intercalation will be 
considered here since the structural requirements for 
this DNA/drug interaction can be readily identified. 
Proflavine (3) and ethidium bromide (4) (figure 6) are 
classic examples of intercalating compounds, and 
therefore the mode of interaction of these compounds 
will be considered first. 
1.6.1. Lerman model for Intercalation. 
The first detailed description of the model for 
drug intercalation into DNA was proposed by Lerman 
(1961). This model was based on the X-ray diffraction 
patterns of proflavine (3)-DNA complexes, and on the 
observation that there was an increase in viscosity 
with an associated decrease in sedimentation coeff- 
icient of DNA/drug complex. The hydrodynamic changes 
were attributed to a lengthening of DNA molecules 
caused by proflavine (3) binding, such that thay 
behaved as stiffer, more slender rods with a diminished 
mass per unit length. X-ray diffraction patterns of the 
DNA-proflavine (3) complex revealed the loss of 
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long-range regularity of the helical structure but 
retention of 3.4A meridional reflections due to regular 
stacking of base pairs perpendicular to the helix axis. 
Lerman (1961) proposed that the planar aromatic 
proflavine (3) molecule becomes inserted between 
adjacent base pairs of the double helix of DNA (Figure 
7). The base pairs remain perpendicular to the helix 
axis, but they are moved apart, by 3.4A, to accomodate 
the acridine molecule which lies in van der Waals 
contact between the base pairs. The intimate contact 
between the it -orbitals of the drug molecule and the 
base pairs would help to stabilize the complex via 
hydrophobic and charge-transfer forces. Local 
distortion of the helix occurs since it has to unwind 
in order to accomodate the drug molecule. Distortion of 
the helix due to local unwinding at intercalation sites 
would destroy the long-range regularity of the helix, 
as observed by X-ray diffraction studies. Lerman (1961) 
proposed an unwinding of angle 450 in his original 
model which he subsequently revised to 36°, (Lerman, 
1964a). 
Based on the results of studies with 
ethidium/DNA mixtures (4) Fuller and Waring (1964) 
further refined the intercalation model. This amended 
model was similar to that proposed by Lerman; but in 
addition suggested the formation of hydrogen bonds 
between the amino groups of the drug molecule and 
charged oxygen atoms of the phosphate groups of the DNA 
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backbone. They suggested an unwinding angle of 12°, the 
minimum necessary to permit, intercalation of an 
aromatic ring system and the preferred angle since this 
would preserve maximal separation of the negatively 
charged phosphate groups. However,, the, currently 
accepted value for unwinding angle is 26°, (Wang, 1974, 
Waring, 1981). The model could readily accomodate 
proflavine (3), since the aromatic, ring systems and the 
intramolecular distance between the amino groups of 
both proflavine (3) and ethidium (4) are very similar 
(Jones and Neidle, 1975). The phenyl and ethyl groups 
of these intercalating agents are thought to project 
into the minor groove of the DNA helix. 
Further evidence has been obtained supporting 
the validity of the Lerman, Fuller-Waring model for 
intercalation. This further evidence came from 
fluorescence and dichroism studies (Lerman, 1963), 
X-ray diffraction studies (Neville and Davies, 1966; 
Luzati et al., 1961), auto-radiography (Cairns, 1972), 
amino group reactivity (Lerman, 1964b), electron 
microscopy (Freifeilder, 1971), and studies on the 
thermal denaturation of the DNA helix (Le Pecq and 
Paoletti, 1967). 
In addition to intercalation, at relatively high 
drug concentrations, there is a weaker secondary 
binding which is a "stacking" process in which drug 
molecules bind to the exterior of the DNA helix and 
stack upon each other (Stone and Bradley, 1961; Blake 
and Peacock, 1968). This stacking is due to 
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electrostatic interaction of the positive centre of 
drug with negatively charged phosphate groups. However, 
this interaction is unlikely to be of significant 
importance in vivo, where relatively low drug 
concentrations are found. The intercalation process 
leads to the binding of one drug molecule per 2 to 2.5 
nucleotide base pairs (Waring, 1981). The secondary 
external binding proceeds until one basic drug molecule 
is bound for every anionic phosphate group. 
The factors which limit the intercalation to a 
maximal binding of one drug molecule per 2-2.5 base 
pairs is not fully explained by the Lerman model for 
intercalation. However the site excluded (or neighbour 
exclusion) model is now generally accepted. The model 
was first proposed by Cairns (1962) and assumes that 
drug molecules may intercalate anywhere along the 
length of DNA, subject only to the restriction that 
intercalation may not occur at adjacent base pairs. 
This restriction does not apparently result from any 
steric interference between bound drug molecules 
(Fuller and Waring, 1964), although it is possible that 
electronic interactions between the drug molecule and 
the base pairs in some way affects the charge 
distribution on base pairs rendering them less capable 
for interaction with drug molecule. Cairns (1962) 
showed, by theoretical calculations, that the maximum 
number of drug molecules which may occupy a potential 
binding site was 0.436 or one drug molecule per 2.3 
base pairs; in agreement with the experimental values. 
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" The use of synthetic self-complementary 
nucleotides such as dCpG has enabled, subsequent workers 
to support and clarify the concept of intercalation. In 
addition to ethidium and proflavine, other DNA binding 
drugs such as daunorubicin have been shown to form 
intercalation complexes with dinucleotides (and 
tetranucleotides) in solution (Patel 1979,1980). 
Detailed information of the nature of interaction was 
obtained by the use of high resolution NMR studies, and 
X-ray crystallography of the crystalline DNA/drug 
complexes (Sobell et al., 1978; Patel, 1980; Neidle, 
1980). Based on these studies, a detailed model has 
been proposed to explain the interaction of ethidium 
with DNA (Sobell et al., 1978). This model suggested an 
unwinding angle of -26° (the currently accepted value) 
at the immediate site of drug intercalation, producing 
an effective angular unwinding of the helix by about 
-10°. This model also assumed that DNA "kinks" in order 
to accomodate- ethidium molecules. DNA was proposed to 
bend towards the major, groove, since the negatively 
charged phosphate groups do not approach each other 
significantly even after bending the DNA helix by up to 
30°. In the kinked DNA structure, the base pairs are 
partially unstacked and the helical axis for the B-DNA 
sections above and below the kink are displaced by 
about -1.0L. It is suggested that ethidium intercalates 
into the minor groove- of this kinked DNA (Sobell 
et al., 1977). Three types of intercalation are 
possible; firstly, a drug (for example, ethidium) may 
intercalate exclusively from the minor groove of DNA, 
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binding first to the kink in 
intercalating into the interior of 
a drug (for example, daunorubicin) 
the major groove or thirdly, the 
9-aminoacridines) may enter fro 
the minor groove. 
DNA and then later 
the helix; secondly, 
may intercalate from 
drug (for example, 
m either the major or 
An important feature of this model is its 
requirement for strictly alternating C3'endo- 
-(3', 5')-C2'-endo sugar puckering. -All the sugars in 
the Watson-Crick B-DNA model are puckered C2' endo, 
this necessitates a change of pucker , 
in one deoxyribose 
ring of each strand at. the intercalation site and 
therefore automatically imposes a condition of 
neighbour exclusion. However this may not be the only 
explanation for neighbour exclusion (Neidle, 1980) 
since alternating patterns of, sugar puckering are not 
invariably seen with drug-dinucleotide complexes. 
The classical intercalation models of Lerman 
(1961) and Fuller-Waring (1964) have been criticised in 
the literature. Both acridines and ethidium bind 
equally well at room temperature to heat-denatured DNA 
as well as to native DNA. A modified intercalation 
model has been proposed, based on this finding (Blake 
and Peacocke, 1968; Pritchard et al., 1966). In this 
model the positioning of the intercalated ring system 
with respect to DNA bases is shifted to lie between two 
adjacent bases on the same polynucleotide chain with 
the positively charged nitrogen in close proximity to 
the phosphate group. This type of model allows, several 
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a 
different modes of orientation of the aromatic 
chromophore intercalated between the stacked bases or 
base-pairs of DNA. Daunorubicin, is one of several 
compounds known to orientate perpendicular to the DNA 
helical axis (see 1.8.1). 
An intensive effort, has been made in the past 
two decades to synthesise drugs which intercalate into 
DNA. Daunorubicin and doxorubicin are two examples of 
drugs which have been isolated from microbiological 
sources, have proved to be useful as antitumour agents 
and subsequently shown to intercalate into DNA. The 
following section describes some of these intercalating 
compounds. 
1.6.2. Other intercalating compounds. 
1.6.2.1 Monofunctional intercalating agents. 
Substitution of various groups at the C-9 
position of the acridine nucleus results in compounds 
which are still capable of intercalation. For example 
9-aminoacridine (5) (figure 8) binds strongly to DNA by 
intercalation (Dalgleish et al., 1971). The 
anti-malarial drug mepacrine (6) (figure 8) has been 
shown to intercalate into DNA (Ciak and Hahn, 1967) 
with an absolute preference for B-DNA (Plumbridge and 
Brown, 1977). Amsacrine (mAMSA, Figure 8), (7), was 
first reported in 1974 as an 9-anilincacridine 
derivative showing high activity against L1210 
leukaemia (Cain and Atwell, 1974) and has subsequently 
been shown to be active in a number of experimental 
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Figure 8: Structure of the intercalating agents 
9-aminoacridine (5), mepacrine (6), m-AMSA 
(7) and lucanthone (8). 
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tumours (Denny et al., 1983). Amsacrine has recently 
been marketed for treatment of neoplastic diseases. 
AMSA has been shown to preferentially bind to native 
DNA compared to heat denatured DNA or RNA (Wilson 
et al., 1981). 
Lucanthone, (8) (figure 8), and its 
4-hydroxymethyl analogue have been shown to be potent 
schistosomicidal drugs (Hirschberg, 1974). Both 
analogues have been shown to have a planar structure 
(Neidle, 1976) and are therefore able to intercalate 
into DNA. Lucanthone analogues with varying side chains 
have been prepared and a correlation between 
antibacterial activity and DNA binding ability 
established. It was shown that both a 
non-alkyl-substituted proximal nitrogen atom, and a 
correctly positioned terminal nitrogen atom were 
essential for DNA binding activity (Hirschberg et al., 
1968). 
Actinomycin D, (9) (figure 9) has been shown to 
be a potent antitumour antibiotic and contains a planar 
phenoxazine chromophore linked to two identical 
pentapeptides. This antibiotic has been shown to bind 
specifically to G-C base pairs with the requirement for 
the 2-amino group of guanine for interaction. The amino 
and quinoid groups on the chromophore are essential for 
intercalation. From these structural features and X-ray 
diffraction studies, Hamilton et al. (1963) proposed 
that the complex was stabilised by hydrogen bonds from 
the 2-amino group of the guanine base to the quinoidal 
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Figure 10 : Schematic representation of the interaction 
of actinomycin D (9) with DNA. The 
chromophore is represented as a simple 
anthracene ring system in perspective, the 
peptide lactones are shown as rings. 
(adapted from Waring, 1981). 
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oxygen of the actinomycin chromophore, and from the 
2-amino group of the'chromophore to N3 of the base and 
the sugar ring oxygen of deoxyguanosine. This would 
locate the chromophore in the minor groove of' the DNA 
with its plane inclined at an angle of about 200 to the 
base pairs (figure 10). The peptide ring could then 
pack into the minor groove and stabilize the complex 
(Waring, 1968) further via four hydrogen bonds from the 
NH groups of the peptide to the phosphate oxygen atoms 
in the chain complementary to the the one containing 
the deoxyguanosine. 
Ellipticine, (10) (figure 9) is an alkaloid 
which has pronounced antineoplastic activity in 
experimental tumours (Hartwell and Abbott, 1969). The 
compound is planar with approximately the same 
molecular dimensions as proflavine and is protonated in 
mildly acidic conditions. The compound has been shown 
to intercalate into DNA by both spectroscopic methods 
and by its ability to unwind closed circular DNA 
(Neidle, 1979). 
1.6.2.2 Bifunctional intercalating agents. 
' -There are many instances where increasing 
affinity of drugs for DNA improves therapeutic index 
(Neidle 1979). In the past decade attempts have been 
made to capitalise on this by using drugs which 
intercalate simultaneously at more than one base pair 
site. Such compounds, with two or more intercalating 
chromophores, were shown to, have significantly higher 
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DNA-binding affinity than mono-functional intercalating 
agents. From the neighbour exclusion principle (see 
1.6.1) the minimum theoretical distance between the two 
intercalating chromophores to achieve two-site binding 
is about 10.2A. Therefore by appropriate choice of 
intercalating chromophores linked together by a 
"spacer" of an appropriate length it should be possible 
to design compounds which bind preferentially to a 
specific DNA sequence. For example, acridine 
chromophores have been utilised in a number of 
investigations for the synthesis of bifunctional 
intercalating molecules. A series of diacridines were 
synthesised with the spacer group (CH2)n and their 
binding to DNA was investigated (Wakelin, et al., 1976, 
1978; Chen et al., 1978). These studies showed that the 
minimum length of the spacer chain necessary for 
bis-intercalation to occur was 8.8L. Later studies with 
diacridines substituted in the chromophores showed that 
the ability of these compounds to bis-intercalate was 
also dependent on the substitution pattern as well as 
on the nature of the spacer chain (Wright et al., 
1980). 
In addition to the acridines a number of other 
bis-intercalating agents are also known. These include 
derivatives of ethidium such as bis(methidium)spermines 
(Dervan and Becker, 1978), and quinoxaline antibiotics 
such as echinomycin and luzopeptin (Neidle, 1979; 
Waring and Fox, 1983). The nature of interaction of 
these bis-intercalating agents has been extensively 
studied (Waring, 1981; Waring and Fox, 1983). A common 
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feature of, all bisintercalating agents is the 
relatively high affinity constants (109 to 1014 M-1 
compared to 105 to 107 M-1 for monofunctional 
intercalating agents) and large unwinding angles 
(Waring, 1981) (35-55° for bis-intercalating agents 
compared to 8-26° for the monofunctional' intercalating 
agents). 
Recently a triacridine derivative has also been 
described and shown to bind to DNA (Atwell et al., 
1983). The tris-intercalating agent unwinds closed 
circular DNA by angle of 450, which is significantly 
larger than those produced by monofunctional and 
bifunctional intercalating agents. 
It is apparent from the preceding discussion 
that certain minimum structural requirements must be 
satisfied before a drug can intercalate into DNA. These 
requirements consist of a planar, tri or tetracyclic 
ring system, containing a substituent amino group which 
can initially bind electrostatically to`the phosphate 
groups on the DNA. Further stabilisation would be 
afforded by groups, such as hydroxyl groups, which 
could hydrogen bond to other groups in the DNA. 
Anthracycline antibiotics have been widely 
studied in the recent years, since some possess potent 
antitumour activity. Doxorubicin in particular has been 
shown to possess a broad spectrum of activity. However 
all anthracyclines have severe dose-limiting toxicity. 
The principal aim of this project is to design 
potential antitumour agents with at least equivalent 
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cytotoxicity, but without the dose limiting toxicity of 
the anthracyclines. Many of the anthracyclines have 
been shown to intercalate into DNA (Brown, 1978). 
Intercalation is only one of several biochemical 
mechanisms by which the anthracyclines are thought to 
exert their cytotoxic action. It is therefore necessary 
to. review the clinical activity and the biochemical 
mechanisms by which the anthracyclines are thought to 
exert their antitumour action., 
1.7. THE ANTHRACYCLINES. 
1.7.1 Introduction. 
The anthracycline group of antitumour 
antibiotics were isolated from various species of 
Streptomyces; their discovery, isolation and structure 
elucidation have been extensively reviewed (Arcamone, 
1981; Brown, 1978,1983; Remers, 1979). The 
anthracyclines are planar naphthacenediones and usually 
occur as glycosides. Doxorubicin and daunorubicin are 
glycosides of the amino sugar daunosamine, and the 
aglycones adriamycinone and daunomycinone respectively 
(figure 1). 
Following the isolation of these anthracyclines 
in the late 1960's there have been considerable efforts 
made to produce structural analogues of daunorubicin 
and doxorubicin with improved antitumour activity. 
Previous work on the development of anthracyclines has 
been of an empirical nature (reviewed by Brown, 1978). 
The earliest approach has been to search for novel 
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anthracyclines produced by newly isolated 
microorganisms or by strains of anthracycline-producing 
organisms derived by exposure to some form of mutagenic 
treatment. Doxorubicin was isolated as a product of a 
mutant strain of the daunorubicin-producing organism 
(Arcamone, 1981). A second approach has been to 
chemically modify known anthracyclines, or to couple a 
synthesised aglycone to daunosamine or a synthesised 
alternative sugar to a natural aglycone. A final 
approach has been to attempt to mimic the biological 
actions of doxorubicin (and daunorubicin) in 
simplified, totally synthetic analogues. This latter 
approach has been used in this project. Each of these 
approaches has led to the introduction of new analogues 
which have a higher therapeutic index than the parent 
anthracyclines. This work has been extensively 
reviewed, (Brown and Imam, 1984; Brown, 1978,1983; Du 
Vernay, 1981; Di Marco, 1981; Crook et al., 1981; 
Henry, 1979; Arcamone, 1981), and therefore only 
developments which have had a significant impact on the 
understanding of the modes of antitumour action and 
toxicity of anthracyclines will be considered here. It 
is necessary to discuss the clinical activity of 
anthracyclines before considering the mode of action of 
these drugs. 
1.7.2. Clinical activity of anthracyclines. 
The two most prominent anthracyclines used in 
the clinic are doxorubicin and daunorubicin. They are 
important drugs in cancer chemotherapy, despite their 
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inhibitory effects on rapidly dividing tissues. (which 
leads to myelosuppression, alopecia, and stomatitis) 
and their specific toxicity to the heart (Carter, 1980, 
Young et al., 1981). Daunorubicin has been used in the 
induction of remission in acute lymphocytic leukaemia, 
however its use in maintenance of remission is limited 
by the dose-related cardiotoxicity. Doxorubicin in 
contrast is used as a single agent or in combination 
therapy for the treatment of a wide spectrum of solid 
tumours (Wiernik, 1980). It should be noted that there 
is only a small structural difference between 
daunorubicin and doxorubicin. However as a result of 
the replacement of one of the hydrogens at C14 of 
daunorubicin by a hydroxyl group the spectrum of 
antitumour activity of doxorubicin is profoundly 
altered. 
When daunorubicin is used, as a single agent, 
for the treatment of acute nonlymphoblastic leukaemia 
(ANLL) it produces a complete remission in 40-50% of 
patients (Wiernik and Serpik, 1972). It also has 
significant activity against childhood and adult acute 
lymphoblastic -leukaemia (ALL); although it is rarely 
necessary to add this drug to vincristine and 
prednisone induction therapy, however, the drug is of 
use in refractory or relapsed patients (Aur et al., 
1971). Daunorubicin has not been fully evaluated for 
maintenance therapy in acute leukaemia. This is 
primarily due to the fact that induction therapy 
usually requires most of the allowable dose (ie before 
the cumulative cardiotoxic effects become prominent). 
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However by the use- of combination chemotherapy 
employing a relatively low dose of'daunorubicin it is 
possible to employ daunorubicin for reinduction and 
maintainence therapy, (Wiernik, 1980). 
Doxorubicin has the broadest spectrum of 
anticancer activity of any drug in use today (Carter, 
1975; Weirnik, 1980). It is active in haematological 
malignancies, metastatic or inoperable sarcomas, 
hepatoma and a variety of childhood solid tumours 
(O'Brian et al., 1973, Carter, 1982). Following the use 
of doxorubicin in combination with cyclophosphamide, 
methotrexate and 5-fluorouracil for the treatment of 
metastatic breast cancer, a 50% response rate was 
obtained (Kennealy et al., 1978). Doxorubicin has been 
used either alone or in combination with other 
chemotherapeutic agents in the treatment of a variety 
of sarcomas and also the following solid tumours: 
pancreatic cancer, hepatocellular carcinoma, metastatic 
hepatoblastoma, ovarian adenocarcinoma, advanced 
endometrial cancer, metastatic prostate carcinoma, 
metastatic testicular cancer and most forms of 
broncogenic carcinoma (Cortes et al., 1974; Blum and 
Carter, 1974; Horton et al., 1978; Wiernik, 1980). 
Doxorubicin is also useful against metastatic disease 
and as an adjuvant to surgery for the primary treatment 
of some sarcomas (Benjamin et al., 1975). 
The 
, 
anthracyclines represent a significant 
advance in the treatment of ANLL, doxorubicin has the 
broadest spectrum of clinical activity of all known 
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anticancer drugs. However the anthracyclines have 
limiting toxicities in man which prevents exploitation 
of their antitumour activity to the full extent. These 
toxicities are summarised in the following section. 
1.7.3. Toxicity of anthracyclines. 
Both daunorubicin and doxorubicin produce toxic 
effects typical of drugs which inhibit nucleic acid 
synthesis (Bonadonna et al., 1970). All patients 
treated with these agents experience alopecia, 
stomatitis occurs in about 75% of patients. Nausea and 
vomiting are also common side effects (Brown, 1978). 
Unusual pigmentation of nails or tongue may result 
following administration of daunorubicin or doxorubicin 
(Weirnik, 1980). Other side effects of these drugs 
include sublingual haemorrhage, nephrotoxicity and 
severe local necrosis during administration due to 
extravasation at the site of injection (Reilly, et al., 
1977). These drugs are also carcinogenic (Brown, 1978). 
However the most serious dose limiting toxicity 
of these drugs is cardiotoxicity. This can be 
subdivided into types; firstly reversible and transient 
electrocardiographic changes which occur within a few 
hours of administration of the drug (Gilladoga et al., 
1976); secondly an irreversible cardiomyopathy which 
develops one to six months after therapy; which may 
lead to congestive cardiac failure. The incidence of 
this fatal cardiotoxicity increases with a cumulative 
dose in excess of 550mgM 
2 (Blum and Carter, 1974; 
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0 
Young et al., 1981). Although the monitoring of cardiac 
function can reduce the risk of cardiotoxicity, (Minow 
et al., 1977), the ideal solution would be to identify 
and negate the cause of the toxic effect. 
In tho last 15 years an intensive effort has 
been made to differentiate between the biochemical 
mechanisms involved in the cardiotoxic effects and 
antitumour action of anthracyclines. The following 
sections describe these mechanises. 
1.8. MECHANISM OF ACTION OF DOXORUBICIN AND 
DAUNORUBICIN. 
The anthracyclines have many cellular actions 
and these can broadly be divided into three mechanisms; 
namely interaction with DNA, free radical generation 
and interaction with membranes. 
1.8.1. Interaction of anthracyclines with DNA. 
The most recognised property of doxorubicin and 
daunorubicin is their effect on the nucleus; they can 
intercalate into DNA (Arcamone, 1981; Brown, 1978, 
1983; Neidle and Sanderson, 1983; Patel et al., 1981; 
Plumbridge and Brown, 1977; Quigley et al., 1980), and 
cause sister chromatid exchange and chromosome 
aberrations (Nersted, 1978). The DNA shows protein 
associated single strand and double strand breaks 
possibly due to binding of topoisomerase which 
ineffectually attempts to relieve the strain in the 
helix induced by intercalative binding of the drug 
(Ross et al., 1978; Ross and Smith, 1982). For both 
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drugs the maximum binding that can occur is about two 
drug molecules per five base pairs (Phillips et al., 
1978). On saturation of the intercalation sites, 
further drug molecules can bind to the exterior of the 
helix, presumably by electrostatic interaction with the 
phosphate groups (Zunino et al., 1977). It has recently 
been shown that at low levels of drug binding, 
doxorubicin (or daunorubicin) bind in a cooperative 
manner to DNA (Graves, and Krugh, 1983); the binding of 
the first drug molecules induce further molecules to 
bind more readily to DNA. The cooperative binding is 
dependent upon the ionic strength, which suggests DNA 
flexibility is necessary in this cooperative binding 
process. Data on the interaction of doxorubicin and 
daunorubicin with chromatin, in general parallel 
results obtained with calf thymus DNA, with only a 
slight reduction in the apparent binding constants 
(Zunino et al., 1980; Sabeur et al., 1979) 
Two models have been proposed for the 
intercalation of daunorubicin into DNA. The first 
model, based on X-ray diffraction data, was proposed by 
Pigram et al, (1972) and has been refined by Ne idle 
(1979). In this model the planar aromatic ring system 
is inserted into the DNA helix, with the plane of the 
chromophore being parallel to the planes of the DNA 
base pairs, accompanied by a small. degree of untwisting 
of the DNA sugar-phosphate backbone. The daunosamine 
sugar lies in the major groove of the DNA with its 
amino group interacting electrostatically with the 
second phosphate residue away from the intercalation 
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site. This model has received a widespread acceptance 
since it satisfactorily explains much of the -DNA 
binding data for daunorubicin and doxorubicin (Neidle, 
1979). The total binding site spans three base pairs, 
in good agreement with the experimental data of 
approximately 0.17 binding sites per nucleotide. When 
daunosamine is altered by acetylation of the amino 
group, or the configuration of the sugar is altered the 
biological activity and DNA-binding is diminished 
(DiMarco et al., 1976,1977). 
This model for the interaction of daunorubicin 
with DNA has however been superceded by a new model in 
which the drug "skewers" the DNA. This model is based 
on evidence from X-ray crystallographic data of 
daunorubicin-oligonucleotide complexes (Quigley et al., 
1980; Rich et al., 1981) and high resolution NMR 
studies (Patel et al., 1981). This second model is 
consistent with theoretical model building (Henry, 
1976; Neidle and Taylor, 1979; Nakata and Hopfinger, 
1980). It was shown from X-ray crystallography that two 
drug molecules are bound per self-complementary 
oligonucleotide (d(CpGpTpApCpG)) duplex. In spite of 
the choice of four possible sites (CG, GT, TA, or AC), 
the drug is preferentially intercalated between the 
terminal CG base pairs. The drug molecules show minor 
groove intercalation, in contrast to the earlier 
molecular models proposed. The amino sugar fits into 
the minor groove; however this position excludes any 
interaction between the charged amino group and 
backbone phosphates. The chromophore lies skew to the 
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GC base pairs, and rings A and D protude from them, in 
complete agreement with NMR observations (Patel et al., 
1981). The B and C ring overlap with base pairs is 
small, although the hydroxyquinone oxygen atoms on each 
side of the drug molecule play a stabilising role, by 
being stacked with G2 and G6 guanine bases. The least 
understandable feature of this model is its inability 
to account for the role of the charged amino group in 
DNA binding. It is possible that the amino group acts 
in the initial electrostatic recognition of the 
exterior of the DNA molecule, and thus brings the 
intercalative grouping into the appropriate orientation 
for its binding (Quigley et al., 1980). 
Doxorubicin and daunorubicin both inhibit the 
synthesis of DNA and RNA in vitro, in support of the 
observation that template DNA is the site of binding 
(Arcamone, 1981). It is not known whether they inhibit 
DNA and RNA synthesis to the same extent (Wang, et al., 
1972; Zunino et al., 1974). However there is evidence 
to suggest that DNA replicative enzymes are inhibited 
to a greater extent than DNA repair enzyms (Sartiano, 
et al., 1979); This enzymic inhibition can only 
be reversed by the addition of excess DNA and not by 
additional enzyme (Zunino et al., 1974), consistent 
with a direct drug template (DNA) interaction. 
1.8.2. Free radical generation. 
The anthracyclines, daunorubicin and 
doxorubicin, contain a quinone moiety which can be 
enzymatically reduced to semiquinone and hydroquinone, 
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and may then reoxidise, generating reactive oxygen 
species including the superoxide anion, hydrogen 
peroxide and hydroxyl radicals. This redox cycling of 
anthracyclines may occur under aerobic or anaerobic 
conditions. 
1.8.2.1. Aerobic redox cycling of Anthracyclines. 
One electron reduction of the anthraquinone 
moiety of anthracyclines generates a semiquinone free 
radical. Bachur et al., (1977) suggested that the 
anthracycline antibiotics enter the single electron 
transfer chain at a point between NADPH and cytochrome 
P-450, forming semiquinones which reduce molecular 
oxygen to the superoxide anion (Figure 11); an 
analogous mechanism was proposed by Thayer (1977). It 
is now known that NADPH-dependent cytochrome P-450 
reductase is one of several enzymes which can provide 
the electron necessary for the reduction (Bachur 
et al., 1979; Doroshow and Reeves, 1981). Xanthine 
oxidase is also capable of transferring electrons to 
the anthracycline chromophore. Superoxide anions formed 
via redox cycling of the anthracycline are further 
converted to hydroxyl radicals and peroxides 
(Winterbourne, 1981). It is the hydroxyl radicals which 
are thought to be involved in cellular damage. The 
general mechanism for the formation of OH' radicals may 
be represented by the following equations: 
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where SOD = superoxide dismutase and CMX. Fe(II) = iron 
complexed with ATP or protein. The OH' radical is the 
most reactive radical formed in biological systems and 
reacts indiscriminately to degrade any molecule within 
diffusion distance (Fridovich, 1977). It may for 
example, react with lipid membranes (hence initiating 
lipid pe roxidation), or with DNA, causing lesions 
including single strand breaks (Gutteridge and Togg, 
1982, Berlin and Haseltine, 1981). Hydroxyl radicals 
may also be produced by reaction of semiquinone free 
radicals with hydrogen peroxide, this is not dependent 
on the presence of an iron complex (Winterbourn, 1981). 
Goodman and Hochstein (1977) suggested that 
cardiotoxicity resulting from anthracycline 
chemotherapy is caused by this superoxide production 
leading to the initiation of lipid pe roxida tion. 
Doxorubicin is known stimulate lipid peroxidation in 
rat heart tissue (Mimnaugh et al., 1981). Several 
enzymes are known to catalyse the removal of these 
reactive oxygen species. For example, superoxide 
dismutase catalyses the dismutation of superoxide 
anions to hydrogen peroxide which in turn may be 
converted to water by catalase or by glutathione 
peroxidase using reduced glutathione (GSH) as a source 
of reducing equivalents. The concentrations of these 
protective enzymes is much lower in the cardiac tissue 
(Herzog and Fahimi, 1974) compared to other tissues 
such as liver and kidney. Nohl and Jordan (1983) showed 
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that in the cardiac tissue the anthracycline 
semiquinone radical shuttels electrons to hydrogen 
peroxide rather than molecular oxygen. This results in 
the generation of highly reactive hydroxyl radicals, 
instead of superoxide anion radicals. 
The deleterious effects of reactive oxygen 
species in biological systems is well documented 
(Fridovich, 1979; Bachur, 1982a, 1982b, 1982c; 
Morehouse et al., 1983). The most important consequence 
of free radical generation is the damage to membranes 
as a result of lipid peroxdation, resulting in cellular 
damage. Furthermore these reactive oxygen species are 
capable of reacting with proteins and nucleic acids. 
One of the mechanisms involved in the cytotoxic action 
of doxorubicn is suggested to be the reaction of free 
radicals with deoxyribose (Bates and Winterbourn, 1982) 
resulting in DNA strand scission (Someya and Tanaka, 
1979). Bachur et al., (1982c) showed that isolated 
nuclei were capable of reducing doxorubicin to the 
corresponding semiquinone with concurrent formation of 
reactive oxygen metabolites. 
1.8.2.2. Anaerobic reduction of Anthracyclines. 
Under anaerobic conditions the sugar moiety, 
(daunosamine in the case of daunorubicin and 
doxorubicin), of anthracycline glycosides may be 
eliminated by enzymatic reduction (Komiyama et al., 
1979). A one electron reduction of the quinone, 
mediated by NADPH-dependent cytochrome P-450, is 
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Figure 12 : Anaerobic reduction of anthracyclines. 
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followed by the elimination of the C-7-substituted 
sugar residue (figure 12). However it is possible that 
a free radical at C-7 may also be formed (Sinha and 
Gergory, 1981). A two electron reduction of 
anthracycline is also possible, which may give rise to 
an alkylating C-7 quinone methide metabolite (Moore, 
1977). The reactive metabolites thus formed may bind 
covalently to cellular constituents, for example DNA. 
Sinha and Chignell (1979) showed that the covalent 
binding of anthracyclines to DNA correlates with 
chromosomal damage and with increased frequency of 
sister chromatid exchange. 
1.8.2.3. Interaction of Anthracyclines with membranes. 
Both doxorubicin and daunorubicin interact with 
components of cell membranes. Doxorubicin has been 
shown to have a high affinity for phospholipids such as 
cardiolipin; the complex formed is stabilised by 
electrostatic interaction between the amino group of 
daunosamine and the phosphate residues of the lipid 
(cf. DNA) (Goormaghtigh et al., 1980). The interaction 
between doxorubicin (or daunorubicin) and phospholipids 
results in the alteration of membrane fluidity 
(Kraczmar and Tritton, 1979; Goldman et 21-j 1978). 
The formation of complexes between 
anthracyclines and phospholipids excludes cytochrome c 
oxidase from its essential cardiolipin environment, 
thereby inhibiting the electron transport chain of 
mitochondrial respiration. Since cardiac muscle cells 
are densely populated with respiring mitochondria, the 
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normal functioning of the cardiac muscle may be 
hindered. 
It has been shown that doxorubicin can be 
cytotoxic without entering cells; presumably this is 
mediated via a membrane effect (Tritton and Yee, 1982; 
Tokes et al., 1982; Tritton et al., 1983). The inactive 
anthracycline analogue 4-demethoxy-7,9-epi-daunorubicin 
when covalently coupled to polyglutaraldehyde 
microspheres, acquired a significant cytostatic 
activity when evaluated with doxorubicin resistant and 
sensitive L1210 leukaemia cells (Rogers and Tokes, 
1984). 
The dose-limiting cardiomyopathy associated with 
doxorubicin (and daunorubicin) treatment may be as 
result of reductive metabolism of the drugs. This 
reductive metabolism leading to formation of highly 
reactive oxygen metabolites (eg. hydroxyl radicals), 
with subsequent lipid peroxidation. The damage to 
cardiac tissue may partially be exacerbated due to the 
presence of low levels of protective reducing agents 
(eg. GSH); further damage would also occur as a result 
of association of the anthracyclines with essential 
phospholipids. 
In the past two decades several anthracyclines 
have been isolated or prepared, in an attempt to 
improve the therapeutic indices of these drugs. These 
attempts have been reviewed elsewhere (Brown, 1983; 
Arcamone, 1981). Aclacinomycin A (10) (figure 13) has 
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Figure 13 : Some anthracyclines with high therapeutic 
index. 
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been shown to be almost as active as doxorubicin, but 
is less cardiotoxic (Hora et al., 1977). Aclacinomycin 
A preferentially inhibits the synthesis of RNA, both 
in vitro and in vivo (Oki, 1977; Yamaki et al., 1978). 
It is the quinone moiety of anthracycline which 
undergoes redox cycling, and hence replacement of the 
quinone group by another group would be likely to yield 
a compound which is not able to redox cycle. For 
example 5-imino- derivatives of doxorubicin and 
daunorubicin (11,12) (figure 13) have been synthesised 
(Acton and Tong, 1981; Tong et Al.,, 1979) in an attempt 
to reduce the cardiotoxic effects of the parent 
compounds. Both analogues are as active as the parent 
compounds but 5-iminodoxorubicin (12) is less potent 
than doxorubicin. Both compounds are more difficult to 
reduce polarographically and to reoxidise, with a 
resultant decrease in nicking of DNA (Lown et al., 
1979). Recently morpholinyl derivatives of 
anthracyclines have also been synthesised, these 
compounds have been found to be 100 to 1000 fold more 
potent than doxorubicin against P388, and L1210 
leukaemias, and B16 melanoma (Acton et al., 1984). 
Anthracyclines can be viewed as substituted 
anthraquinones, so an analysis of the antitumour 
effects of anthraquinones would be worthwhile 
particularly since some anthraquinones and their 
glycosides have antibacterial and antipsoriatic 
activity (Friedman, 1980; Anton and Haag-Berrurier, 
1980). A number of amino-, hydroxy-, and 
nitro-anthrquinones are known to be mutagenic (Brown 
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and Brown, 1976; Brown and Dietrich, 1979) and the 
related anthrone dithranol has been widely used in the 
treatment of psoriasis because of its cytotoxic effects 
(Brown, 1983). 
In this work substituted anthraquinones will be 
designed and synthesised with structural similarities 
to the anthracyclines. It is therefore necessary to 
review the synthesis and biological activity of 
antitumour anthraquinones. 
1.9. SUBSTITUTED ANTHRAQUINONES. 
The essential structural requirements for an 
intercalating agent were described earlier (see 1.6). 
An intercalating agent should have a planar, w electron 
rich chromophore, the optimal size of which is 
equivalent of 3 or 4 annelated benzene rings, and hence 
is of about the same dimensions as the 
purine-pyrimidine hydrogen-bonded base pairs of DNA 
(Cain, 1974). Intercalation into DNA is found to be 
enhanced when an amino group is also present in the 
drug. However since it is the anthraquinone moiety of 
the anthracyclines which intercalates into DNA (see 
1.9.1), suggests that it should be possible to design 
anthraquinones which mimic anthracyclines. In 1966 it 
was shown that some anthraquinones undergo spectral 
shifts in the presence of DNA (Swanbeck, 1966). 
Subsequently Müller at al., (1971), showed that it is 
possible to delete the cyclohexene ring of the 
anthracyclines, leaving the simpler anthraquinone 
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DNA. Since 1971 
synthesised and 
and mitoxantrone) 
Mitoxantrone (No' 
for the treatment 
still retain the ability to bind to 
many anthraquinones have been 
of these, two compounds (ametantrone 
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of breast cancer. 
1.9.1 Substitution at the 2 and / or 3 positions. 
Doxorubicin can be regarded as a 
1,4-dihydroxy-2,3-disubstituted anthraquinone (figure 
1); the first anthraquinones modelled on doxorubicin 
were of this type. Müller et al., (1971) studied such 
compounds, 13-15 (figure 14) and found they bind to 
DNA: however no details were given. Subsequently it was 
shown that the 2-substituted-1,4-dihydroxy- 
anthraquinones (16) and (17) (figure 14) inhibited DNA 
and RNA synthesis (Henry, 1976). It was shown that 
anthraquinones such as (18) did not bind to DNA (Double 
and Brown, 1976). It was suggested that this was due to 
the side chain being insufficiently basic to be ionised 
at physiological pH. Henry (1979) also reported the 
syntheses of daunosamine substituted anthraquinones for 
example compound (19), and showed that the compound 
inhibited DNA and RNA synthesis in vitro; however 
compound (19) was inactive against P388 tumours. 
Compounds such as (20) were shown to intercalate into 
DNA (Bennett et al., 1982), however no in vivo 
antitumour activity was shown. Bis-substituted 
sulphonamides, ethers and esters of anthraquinones (eg. 
compounds 21-23, figure 15) have been shown to have 
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(cH3)2 
13 R= 
(CH=) 
R' =H R2= OH 
14 R=CH2N(CH3)2 R1 =H R2=OH 
15 R=R1= (CH2)2N(CH3)2 R2=H 
16 R=NH(CH2)3N(CH3)2 R1= R2 =H 
17 R=S(CH2)2N(CH3)2 R1= R2 =H 
18 R=CH 2-C6H5-(PN(CZH5)2) R1= R2 =H 
19 R=CH2-0-daunosamine R1= H R2= OCH3 
20 R=CH2CONH(CH2)2NCH3 R1= R2 =H 
Figure 14 : Some 2-substituted anthraquinones shown to 
intercalate into DNA. 
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21 R= SO2NH(CH2)3N(n-C4H9)2 
R 
22 Ra O(CH2)2N(C2H5)2 
23 R= CO2(CH2)3N(C2H5)2 
24 R= -N=CO CH-H(CH3)2 
25 R= -NH-CO(CH2)n-N(CH3)2 n= 1 or 2 
Figure 15 : Chemotherapeautically active bis-substit- 
uted anthraquinones. 
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antiviral activity (Grisar et al., 1974; Sill, et al., 
1974). Some basic substituted 2,6-diamidino and 
2,6-diacetamino anthraquinones (24,25) have been shown 
to be active against Entamoeba histolytica and 
Trichomonas vaginalis (Winkelman and Raeter, 1979). 
There is thus evidence that 2-substituted 
anthraquinones may have a potential as chemotherapeutic 
agents, and can intercalate into DNA (Bennett et al., 
1982; Brown, 1983). 
1.9.2. Substitution at 1,4,5, and 8 positions. 
In 1975, Double and Brown reported the synthesis 
of 1-, 1,4-, 1,5-, and 1,8- aminoalkylamino- 
substituted anthraquinones (compounds 26-30, figure 
16), which were designed as intercalating agents 
incorporating those features of the anthracyclines 
which were essential for intercalation. These compounds 
were found to intercalate into DNA, with affinity 
constants of 0.5-4.2 X106M-1 ; however they were devoid 
of in vivo antitumour activity (Brown, 1983). Further 
work by Lederle Research, Inc., showed that similar 
anthraquinones were active in vivo against a number of 
experimental tumours, with ametantrone (31) showing 
optimum activity (Murdock, et al., 1979). It was also 
shown that activity and potency were further enhanced 
by 5,8-hydroxylation of the anthraquinone chromophores 
with mitoxantrone (32) showing optimum activity. Some 
of these compounds were also reported by Zee-Cheng and 
Cheng (1978); notably compound (31). From these earlier 
studies on 1,4-substituted anthraquinones, it was shown 
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26 Rx NHC H(CH3)(CH2)3N(C2H5)2 R1= R3=R4=H 
27 R1=R2= NHCH(CH3)(CH2)3N(C2H5)2 R3= R4=H 
28 R1=R3m NHCH(CH3)(CH2)3N(C2H5)2 R2= R4=H 
29 R1=R4= NHCH(CH3)(CH2)3N(C2H5)2 R2= R3=H 
30 R1= NHCH(CH3)(CH2)3N(C2H5)2 R2= OH R3=R4=H 
31 R1=R2= NHCH2CH2NHCH2CH2OH R3= R4= H 
32 R1sR2= NHCH2CH2NHCH2CH2OH R3= R4= OH 
33 R1sR2sº1 CH2)2NHCH2CH3 R3= R4= H 
34 R1-R2= (CH2)2NH(CH2)2OH R3= R4= H 
35 R1=R2= (CH22 N, - NC5H10 R3 =R4= H 
36 R1=R2= (CH2)5OH R3 =R4= H 
37 R1aR2a (CH2)2S(CH2)2OH R3 =R4= H 
Figure 16 : 1-, 1,4- 1,5-, and 1,8- Substituted anthra- 
quinones 
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that cytotoxic activity is greatest where (a) there is 
disubstitution on the anthraquinone chromophore; (b) 
where there is a dimethylene spacer between the two 
nitrogens; (c) where the aliphatic amine is secondary; 
and (d) the substituent is an hydroxyethyl group 
(Murdock et al., 1979; Zee-Cheng and Cheng, 1978, 
Zee-Cheng et al., 1979). Mitoxantrone (32) showed 
activity which was either equivalent, or superior to 
that of doxorubicin against certain experimental 
tumours (Johnson et al., 1979). Since these earlier 
studies, mitoxantrone (32) and ametantrone (31) have 
undergone extensive trials in animals as well as in 
man, this work will now be reviewed. 
1.9.2.1. Antitumour activity of Mitoxantrone (32) and 
Metantrone (31). 
Mitoxantrone has a wide spectrum of activity 
against experimental murine tumours including L1210 and 
P388 leukaemias, B16 melanoma and mouse colon 26 tumour 
(Cheng et al., 1979; Fujimoto and Ogawa, 1982; Johnson 
et al., 1979; Wallace et al., 1979; Zee-Cheng and 
Cheng, 1978; Zee-Cheng et al., 1979). It was also shown 
to be active against mouse colonic adenocarcinomas, and 
mouse mammary carcinomas (Smith, 1983). Mitoxantrone is 
more effective than doxorubicin in extending survival 
times of animals bearing tumours (Murray and Wallace, 
1980) and it has a wide spectrum of activity in a human 
tumour-cloning system (Von Hoff et al., 1981). However 
the only tumour type to show complete resistance to 
mitoxantrone was colon carcinoma. In another study, 
using the same clonogenic assay system, it was shown 
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that mitoxantrone was more effective as a cytotoxic 
agent than doxorubicin (Cowan 'et al, 1983) and there 
was a lack of cross resistance 27-34% of the time, with 
mitoxantrone being more active than doxorubicin. 
Ametantrone has been shown to be less active than 
mitoxantrone and doxorubicin (Drewinko et al., 1983; 
Smith, 1983; Johnson et al., 1979). 
Synergism has been demonstrated between 
witoxantrone and cis-platin, 5-fluorouracil, 
vincristine, and DTIC against murine colonic and 
mammary adenocarcinoma (Corbett et al., 1982), and with 
irradiation against L1210 leukaemia (Kimler and Hacker, 
1981). Following these encouraging results, 
mitoxantrone rapidly entered phase I clinical trials 
(Von Hoff et al., 1980; Valdivieso et al., 1981; 
Alberts, et al., 1980). Mitoxantrone was generally well 
tolerated, with leucopaenia being the dose limiting 
toxic effect. Mitoxantrone treatment induced remission 
in some patients (Alberts et al., 1980) and showed 
little evidence of cardiotoxicity. Phase I trials were 
also started for ametantrone (Van Echo et al., 19811 
Loesch et al., 1983). 
In phase II clinical trials it was shown that 
mitoxantrone induced a partial tumour regression in 
patients with metastatic breast cancer (Yap et al., 
1981; Stuart-Harris and Smith, 19821 Stuart-Harris, 
et al. 1984). A complete response was obtained in some 
patients with refractory acute leukaemia (Estey et al., 
1983). On the basis of these clinical trials 
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©itoxantrone (Mitozanthrone, Novantrones) has recently 
been marketed in the United Kingdom for the treatment 
of breast cancer. 
In the last three years there have been some 
reports of cardiotoxicity induced by mitoxantrone, 
however in most cases patients had received prior 
chemotherapy (including doxorubicin) or irradiation and 
therefore at this early stage it is uncertain if 
mitoxantrone is less cardiotoxic than doxorubicin. 
Earlier trials in animals showed that mitoxantrone was 
less cardiotoxic than doxorubicin (Henderson et al., 
19821 Cheng et al., 1979). The biochemical mechanisms 
involved in the cytotoxicity of mitoxantrone, including 
intercalation are described in the following sections. 
1.9.2.2. Mecanisa of action of mitoxantrone. , 
The principal mode of cytotoxic action of 
mitoxantrone is thought to be due to interaction of the 
drug with DNA. Mitoxantrone has been shown to inhibit 
nucleic acid synthesis in vitro (Johnson et al., 1981). 
It gives nuclear aberrations similar to those produced 
by doxorubicin. It is not cell-cycle specific and 
although it is more effective against cells in the 
growth phase, it is also cytotoxic against non-dividing 
cells (Murray and Wallace, 1980). Treatment with either 
mitoxantrone or ametantrone produces an accumulation of 
cells in the G2 phase (Evenson et al., 1979,1980; 
Kimle r, 1980; xapuscinski et-al., 1981). Mitoxantrone 
has been shown to be localised in the cell nucleus 
following exposure to drug, although some is found in 
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the cytoplasm (Kapuscinski et al., 1981). It is 
associated with DNA and RNA, and cells treated with 
DNAase and RNAase fail to bind the drug. Both 
mitoxantrone and ametantrone cause sister-chromatid 
exchange and chromosome breaks (Au et al., 1981). As 
with other intercalating agents mitoxantrone has been 
found to give protein-associated single strand breaks 
in DNA (Cohen et al., 1980) and to unwind covalently 
closed circular DNA (Kapuscinski et al., 1981; Lown 
et al., 1984). Mitoxantrone thus appears to exert its 
cytotoxic action by a similar mechanism to that of 
doxorubicin. 
Mitoxantrone and other related compounds were 
shown to stabilise DNA to thermal denaturation (Johnson 
et al., 1979); however this property could not be 
related to the antitumour activity of these drugs. For 
example, the 1,4-bis-ethylaminoethylamino analogue (33) 
gave a greater stabilisation of DNA than did 
mitoxantrone but was shown to be much less active 
against all tumour systems evaluated (Johnson et al., 
1979). Comparison of a 1,8-bis-substituted compound 
with its 1,4-bis-substituted analogue showed the latter 
to be a more effective DNA-binding agent. However it 
was shown that the 1,5-bis-substituted analogue 
stabilised DNA to a greater extent than did its 
1,4-bis-substituted counterpart and required much lower 
concentrations to inhibit nucleic acid synthesis. 
However, 1,5-substituted anthraquinones were found to 
be totally inactive in vivo (Johnson et al., 1979). 
However when interpreting the data of Johnson et al. 
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(1979), an explanation for these observations unrelated 
to DNA binding should not be ruled out. One explanation 
of these results is that analogues inactive in vivo may 
have a poor access to tumour cells due to differences 
in lipid solubility, or may be differentially bound to 
proteins, or may be inactivated. 
Although the above evidence indicates that 
intercalation is the most important mechanism of DNA 
binding of mitoxantrone (and related compounds), the 
precise nature of the interaction of drug with DNA is 
not known. Mitoxantrone has been implicated as 
cardiotoxic in several patients, and recent work 
elsewhere has concentrated on the biochemical 
mechanisms involved in its possible cardiotoxicity and 
these will now be described. 
1.9.2.3. Potential cardiotozicity of mitoxantrone and 
related compounds. 
In the last 3-4 years there have been a number 
of reports in the literature which indicate that 
mitoxantrone may be cardiotoxic (Pratt et al., 1983; 
Schell et al., 1982; Sparano et al., 1982; Henderson 
et al., 1982; Unverferth et al., 1983); in the majority 
of these clinical studies patients had received prior 
chemotherapy and hence cardiotoxicity may have resulted 
frota exposure to other agents. Both mitoxantrone and 
ametantrone were found to be less cardiotoxic than 
doxorubicin in animal studies (Cheng et al., 1979). 
Kharasch and Novak (1981,1983), showed that 
mitoxantrone and ametantrone are not as readily 
II 
activated to semiquinone free radicals as are the 
anthracyclines. These drugs stimulate NADPH oxidation 
and superoxide generation to a lesser extent than the 
anthracyclines. Furthermore mitoxantrone was found to 
be a poor substrate for cytochrome P-450 reductase as 
well as being an inhibitor of this enzyme. Both 
mitoxantrone and ametantrone inhibited lipid 
peroxidation in vitro (Mimnaügh et al., 1982); indeed 
mitoxantrone (and ametantrone) actually inhibited 
doxorubicin-stimulated lipid peroxidation (Kharasch and 
Novak, 1982a). Mitoxantrone has also been shown to 
inhibit the formation of doxorubicin semiquinone free 
radicals in vitro, (Basra, J., personal communication). 
A etantrone has been shown to inhibit microsomal 
oxidative drug metabolism, in addition to inhibiting 
lipid peroxidation, (Kharasch and Novak, 1982b). 
These studies show that mitoxantrone (and 
related compounds) probably exert their antitumour 
action by interacting with DNA and are probably less 
cardiotoxic than doxorubicin. It remains to be seen 
whether mitoxantrone is as useful a cancer 
chemotherapeutic agent as doxorubicin. Whatever the 
outcome, synthetic anthraquinones have provided new 
ammunition in the arsenal of drugs used for the 
treatment of cancer. 
To date little information is available on the 
nature of interaction of anthraquinones with DNA. In 
this work an attempt will been made to rationalise the 
precise nature of the anticipated interaction of 
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substituted anthraquinones with DNA in order to allow 
the design of more selective antitumour agents. 
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1.10. AIMS 
The anthracycline antibiotics daunorubicin and 
doxorubicin, have been used extensively in the 
treatment of neoplastic diseases (see 1.7.2). They have 
a multiplicity of cellular effects including metabolic 
reduction (see 1.8.2), and interaction with 
phospholipids and cellular membranes (see 1.8.3). 
However the most obvious effect of these drugs is their 
effect on the nucleus. As well as their ability to 
intercalate into DNA (see 1.8.1), they cause protein 
associated double and single strand breaks in DNA, they 
give rise to sister chromatid exchange and chromosome 
aberrations. Whatever the mode of cytotoxic action it 
is clear that intercalating anthracyclines are 
cytotoxic. 
The minimal structural requirements for 
intercalation are a planar, tricyclic chromophore (such 
as the anthraquinone chromophore of doxorubicin), with 
a positively charged group, such as an amino group, 
capable of interacting with phosphate residues in the 
DNA (see 1.6.1). Based on these structural requirements 
several anthraquinones have previously been synthesised 
(see 1.9), and shown to intercalate into DNA, in 
accordance with their design; with the 
1,5-disubstitution pattern having the highest affinity 
for DNA (Plumbridge 2. t al., 1980). The majority of 
these anthraquinones were shown not to posses 
antitumour activity in vivo. It was later shown that 
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some 1,4-bis-(2'hydroxyethylamino)ethylamino substi- 
tuted anthraquinones (notably ametantrone and 
mitoxantrone, see 1.9.2) possesed in vivo antitumour 
activity (Zee Cheng and Cheng, 1978; Murdock et al., 
1979). However these are 1,4-disubstituted derivatives 
and as indicated above it had previously been shown 
that the 1,5-disubstituted anthraquinone had a higher 
affinity to DNA. 
The effect of substitution pattern on the 
binding of anthraquinones to DNA, in two series of 1-, 
1,4-, 1,5-, and 1,8-substituted anthraquinones (Figures 
17a and 17b), will be examined in this project. It has 
previously been shown (Johnson et all 1979) that the 
1,4-disubstituted anthraquinones containing 2-(hydroxy- 
ethylamino)e thylamino side chains were cytotoxic 
against tumour cells in vivo. In order to exploit this 
cytotoxic property, anthraquinones substituted with this 
side chain will be synthesised. The two nitrogen atoms, 
in this case, are separated by two methylene units, and 
the 2-(diethylamino)ethylamino side chain will be used 
for the synthesis of the second series of 
aminoalkylamino- anthraquinones. 
The ability of these proposed anthraquinones, to 
bind to DNA will be investigated. Suitable methods will 
be selected to distinguish qualitatively between 
external binding and intercalation of anthraquinones 
into DNA including the effect of DNA on spectral 
properties of drug, and the effect of drug on thermal 
denaturation of DNA. Further methods will be chosen to 
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1-(2'-(Diethylamino)ethylamino]anthracene-9,10-dione 
(compound IA) . 
i 11 c 11 
i 
1,5-bis(2'-(Diethylamino)ethylaminojanthracene-9,10- 
dione (compound 2A). 
1,8-bis(2'-(Diethylamino)ethylaminojanthracene-9,10- 
dione (compound 3A). 
ýý ýý 
ZZIN 
1,4-bis(2'-(Diethylamino)ethylamino)anthracene-9,10- 
dione (compound 4A). 
R= -NHCH2CH2N(C2Hs)2 
Figure 17a : Proposed 2'-Diethylaminoethylamino subst- 
ituted anthraquinones (A series). 
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1-(2'-(Hydroxyethylamino)ethylamino]anthracene- 
9,10-dione (compound 1B). 
1,5-bis(2'-(Hydroxyethylamino)ethylamino)anthracene- 
9,10-dione (compound 2B). 
.i iý . 000,10.0 
1,8-bis[2'-(Hydroxyethylamino)ethylamino]anthracene- 
9,10-dione (compound 3B). 
ýI Iý 
1,4-bis(2'-(Hydroxyethylamino)ethylamino)anthracene- 
9,10-dione (compound 4B). 
R=-NHCH2CH2NHCH2CH=OH 
Figure 17b : Proposed 21-Hydroxyethylaminoethylamino- 
substituted anthraquinones (B series). 
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quantitate differences between the binding of 
anthraquinones to DNA; these include determination of 
affinity constants (by spectrophotometric titration), 
determination of dissociation constants by stopped-flow 
spectrophotometry and the effect of the compounds on 
the unwinding of closed circular DNA. The results from 
solution studies on DNA-binding of substituted 
anthraquinones will be correlated with the results from 
computer graphics modelling (performed by S. A. Islam and 
S. Neidle at King's College, London), of their fit into 
a DNA intercalation site. 
The use of chemotherapeutic agents in the 
treatment of neoplastic disease is limited by the 
severe toxicity of these agents to the patient and a 
rapid development of resistance to the drugs. 
Furthermore certain tumours, eg. liver tumours, are 
refractory to most currently available drugs. As seen 
previously, doxorubicin is one of the drugs which has 
been extensively used in the treatment of solid tumours 
including the treatment of hepatocellular carcinoma. 
Pro-drugs will be designed, based on doxorubicin, which 
can be selectively activated by the tumour cells. The 
pro-drugs proposed (figure 17c) have been designed so 
that they should not intercalate into DNA but should 
release the intercalating anthraquinone (Fig. 17c) when 
metabolised by intracellular enzymes. 
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0 N=N 
GH 
1-(4'-Hydroxyphenyl)azoanthracene-9,10-dione (compound 
1C). 
N=N 
ýýH 
H 
1-(2'-(Diethylamino)ethylaminoj-4-(2", 4"-dihydroxyphen- 
yl)azoanthracene-9,10-dione (compound 2C). 
=N HQ 
H 
1-(2'-(Diethylamino)ethylaminoj-5-(2", 4"-dihydroxyphen- 
'yl)azoanthracene-9,10-dione (compound 3C). n3 n 
-II\ 
R 
R= NHCH2CHZN(C2H$)2 
1-A: wino-4-(2'-(diethylamino)ethylaminojanthracene-9,10- 
dione (compound 2Ci; R1=NH2, R2=R3=H). 
1-Amino-S-(2'-(diethylamino)ethylamino]anthracene-9,10- 
dione (compound 3Ci; R1=R3=H, R2=NH2). 
1-Amino-5,8-bis-(2'-(diethylamino)ethylaminoj-4-hydroxy- 
anthracene-9,10-dione (Compound 4Ci; R1 = R, R2=NH2, 
R3=OH). 
Figure 17c: Proposed Anthraquinone pro-drugs and their 
potential metabolites. 
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2. RESULTS AND DISCUSSION. 
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In this chapter, the synthesis of the compounds 
will be discussed first. Then their binding to DNA will 
be considered, and the data compared with that obtained 
from computer graphics molecular modelling. Finally the 
in vitro metabolism of the synthesised pro-drugs will 
be discussed. The in vivo and in vitro antiproli- 
ferative testing of compounds, synthesised in this 
work, will also be discussed. 
2.1. SYNTHESES. 
The compounds synthesised in this work will be 
divided into three groups: 
A. 2'-(Diethylamino)ethylaminoanthracene-9,10-diones 
(Compounds 1A-4A) 
B. 2'-(Hydroxyethylamino)ethylaminoanthracene-9,10- 
diones (Compounds 1B-4B) 
C. Pro-drugs and their potential metabolites 
(Compounds 1C-3C and 2Ci-3Ci). 
The term anthracene-9,10-dione follows the IUPAC 
nomenclature and is used throughout the experimental 
chapter. However, in this chapter the more usual (but 
trivial) name anthraquinone will be used. 
The final compounds synthesised in this work are 
shown in figures 17a-17c, together with their codes. 
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2.1.1. Synthesis of 2'-(dieth lamino)eth laminoanthra- 
auinones (A series). 
There are at least four possible methods for 
synthesis of aminoalkylaminoanthraquinones, these 
include Friedel Craft's acylation, Diels-Alder 
reaction, alkylation of aminoanthraquinones, and 
substitution of appropriate haloanthraquinone. 
Friedel-Crafts acylation is the classical method 
for anthraquinone synthesis. Substituted phthalic 
anhydrides have been utilised in either a double 
concurrent (A1C13/NaCl melt), or consecutive, process. 
The reaction lacks regioselectivity, and furthermore in 
the case of aminoalkylamino substituted anthraquinones, 
protection of amino groups is required. 
+Iý 
AICI3NaC; 
RR 
The Diels-Alder reaction may be used in the 
synthesis of anthraquinones. This method usually 
involves the reaction of a suitable dienophile with a 
quinone eg. 
oR0 
+1 
This method has been used extensively in the synthesis 
of anthracyclinones (reviewed by Brown and Imam, 
1984. ). 
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As an alternative to synthesising the 
anthraquinone chromophore as a last step, commercially 
available anthraquinones can be utilised. One possible 
method is to use aminoanthraquinones and alkylate the 
amino groups, this is possible where the appropriate 
alkylating agent is available or can be synthesised 
readily. 
9 NHZ HNCHzR 
L*)+CH2R -ý 
/I\ 
A more versatile route is by substitution of a 
haloanthraquinone with an appropriate amine, and this 
route has previously been used in the synthesis of 
aminoalkylaminoanthraquinones (Double and Brown, 1975). 
The reaction would be expected to proceed readily due 
to a reduced electron density at Cl (figure 18). In 
this work 1-, 1,5- and 1,8- aminoalkylaminosubstituted 
anthraquinones were prepared by this method; the 
1,4-bis substituted analogue could not be readily 
prepared by this method since the corresponding 
dihaloanthraquinone in not available commercially. This 
compound was therefore prepared by an alternative 
route. 
A two electron reduction of 1,4-dihydroxy- 
anthraquinone (quinizarin), yields leucoquinizarin 
(1,4,9,10-tetrahydroxyanthracene). The latter compound 
has previously been used in the synthesis of 
1,4-disubstituted anthraquinones (Greenhalgh and 
Hughes, 1968). A major advantage of this method is that 
d- 
t ý" 
7ý 
S 
S 
%-Z 
3 
4 
r 
IH= 
N-R 
-Hý 
H -R 
Figure 18: Mechanism of reaction of chloroanthra- 
quinones with primary amines. 
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" IVH2 
4 
much milder conditions may be used (see later). 
2.1.1.1. Synthesis of 1-[2'-(diethylamino)ethylaminol- 
anthraquinone (lA). 
This compound was synthesised (see 3.1.1.1) by 
heating 1-chloroanthraquinone under reflux in excess 
(10 fold) of 2-(diethylamino)ethylamine until all the 
chloroanthraquinone had reacted. The reaction was 
monitored by the colour change of the mixture from pale 
orange U. max 380nm) to deep red (X max 490nm). 
Throughout this work it was found that the shift in 
X max, of the reaction mixture was a good indication 
that the reaction had taken place. Furthermore, since 
the final product is much more polar (due to the 
basicity of the tertiary amine side chain), the 
reaction was also monitored by TLC. 
After completion of the reaction the mixture was 
cooled, excess acid added and the mixture extracted 
with ether, to remove any non-polar products. The 
desired product and unreacted amine would be expected 
to remain dissolved in the aqueous layer as the 
hydrochloride salts. It was found that the 
anthraquinone hydrochloride could be extracted from the 
aqueous layer with chloroform. The chloroform was 
dried, evaporated in vacuo and the residue redissolved 
in deionised water. The solution was then made alkaline 
and extracted with chloroform. The free base of the 
product was obtained by evaporation of chloroform 
followed by recrystallisation. 
The structure of the final product was 
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elucidated by spectroscopic methods, elemental analysis 
and also by X-ray crystallography, the latter was 
performed by Dr. S. Neidle and Dr. R. Kuroda (King's 
College, London). The X max of the product was 495 nm 
compared to 380nm of the starting material. This 
bathochromic shift is expected due to the contribution 
of the lone pair of electrons of the nitrogen to the 
chromophore. This change in X max is similar to that 
reported by other workers (Double and Brown, 1975). The 
final product was basic also indicates that there is an 
aliphatic as well as an aromatic amino group present. 
The infrared spectrum confirmed the presence of an NH 
(bonded) group and quinone carbonyl at 1660 cm-1. The 
NMR spectrum of the product was in agreement with the 
structure except that the amino proton (NH) was found 
not to be washed by D20 shake, this is undoubtably due 
to the fact that the NH proton forms a strong 
intramolecular hydrogen bond with the quinone carbonyl. 
Mass spectral data were also as expected. The 
fragmentation pattern is shown in figure 19. The purity 
of the free base was confirmed by elemental analysis. 
Further evidence for the structure was obtained 
by X-ray crystallography, (Almond et a1., 1983), the 
anthraquinone chromophore was found to be highly planar 
with a dihedral angle of 2.7° between the two terminal 
aromatic rings. The amino proton forms a strong 
intramolecular hydrogen bond with the carbonyl oxygen 
(hence the lack of exchange with D20 seen in the NMR 
spectrum) with an overall effect to somewhat increase 
the effective planar area of the molecule. 
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S, HNCH2CH2N`C2H 
C2HS 
zxÖ -- --. -------* N(C. H. ) 
" rcH2cH2cc 
HNCHZCH2 
/1 **ý 
0 
L : 'ACH2 
HNCHJ2 
f 
\II/ 
M-86 
NHCH2 
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xco 
ýý 
iý 
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Figure 19: A common fragmentation pathway of 2'-(di- 
ethylamino)ethylaminoanthraquinones. 
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2.1.1.2. Synthesis of 1,5-bis and 1,8-bis-(2'-(diethyl- 
anino)ethylaoino]anthraquinones(2A, 3A). 
These compounds were synthesised by a method 
which was similar' to the synthesis of 
1-(2'-(diethylamino)e thylaminojanthraquinone (see 3.1.1 
.2&3.1.1.3). The appropriate dichloroanthraquinone, 
in ten fold excess of 2-(diethylamino)ethylamine, was 
heated under reflux until all the chloroanthraquinone 
had reacted. The reaction was monitored by the change 
in colour from pale orange (k max 380nm) to deep red 
(A max 515nm) in the case of the 1,5-, and mauve (X max 
536nm) in the case of the l, 8-disubstituted analogue. 
The reaction was also monitored by TLC, the compounds 
would be anticipated to be more polar than the starting 
chloroanthraquinones and monosubstituted anthraquinone 
(compound la). The Rfs in MeOH/CHC13 (1/1) were 0.95, 
0.70,0.50, and 0.55 for dichloro-, monosubstituted-, 
1,5-, and 1,8-disubstituted anthraquinones 
respectively. 
After completion of each reaction, the mixture 
was cooled and excess acid added; the mixture was then 
extracted with ether, to remove any non-polar products. 
The hydrochloride salts of unreacted amine and 
substituted anthraquinones would be expected to remain 
in the aqueous phase. The hydrochloride salts of the 
disubstituted anthraquinones are less lipophilic than 
the monosubstituted compounds, therefore the latter 
were readily removed by extraction of the aqueous phase 
with chloroform. The monosubstituted anthraquinones 
would be expected to have a) max similar to compound 
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(1), whilst the disubstituted anthraquinones should 
have a longer X max due to the presence of two amino 
groups on the chromophore. Basification of the aqueous 
phase followed by extraction with chloroform and 
evaporation in vacuo yielded a mixture of the 
disubstituted anthraquinone and the starting amine; the 
latter could be readily detected by its distinctive 
smell. The amine was removed by washing the residue 
several times with water until further amine could not 
be detected. The last traces of water were removed by 
suspending the residue in absolute ethanol and 
evaporating in vacuo. Recrystallisation of the products 
from absolute ethanol yielded the free bases. 
The structures of the final products were 
elucidated by spectroscopic methods, elemental analyses 
and also by X-ray crystallography. The x max in the 
visible region were 515nm and 536nm for 1,5- and 
1,8-disubstituted anthraquinones respectively compared 
to 380nm for dichloro- and 495nm for monosubstituted 
anthraquinones. The final products were basic and 
polar, as expected. Both compounds were shown to be 
more polar than monosubstituted anthraquinone. Infrared 
spectra were similar to that of the monosubstituted 
anthraquinone and confirmed the presence of NH (bonded) 
group (3420 and 3280 cm-1 respectively for 1,5- and 
1,8- disubstituted compounds), and quinone carbonyls at 
1660, and 1670 cm-1. The 
1Hnmr 
of the products was in 
agreement with the assigned structure. Mass spectral 
data were also as expected with a fragmentation pattern 
similar to that of monosubstituted anthraquinone 
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(figure 19). The purity of the free bases was confirmed 
by elemental analysis. 
X-ray crystallography revealed that the 
anthraquinone chromophores are highly planar with 
dihedral angles of 2.4°, (Almond et al., 1983), and 
2.00 (Islam et al., 1983), between the two terminal 
aromatic rings, for the 1,5- and 1,8-disubstituted 
anthraquinones respectively. The amino proton forms a 
strong intramolecular hydrogen bond with the carbonyl 
oxygen with an overall effect to somewhat increase the 
effective planar area of the molecule. 
2.1.1.3. Synthesis of 1,4-bis-[2'-(diethylanino)ethyl- 
anino]anthraquinone (4A). 
This compound could not be readily synthesised 
from the appropriate dihalo anthraquinone as the latter 
is not available commercially, however the compound was 
readily synthesised by the method of Greenhalgh and 
Hughes (1968). This method involves the reaction of 
leucoquinizarin (1,4,9,10-tetrahydroxyanthracene) with 
an appropriate primary amine (figure 20). 
Leucoquinizarin exists as the keto form in solution 
(Bloom and Hutton, 1963). The reaction proceeds by 
nucleophilic attack by the amine at the carbonyl group 
with subsequent elimination of H2 0 to yield the imine. 
Oxidation of the imine with tautome risen to the enamine 
yields the free base, and this mechanism is shown in 
figure 20. 
A major advantage of this method of synthesis is 
that the reaction can proceed at much lower 
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Figure 20: Mechanism of reaction of leucoquinizarin 
with primary amines. 
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H 
temperatures, 50-60°C compared to 100-140°C in the case 
of substitution of chloroanthraquinones. As will be 
seen later, cyclisation of a side chain containing 
primary or secondary amino groups, can occur at the 
higher temperatures. 
Compound (4A) was synthesised by heating 
leucoquinizarin and excess amine (10 fold excess) in 
butan-l-ol at 50-60°C under nitrogen, until all the 
leucoquinizarin had reacted (as determined by TLC). 
During this time the colour of the reaction mixture 
changed from dark brown to deep green. TLC of the 
reaction mixture indicated that the green compound was 
polar and basic (Rf 0.5; CHC13/MeOH, 1/1), furthermore 
the colour of the spot changed over a period of 2 hours 
to blue. At the completion of the reaction the mixture 
was aerated at 50°C to oxidise the substituted 
leuco-anthraquinone to the substituted anthraquinone. 
This product was purified essentially as for 1,5- 
disubstituted anthraquinone. 
Visible spectroscopy revealed that the compound 
has two peaks at 626nm (% max) and 582nm, compared to 
the 7. max of 440nm of quinizarin. The compound was 
polar as would be expected. The spectral data were 
similar to that of 1,5-disubstituted anthraquinone, the 
infrared spectrum confirmed the presence of NH 
(bonded), and quinone carbonyl. 
1Hnmr 
and mass spectra 
were consistent with the assigned structure and 
elemental analysis confirmed that the compound was 
pure. 
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2.1.2. Synthesis of 2'-(h drox eth lamino)eth la. ino- 
ant raquinones (B series). 
These compounds may be synthesised by analogous 
methods to those described for the synthesis of 
2'-(diethylamino)ethylamino substituted anthraquinones, 
however since a secondary amino group is present in the 
side chain the products may cyclise to yield 
1,2,3,4-tetrahydronaptho-2,3-quinoxaline-7,12-dione 
derivatives (figure 21). This occurs more readily at 
the higher temperatures involved in substitution of 
chloroanthraquinones. The mechanism for this reaction 
is shown in figure 21. 
As seen previously leucoquinizarin may be 
utilised in the synthesis of 1,4-disubstituted 
anthraquinones and this route has been used by other 
workers for the synthesis of 1,4-bis[2' (hydroxyethyl- 
amino)ethylaminojanthraquinone (Zee Cheng and Cheng, 
1978; Murdock et al. 1979)'. Since the 
hydroxyanthraquinones can be readily prepared (by 
Friedel Craft's acylation), and are also available 
commercially, the possibility of utilising 1-, 1,5-, 
and 1,8-dihydroxy anthraquinones for the synthesis of 
substituted anthraquinones was investigated. 
The dihydroxy anthraquinones could be reduced to 
their leuco forms by di thionite, under nitrogen, in 
sodium hydroxide. However, unlike leucoquinizarin, 
these anthraquinones could not be isolated and were 
found to readily reoxidise to the dihydroxy 
anthraquinones. An alternative to isolating the leuco 
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Figure 21: Mechanism of cyclisation of 2'-(hydroxy- 
ethylamino)ethylamino- anthraquinones. 
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anthraquinones would be to synthesise and react them 
in situ. After reduction of the dihydroxy anthraquinone 
the appropriate amine was added and the reaction 
allowed to proceed for a period of 72 hours, at 
60-65°C. During this time there was no change in 
overall colour; TLC of the reaction mixture indicated 
the presence of only the starting 
dihydroxyanthraquinone. 
The reaction conditions as described above were 
unsuitable for the synthesis of 1-, . 
1,5- and 1,8- 
bis-(2'-(hydroxye thylamino)ethylamino)anthraquinones, 
and therefore the substitution of chloro anthraquinones 
at lower temperatures was investigated. In a 
preliminary experiment 1-chloroanthraquinone was 
suspended in 2-(hydroxyethylamino)ethylamine by 
mechanical stirring and the temperature raised to 40°C. 
The mixture was maintained at this temperature for a 
period of 8 hours and the reaction monitored by TLC. 
The temperature of the reaction mixture was then raised 
by steps of 50C. After each increment, the reaction was 
maintained at that temperature for 4 hours, whilst 
monitoring the reaction by TLC. It was shown that the 
minimum temperature necessary for the reaction to 
proceed was -90°C and therefore this temperature was 
utilised in the synthesis of 1-, 1,5-, and 1,8- 
bis-(2'-(hydroxyethylamino)ethylam"inojantharquinones. 
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2.1.2.1. Synthesis of 1-[2'-(hydroxyethylamino)ethyl- 
amino]-anthraquinone (1B). 
Compound (1B) was synthesised (see 3.1.2.1) by 
heating 1-chloroanthraquinone in excess, (20 fold), of 
2-(hydroxyethylamino)ethylamine at 90°C with mechanical 
stirring until the majority of the chloroanthraquinone 
had reacted. During this time the colour of the 
reaction mixture changed from pale orange (% max 380nm) 
to deep red (X max 495nm). The reaction was also 
monitored by TLC. The compound was purified as for 
1-(2'(diethylaminoethylaminojanthraquinone (1A) except 
that it was found that the impure product could be 
isolated by pouring the reaction mixture into a large 
volume of water. Further purification was achieved by 
solvent extraction- and recrystallisation as for 
compound 1A. 
The X max of the product, in the visible region 
of the spectrum, was 498 nm compared to 380nm of the 
starting material. The bathochromic shift in X max is 
similar to that of 1-(2'-(diethylamino)ethylamino)- 
anthraquinone (compound 1, X max 495nm). The final 
product was found to be basic and polar. The infrared 
spectrum confirmed the presence of OH (3400 cm-1). NH 
(3260 cm-l, bonded) groups and quinone carbonyl at 1670 
cm-l. The NMR spectrum of the product was in agreement 
with the assigned structure. The presence of NH (2.4 6) 
proton (D20) washable, as well as the presence of NH 
(9.9 6) (not replaced by D20) protons indicate that 
the side chain had not cyclised. Mass spectral data 
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Figure 22 :A common fragmentation pathway of 2'-(hydr- 
oxyethylamino)ethylamino-anthraquinones. 
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were as expected and the fragmentation pattern is shown 
in figure 22. Elemental analysis confirmed that the 
product was pure. 
2.1.2.2. Synthesis of 1,5-bis-[2'-(hydrozyethylamino)- 
ethylamino]-anthraquinone (2B). 
Compound (2B) was synthesised (see 3.1.2.2) and 
purified by the same method as for compound (2A) except 
that the reaction was carried out at 90°C and the 
mixture was stirred mechanically. There was a similar 
change in colour, from pale orange to deep red (X max 
518nm) as the reaction progressed. After removal of 
unreacted anthraquinone and monosubstituted 
anthraquinone the compound was precipitated by the 
addition of excess sodium hydroxide, and filtered. 
Recrystallisation of the product yielded the pure 
1,5-bis-(2'-(hydroxye thylamino)ethylamino3anthraquinone. 
The X max of the product, in the visible region, 
was 518 nm compared to 380nm of the starting material. 
The X max of the product was similar to that of 
compound (2A), (515nm). The infra red spectrum was 
similar to that of 1-[2'-(hydroxyethylamino)ethylamino3- 
anthraquinone (1B), confirming the presence of OH, NH, 
and quinone carbonyl. The free base was insufficiently 
soluble in most of the commonly used solvents for 
1 Hnmr, including chloroform, dimethylsulphoxide, and 
methanol therefore the 
1Hnmr 
spectrum of the 
hydrochloride salt was obtained, in D20. The 
1Hnmr 
spectrum was consistent with the assigned structure 
except the resonances corresponding to NH protons were 
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absent, as would be expected. Mass spectral data were 
also consistent with the assigned structure. Elemental 
analysis confirmed that the compound was pure. 
2.1.2.3. Synthesis of 1,8-bis-[2'-(hydrozyethylamino)- 
ethylaminol-anthraquinone (3B). 
Compound (3B) was synthesised (see 3.1.2.3) by 
the same method as for compound (2B), however it was 
found that during the reaction several products were 
formed with similar polarities (difference in Rf <0.3 
when using McOH/EtAc 1/1), and therefore the final 
product could not be purified by the simple solvent 
extraction methods used thus far. Possible structures 
of these compounds are shown in figure 23. The 
monosubstituted products would be expected to be less 
polar than the disubstituted analogues whilst the 
cyclised disubstituted product would be expected to 
have a longer X max than the desired product, due to 
contribution of a lone pair of electrons by the third 
nitrogen to the chromophore 
"Flash" column chromatography, with "sequential 
elution" is a more selective way of separating the 
components with similar polarities than solvent 
extraction. The term "sequential elution" is used here 
to describe gradual stepwise change in the polarity of 
the eluent rather than by a continous gradient. It was 
first necessary to remove any unreacted amine before 
column chromatography, since the amine is not very 
soluble in organic solvents and could therefore block 
the column. The amine was removed by washing the 
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Figure 23 : Possible products following the reaction of 
1,8-dichloroanthraquinone with 2-(hydroxy- 
ethylamino)ethylamine. 
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reaction mixture several times with water, the last 
traces of water were removed by addition of absolute 
ethanol followed by evaporation in vacuo. 
Having removed the amine, the residue was 
dissolved in ethyl acetate/ methanol (2/1) and 
chromatographed (for details of eluent used and the 
technique see chapter 3). Fractions containing a 
particular single component (confirmed by TLC) were 
pooled and evaporated in vacuo. The most polar 
component was characterised first, since it was found 
to be the major component and also for the reasons 
mentioned above it was anticipated to be the desired 
product. The x max of the product was found to be 540nm 
compared to 536nm for compound (3A). This gave an 
initial indication that the most polar fraction was 
most probably compound (3B). This component also had 
very similar Rf to compound (2B) (0.20 and 0.15 
respectively for compounds (2B) and (3B)). 
Further evidence for the structure was obtained 
by IR, 1Hnmr, MS, and elemental analysis. The infrared 
spectrum confirmed the presence of OH (3420cm) , NH 
(3260cm-1), and quinone carbonyl (1660cm-1). NMR of the 
product was in agreement with the assigned structure. 
The presence of NH (2.4 6,2H) protons (D20) washable, 
as well as the presence of NH (9.9 6,2H) (not 
replaced by D20) protons indicate that the side chain 
had not cyclised. The fact that the X max is in the 
same region as for 1,8-bis(2'-(diethylamino)ethylamino- 
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anthraquinone (3A), and that two D2 replaceable protons 
are present indicates that the product is 1,8-bis- 
[2 -(hydroxyethyl)aminoethylamino]anthraquinone. Mass 
spectral data were in agreement with the assigned 
structure and elemental analysis confirmed that the 
compound was pure. 
2.1.2.4. Synthesis of 1,4-bis-[2'-(hydroxyethylamino)- 
ethylamino]-anthraquinone (4B). 
Compound (4B) was synthesised (see 3.1.2.4) by 
the same method as compound (4A) using leucoquinizarin 
and 2-(hydroxye thylamino)e thylamine. After oxidation 
the reaction mixture was filtered to yield the free 
base. Recrystallisation from ethanol/water mixture 
yielded the pure base. As with previous reactions the 
reaction was monitored by change in colour and also by 
TLC. The colour of the reaction changed from dark brown 
to green and, when aerated, to blue. There were two 
peaks in the spectrum of the final product in the 
visible region, at 628nm (x max) and 583nm, the 
spectrum was similar to that obtained for compound (4A) 
(626 and 584nm respectively). 
Further evidence for the structure was obtained 
by IR, 1Hnmr, MS, and elemental analysis. The infrared 
spectrum indicated the presence of OH (3420cm-1), NH 
(3280cm-1), and quinone carbonyl (1610cm-1). 
1Hnmr 
and 
mass spectral data were in agreement with the assigned 
structure and elemental analysis confirmed that the 
compound was pure. 
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In all cases hydrochloride salts were prepared 
by dissolving the base in a minimum quantity of an 
appropriate dry organic solvent (eg. ether, 
2-methoxyethanol) and bubbling dry hydrogen chloride 
through the solution. 
2.1.3. Synthesis of anthraquinone pro-drugs. 
Most currently available antitumour agents are 
not selectively toxic to neoplastic cells. As seen 
earlier (Chapter 1), the most common toxicity of these 
agents to the host is depression of bone marrow 
function. In some cases the use of antitumour agents is 
limited by other ireversible toxicity, for example dose 
limiting cardiotoxicity of the anthracycline 
antibiotics. Furthermore the neoplastic cells become 
resistant to these drugs by a number of mechanisms. One 
method of reducing the toxicity, hence increasing the 
therapeutic index, of these drugs is to design drugs 
which are selectively activated by neoplastic cells. 
In this work anthraquinone pro-drugs were 
designed such that these drugs could be selectively 
activated by target cells. The liver was chosen as the 
target organ because to-date only a limited number of 
chemotherapeutic agents are available for treatment of 
primary hepatocellular carcinoma. The use of 
fluoropyrimidines, nitrosoureas, and folate antagonists 
has usually yielded a poor response rate (Falkson 
et al., 1978). The single most effective drug is 
doxorubicin, which caused tumour regression in 35-50% 
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Figure 24 : Activation of azo-mustard by reduction 
in vivo by azo reductase. (From Connors, 
T980 
. 
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of hepatocellular carcinoma cases and an improved 
survival time (Oon and Friedman, 1982). As described 
earlier (Chapter 1), one of the possible modes of 
action of doxorubicin is by interaction with DNA to 
inhibit replication of genetic material. It was 
anticipated that drugs which interact with DNA could be 
linked to inactive molecules to form pro-drugs. 
Furthermore with appropriate choice of linkages the 
active drug could be released by intracellular enzymes, 
and hence a selective targetting of drug to the tissue 
would be achieved. For example, Bukhari et al. (1973), 
synthesised azomustards (figure 24) and showed that 
these compounds are converted to the highly reactive 
phenylenediamine derivatives, by hepatic azo-reductase. 
It was therefore desirable to synthesise azo 
anthraquinones as pro-drugs, examine their metabolism 
by liver fractions in vitro, and study the interaction 
of these compounds with DNA. The following section 
discusses the syntheses of azoanthraquinones. 
Metabolism studies and DNA interactions will be 
discussed later in this chapter (Section 2 and 3). 
In order to investigate whether 
azoanthraquinones can be metabolised to the 
corresponding aminoanthraquinones, by liver azo 
reductase enzymes 1-(4'-hydroxyphenyl)azoanthraquin- 
one was synthesised from anthraquinone-l-diazonium 
chloride. The latter compound is available commercially 
as a stabilised zinc complex or can be readily 
synthesised from 1-aminoanthraquinone (Saunders, 1949). 
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2.1.3.1. Synthesis of 1-(4'-hydroxyphenyl)azo-anthra- 
quinone (12). 
The zinc complex of anthraquinone-l-diazonium 
chloride is stable at room temperature, the coupling to 
phenol was carried out at room temperature. The 
mechanism of coupling of diazonium cations to phenols 
is shown in figure 25. The diazonium cation can undergo 
electrophilic aromatic substitution. This however, is a 
weak electrophile compared to species such as 
+NO2 and 
will normally only attack highly reactive aromatic 
compounds such as phenols (Sykes, 1975). The 
introduction of electron withdrawing groups into the o- 
or =positions of the diazonium cation enhances its 
electrophilic character. Diazonium cations exist in 
acid and slightly alkaline solution. In more strongly 
alkaline solutions they are converted to 
diazohydroxides, PhN=N-OH and further into diazotate 
anions, PhN=N-0 and coupling reactions are therefore 
carried out under acidic or more usually (in the case 
of phenols) under slightly alkaline conditions. With 
phenols a slightly alkaline pH is used since it is the 
phenoxide (Ph0 ), and not the phenol (PhOH), that 
undergoes attack by the diazonium cation. As with other 
cases of electrophilic attack on phenols, the 
C-substituted product is obtained rather than the 
O-substituted product (Sykes, 1975). Removal of a 
proton from the intermediate is facilitated by one or 
other of the basic species present in solution. 
Coupling usually takes place in the p, rather than the 
o-, position because of the excess of attacking 
NH 
-H+ 
H 
R-N: O -º, R-N-N=O ---P R-N-N=O 1 
r) 
1 
HXHX 
X =ONO 
r .. R- N=N 
R+ NZ 1--- 
LR-J t21-H O 
L----RNNOH 
2 
H 
I/Y 
+RN= Y 
, 
+H N=N-R R-N=N 
=N-R 
R= 
HNCH2CH2N (c2H5)2 
Figure 25 : Mechanism of formation of diazonium cation 
and coupling to phenol. 
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electrophile ArN2+. 
Anthraquinone-l-diazonium chloride (zinc 
complex) was added to a solution of phenol in sodium 
hydroxide and the mixture stirred. The colour of the 
mixture changed from slight yellow to deep orange. The 
coupling reaction was monitored by TLC since the 
azoanthraquinone would be expected to be more polar 
than aminoanthraquinone due to the presence of phenolic 
OH. The mixture was stirred until completion of the 
reaction (as monitored by TLC). The resulting 
precipitate was filtered and washed first with sodium 
bicarbonate solution to remove any unreacted phenol, 
and finally with water. The solid was dried and 
recrystal li sed from ethanol. 
The azoanthraquinone was characterised by 
spectroscopy and elemental analysis. The infra red 
spectrum showed the presence of phenolic OH (3400 
cm-1), and quinone carbonyl (1620 cm-1). The 
observation that there was not a peak for NH2 is 
consistant with coupling having taken place. The 
1Hnmr 
spectrum showed the presence of aromatic protons 
(7.1-7.6m 6 ), and OH (D20 replaceable, 5.2s 6 ). Mass 
spectral data were in agreement with the assigned 
structure and elemental analysis confirmed that the 
compound was pure. 
From DNA binding studies it was shown that 
2'-(diethylamino)ethylamino substituted anthraquinones 
do bind to DNA by intercalation (see later sections) 
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with the 1,4-, and 1,5-disubstituted anthraquinones 
having a higher affinity than the 1- and 
1,8-disubstituted anthraquinones for DNA. The compounds 
also have antiproliferative activity in vitro against 
HeLa cells; however the compounds were inactive in vivo 
against P-388 leukaemia. Therefore pro-drugs 
incorporating these anthraquinones would be of 
particular value if they could be delivered to the 
target organ. Subsequent activation, of the pro-drug, 
by the target organ could be used to release the 
cytotoxic compound. 
In order to synthesise aminoalkylamino- 
anthraquinone pro-drugs it is necessary to first 
synthesise aromatic aminoanthraquinones, substituted 
with aminoalkylamino side chains. The synthesis of 
1-amino-2'-(diethylaminoethylamino) substituted anthra- 
quinones will be described first, and azo coupling of 
these compounds to phenols will then be discussed. 
2.1.3.2. Synthesis of 1-amino-4-[2'-(diethylamino)- 
ethylamino)anthraquinone (2Ci). 
Compound (2Ci) was synthesised (see 3.1.3.1) by 
the same method as compound (1A) using 1-amino-4-bromo 
anthraquinone and 2-(diethylamino)ethylamine. As the 
reaction progressed the colour of the mixture changed 
from deep red (% max 490nm) to blue (% max 600nm). The 
reaction was also monitored by TLC, in this case two 
blue spots were present one had the same Rf as 
1,4-disubstituted anthraquinone (4A), whilst the other 
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was less polar than compound (4A). It was found that 
the two compounds could not be separated by solvent 
extraction and were therefore separated by "flash" 
column chromatography after removing unreacted amine. 
The more polar compound was shown to be compound (4A), 
since the U. V. and IR spectra were identical. The less 
polar of the two components was further purified by 
recrystallisation, and characterised as (2Ci) by 
spectroscopy and elemental analysis. 
A solution of the purified product produced two 
peaks in the visible region of the spectrum, at 606nm 
(X max), and 565nm. These two peaks are characteristic 
of 1,4-diaminoanthraquinones. The infra red spectrum 
indicated the presence of NH2 (3400 cm-1), NH (bonded, 
3260 cm-1), and quinone carbonyl (1645 cm-1). 
1Hnmr 
and 
mass spectral data were consistent with the assigned 
structure. Elemental analysis confirmed that the 
product was pure. 
2.1.3.3. Synthesis of 1-amino-5-[2'-(diethylamino)- 
ethylamino]anthraquinone (3Ci). 
Compound (3Ci) was prepared 
3.1.3.2) by the method described for 
using 1-amino-5-chloroanthraquinone 
amino)ethylamine. In this reaction the 
mixture changed from orange (7ý max 
(). max 507). 
and purified (see 
compound (2Ci) 
and 2-(diethyl- 
colour of the 
450) to deep red 
Compound (3Ci) was characterised by spectroscopy 
and elemental analysis. The X max, of the pure 
compound, was 507nm and this is in the same region as 
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compound (2A). The infrared spectrum was comparable to 
that of compound (2Ci), 1Hnmr and mass spectral data 
were consistent with the assigned structure. Elemental 
analysis confirmed that the compound was pure. 
Having synthesised compounds (2Ci) and (3Ci) as 
model compounds the next step was to synthesise an 
amino-substituted anthraquinone with a higher affinity 
for DNA. On the basis of DNA binding work, on the first 
two series of anthraquinones (see 2.2), it was decided 
to synthesise a 1,4-bis-substituted- anthraquinone with 
a primary aromatic amino group in the 5 (or 8) position 
of the chromophore. Previous workers had synthesised 
compounds of this type also containing a hydroxy group 
in the 8-position (Nippon Kayaku Co., Japan, 1982). 
HN CHzCH2 NHCH2CH2OH 
H2 6 HIPCH=CHZNHCH2CH2OH 
This compound is a structural analogue of mitoxantrone, 
and posseses antitumour properties. 
2.1.3.4. Synthesis of 1-amino-5,8-bis-[2'-(diethyl- 
anino)ethylanino]-4-hydroxy-anthraquinone 
(4Ci). 
Compound (4Ci) was synthesised (see 3.1.3.3) 
essentially by the method described in a patent (Nippon 
Kayaku Co., 1982). 1,5-Diamino-4,8-dihydroxy- 
anthraquinone and 2-(diethylamino)ethylamine (ten fold 
excess) were suspended in aqueous methanol (50%), under 
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nitrogen, and sodium dithionite added. The mixture was 
heated, under nitrogen, in an oil bath at 60-65°C, and 
the reaction monitored by TLC. The product would be 
expected to be more polar than the starting 
anthraquinone due to the presence of an aliphatic amino 
group, Heating was continued until no further product 
was formed, during which time the colour of the 
reaction mixture changed from blue to dark green. This 
change in colour was as expected, due to the formation 
of reduced aminoanthraquinones (starting material and 
the substituted product). The mixture was then aerated, 
at 50-60°C, to oxidise the leucoanthraquinones; this 
was assumed to be completed when the colour of the 
reaction mixture had changed to blue. The mixture was 
evaporated in vacuo and inorganic impurites removed by 
suspending the residue in water and extracting with 
ethyl acetate. The ethyl acetate solution was then 
evaporated in vacuo and the compound purified by 
"flash" column chromatography. Fractions containing a 
single component were pooled and evaporated in vacuo. 
Only two components were present, starting 
anthraquinone and the more polar 2'-(diethylamino)- 
ethylamino substituted anthraquinone. The latter 
component was further purified by recrystallisation, 
and characterised by spectroscopy and elemental 
analysis. 
The compound exhibited two peaks in the visible 
region of the spectrum, at 630nm (% max) and 585nm. 
These two peaks are characteristic for 1,4-bis-amino- 
alkylamino-substituted anthraquinones. The infra-red 
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spectrum showed the presence of NH and OH (bonded) and 
quinone carbonyl. 
1Hnmr 
and mass spectral data were 
consistent with the assigned structure. Elemental 
analysis confirmed that the compound was pure. 
Having synthesised aminoanthraquinones 
(compounds 2Ci-4Ci), they were azotised and coupled to 
resorcinol. Resorcinol was chosen since the presence of 
hydroxyl or amino groups in close proximity to the azo 
bond enhance the enzymatic reduction (Shargel et al., 
1984). Resorcinol was also chosen because it couples 
more readily than does phenol (Saunders, 1949). 
2.1.3.5. Synthesis of 1-[2"-(diethylamino)ethylamino]- 
4-(2`, 4"-dihydrozyphenyl)azoanthraquinone (2C). 
1-Amino-4-(2'-(diethylamino)ethylamino)anthra- 
quinone (see 3.1.3.5) was dissolved in hydrochloric 
acid and cooled in a NaCl/ice bath (0-5°). Sodium 
nitrite was then added and the reaction allowed to 
proceed until all the aminoanthraquinone had reacted. 
During this time the colour of the solution changed 
from deep blue to orange/green. The reaction was also 
monitored by adding a small aliquot of the reaction 
mixture into excess sodium bicarbonate solution; where 
any unreacted amine precipitated out. 
The mixture containing azotized anthraquinone 
was added to a solution of resorcinol in sodium 
hydroxide, also at 0-5°. The coupling reaction was 
allowed to proceed until all the diazonium salt had 
reacted; this was indicated by the colour of the 
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mixture which changed from orange/green to dark green. 
The reaction was also monitored by TLC, since the azo 
compound was expected to be more polar than the amine, 
due to the presence of two phenolic groups. 
After completion of reaction any unreacted amine 
was extracted with dichloromethane and this was 
discarded. The aqueous layer was evaporated in vacuo 
and the last traces of water were removed by adding 
absolute ethanol followed by further evaporation 
in vacuo. Inorganic material was removed by suspending 
the residue in chloroform and filtering. The solution 
was then evaporated in vacuo and the resultant green 
solid purified by "flash" column chromatography. 
Further purification was attained by recrystallisation. 
The azo product was characterised by 
spectroscopy and elemental analysis. There were two 
peaks in the visible region of the spectrum, 626nm 
(> max) and 480nm, compared to 606nm and 565nm for the 
starting amine. This bathochromic shift is as expected, 
due to extention of conjugation by the azo linkage. The 
infrared spectrum indicated the presence of OH, NH, and 
quinone carbonyl. 
1Hnmr 
and mass spectral data were 
consistent with the assigned structure. The purity of 
the azo-anthraquinone was confirmed by elemental 
analysis. 
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2.1.3.6. Synthesis of 1-[2'-(diethylamino)ethylanino]- 
5-(2', 4'-dihydrozyphenyl)azoanthraquinone (3CL 
Compound (3C) was prepared essentially by the 
same method as compound (2C) using 1-amino-5- 
(2'-(diethylamino)e thylamino]anthraquinone. It was 
found that in this case the product precipitated out at 
the completion of reaction. The precipitate was 
collected and washed several times with water, to 
remove inorganic material. The product was then washed 
with cold ethanol to remove traces of water and dried 
overnight in vacuo at 60°. Compound (3C) was further 
purified by "flash" column chromatography. 
Compound (3C) was characterised by spectroscopy 
and elemental analysis. The X max of the purified 
product was 520nm compared to 507nm for the starting 
amine. The infrared spectrum indicated the presence of 
OH, NH, and quinone carbonyl. 
1Hnmr 
and mass spectral 
data were consistent with the assigned structure. The 
final product was confirmed to be pure by elemental 
analysis. 
The hydrochloride salts of compounds (2C) and 
(3C) could not be prepared as it was found that the azo 
compounds degraded to the parent amine in the presence 
of HC1. 
2.1.3.7. Attempted synthesis of 1,4-bis-[2'-(diethyl- 
aaino)ethyla. inoj-5-(2", 4'-dihydroxyphenyl)- 
azo-8-hydrozyanthraquinone (4C). 
Attempts to prepare compound (4C) from 
1-amino-5,8-bis-[2'(diethylamino)ethylaminoj-4-hydroxy- 
o% 
anthraquinone (4Ci) were unsuccesful. The 
aminoanthraquinone could readily be diazotised and 
coupled to resorcinol using the same conditions as for 
the synthesis of compound (2C). The diazotisation and 
coupling were monitored by TLC. However the azo- 
anthraquinone could not be isolated since it was 
rapidly degraded to the parent aminoanthraquinone 
(4Ci). The conversion to the aminoanthraquinone was 
completed in less than 10 minutes, as monitored by TLC. 
Attempts to couple compound (4Ci) to phenol were 
similarly unsuccesful. 
Having synthesised the substituted 
anthraquinones (1A-4A, 1B-4B),, the anthraquinone 
pro-drugs (1C-3C) and their corresponding intermediates 
(2Ci-4Ci ); the interaction of these compounds with DNA 
was examined. 
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2.2. DNA BINDING STUDIES. 
The compounds prepared in this work were 
designed to intercalate into DNA, with or without 
activation, in accordance with the principal mode of 
cytotoxic action of doxorubicin (Brown, 1983; see 1.8). 
Determination of the interaction of these compounds 
(and doxorubicin) with DNA was therefore of fundamental 
importance in the assessment of potential antitumour 
activity of these compounds. Furthermore pro-drugs 
(compounds 2C & 3C) of anthraquinones were designed 
with the intention that they should not intercalate 
into DNA, but that when metabolised, they should yield 
the corresponding anthraquinones (compounds 2Ci & 3Ci) 
which would then intercalate into DNA; therefore the 
interaction of all compounds prepared in this work with 
DNA was examined. 
In order to fully evaluate the DNA-binding of 
the compounds prepared, methods of studying their 
binding to DNA must be selected which will allow both 
the nature of binding and the affinity of the drug for 
DNA to be determined. Drugs can interact with DNA in 
several ways; for example external binding (see 1.5.7). 
However the compounds prepared in this work were 
designed to intercalate into DNA. It is therefore 
important here to use methods which will distinguish 
the intercalative mode of binding from other modes and 
allow determination of the affinity of the drug for DNA 
when intercalation is shown. Consequently, two types of 
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tests have been used; firstly a series of qualitative 
tests, the results of which can collectively show 
whether the compounds intercalate. Secondly, tests to 
quantitate the affinity of the compounds for DNA. The 
methods used in this work will be discussed in detail 
together with the results obtained and then alternative 
methods, not employed here, will be discussed briefly. 
These alternative methods were not used in this work 
since sufficient data were obtained (from the methods 
used in this work) to draw conclusions on the nature of 
interaction and affinity of drug for DNA. 
The methods employed in this work can be 
classified into two groups. Firstly those that monitor 
changes, usually spectroscopic, in the properties of 
drug and secondly those that monitor changes in the 
properties of DNA. 
2.2.1. Changes in the spectral properties of drug. 
Changes in the fluorescence and UV visible 
absorbance properties of drug can occur on its binding 
to DNA (Neidle, 1978; Waring, 1981). Methods which 
monitor such changes were used here to examine the 
interaction of doxorubicin and substituted 
anthraquinones, (compounds IA-4A, 1B-4B, 2C-3C and 
2Ci-3Ci), with DNA. Firstly methods which monitor 
changes in the absorbance properties of the drug will 
be considered then methods which utilise fluorescence 
techniques will be discussed. 
The effect of DNA on the spectral properties of 
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drug can be studied provided the absorbance spectrum 
of the DNA does not significantly interfere with the 
absorbance spectrum of the drug. Since the 7. max of DNA 
is 260nm and the X max of the compounds prepared in 
this work is >400nm these methods can be used. The 
methods monitoring changes in the absorbance properties 
of the drug can further be divided into three groups: 
1. Effect of DNA on the absorbance spectrum of the 
drug. 
2. Spectrophotometric titration - determination of 
the apparent affinity constant. (K) 
3. Stopped-flow analysis of drug/DNA kinetics - 
determination of the dissociation rate constant. 
The first method is a qualitative, and indicates the 
nature of binding of the drug to DNA. The second and 
third methods are quantitative and indicate the 
differences in the binding of drugs to DNA. 
2.2.1.1. Effect of DNA on the absorbance spectrum of 
drug. 
When drug molecule intercalates into DNA, the 
x max of the drug typically shifts to a longer 
wavelength (bathochromic shift) and the molar 
extinction at the X max of the free drug decreases 
(hypochromic shift) (Waring, 1981). If the spectrum of 
a solution of free drug and the spectra of solutions 
containing drug and increasing concentrations of DNA 
are superimposed, then all the spectra will pass 
through a single point, which is termed the isosbestic 
point (Waring, 1981). However this will only occur if 
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there is a single spectroscopically distinct bound form 
of the drug molecule in addition to the free drug. The 
appearance of a clear isosbestic point is mandatory if 
such spectra are to be used quantitatively in the 
determination of the affinity of drug for DNA (see 
later). The intercalation of a drug into DNA gives 
certain spectral characteristics which are not shown by 
drugs which undergo external binding to DNA. However 
some drugs, such as proflavine, which are known to 
intercalate into DNA (Neidle, 1978), do not exhibit a 
clear isosbestic point (Waring, 1981). Thus absence of 
an isosbestic point does not necessarily eliminate 
intercalation as the mode of binding. 
All compounds studied here were shown to obey 
Beer-Lambert's law over the concentration range used in 
this work (1 X 10-7 -5X 10-4M). All compounds were 
next examined to see if their spectra show an 
isosbestic point when the DNA concentration was varied. 
All compounds (except the pro-drugs compounds 2C and 
3C) were shown to give an isosbestic point in the 
visible region of the spectrum. Figure 26 shows the 
effect of increasing DNA concentration on the visible 
spectrum of compound 1A; similar spectra were also 
obtained for compounds 2A-4A, 1B-4B and 2Ci-3Ci. The 
data obtained are summarised in table 1. All compounds 
studied showed bathochromic and hypochromic shifts on 
binding to DNA. The pro-drugs (compounds 2C-3C) however 
did not, show any significant changes in their spectra 
(figure 27). The shifts in X max and decrease in 
extinction of all compounds were of the same order as 
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Isosbestic Shiftiig % decrease in 
Compound points J. max extinction 
(nm) (nm) (efree, ebound) 
Doxo- 
-rubicin 545,410 10 42.0 
(9680,5540) 
2'-(Die thylaminoethylamino)anthraquinones 
1A 538,400 10 37.0 
(3200,2010) 
2A 562,360 12 27.0 
(9500,6930) 
3A 585,340 11 32.0 
(7900,5370) 
4A 637,550 20 42.0 
(14900,8640) 
2'-(Hydro xyethylamino)et hylaminoan thraquinones 
1B 572,344 10 32.0 
(6290,4280) 
2B 574,332 15 32.0 
(11900,8095) 
3B 590,340 11 33.0 
(8450,5660) 
4B 637,430 15 38.0 
(10120,6275) 
Pro-drugs and their "metabolites" 
2Ci 615,382 10 25.0 
(9590,7190) 
2C none - no dec. 
(3220,3220) 
3Ci 560,340 10 33.0 
(11200,7500) 
3C none - no dec. 
(3200,3200) 
1. Shift in ). max at DNA: drug ratio of 10: 1, drug 
concentrations in all cases were 25 DM in tris 
(0.008M), NaCl (0.05M) buffer (pH 7.40). 
2. Difference between . max of fully bound drug and free drug. 
Table 1: Data from the determination of effect of DNA 
on the absorbance spectrum of drug. 
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for doxorubicin. From these preliminary results it 
appears that the anthraquinones (1A-4A, 1B-4B and 
2Ci-3Ci) do indeed interact with DNA by the same mode 
as doxorubicin; ie. intercalation. Furthermore this 
evidence suggests that the prodrugs appear not to 
intercalate into DNA. 
On binding to DNA, compounds 1A-4A, 1B-4B and 
2Ci-3Ci show a 10-20nm bathochromic shift in the X max 
and a decrease in extinction of between 27 and 42%. 
These values are comparable with those for doxorubicin 
which shows a l0nm bathochromic shift in the Amax and 
a 35% decrease in extinction. The pro-drugs (compounds 
2C-3C) did not show any changes in the spectrum as the 
DNA concentration was increased, whilst the 
corresponding potential aminoanthraquinone metabolites 
(compounds 2Ci-3Ci) exhibited isosbestic points, and 
showed bathochromic and hypochromic shifts of the same 
order as compound (iA). 
These results are consistant with an 
intercalative mode of action of the anthraquinones 
(lA-4A, 1B-4B and 2Ci-3Ci). In order to quantitate the 
differences in the binding of these compounds to DNA, 
affinity constants were determined by 
spectrophotometric titration. 
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2.2.1.2. Spectrophotometric titration studies. 
When DNA is added to a solution of a drug which 
intercalates into DNA, for example doxorubicin, there 
is a progressive decrease in the molar extinction of 
the drug at the X max of the unbound drug as the 
proportion of DNA is increased. This occurs up to a 
limiting concentration of DNA, after which there is no 
further decrease in the extinction; at this point the 
drug is fully bound to DNA. Therefore if the 
absorbance is recorded at this X max at various 
DNA: drug ratios, extinctions obtained at these ratios 
may be calculated. The fraction of drug bound can thus 
be calculated, at any particular concentrations of DNA 
and drug as shown later. From this it is possible to 
determine the affinity of the drug for DNA. This method 
is quantitative, giving information on the affinity 
rather than on the nature of the interaction. 
For the spectrophotometric titration method to 
be valid it is essential that both the free drug and 
the bound drug obey Beer-Lambert's Law over the drug 
concentrations used for the assay. A clear isosbestic 
point must also be present, since this indicates that 
there are only two spectroscopically distinct forms of 
the drug; the bound and the free drug. Hence the 
fraction of the bound drug is proportional to the 
fractional decrease in extinction. All compounds 
(except pro-drugs) showed distinct isosbestic points in 
this work and therefore the use of spectrophotometric 
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titration method is valid for this study. Before 
discussing the results obtained by this method it is 
necessary to discuss how the experimental data were 
interpreted. 
The interaction of a drug with DNA may be 
represented as follows: 
Drug + DNA ' Drug-DNA complex 
C n-r[DNAp] r[DNAp] 
Where C is the concentration of drug, r is the number 
of sites occupied by the drug per [DNAp], n-r is the 
number of unoccupied sites per [DNAp). The 
concentration of the bound drug may be related to the 
concentration of the unbound drug by the Law of mass 
action: 
r 
K- -------- (1) 
c(n-r) 
where K is the affinity constant rand is the ratio of 
association and dissociation constants kl and k-,; r is 
the number of drug molecules bound per DNAp 
(concentration of DNA is expressed in terms of 
phosphorus); c is the concentration of unbound drug and 
n is the number of binding sites for drug per DNAp. 
Equation (1) is usually rearranged to a linear 
form, invariably by the method of Scatchard (1949). 
This enables calculation of K and n. 
" r/c = -Kr + Kn (2) 
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A plot of r/c vs r gives a line of slope -K and an 
intercept Kn on the ordinate axis. In order to 
calculate r and r/c, the fraction of bound drug ( a) is 
determined. In order to estimate a it was necassary to 
determine the extinction due to free drug ( cf), the 
extinction due to bound drug ( eb) and the extinction 
of the sample after each addition of DNA (E obs)' 
Extinction of free drug was obtained from the 
absorbance of the free drug, extinction of the sample 
under test is obtained from the absorbance of the 
drug/DNA mixture. The extinction of the bound drug was 
estimated from a plot of Cobs vs DNAp/ct, where ct is 
the total drug concentration (Plumbridge et al., 1978). 
The fraction of drug bound after each addition of DNA 
was calculated by method of Peacocke and Ske rre t 
(1956), equation 3: 
------ 
obs__ (3) a=fe 
Cf cb 
r and r/c can now be calculated from a since: 
c= (1- a)ct and r= a ct/DNAp. 
A plot of r/c vs r was then used to calculate K and n 
by means of regression analysis. However, curvature was 
often encountered since the Scatchard plot will only be 
linear if there is a single type of non-interacting 
site. In the case of interaction of drugs with DNA 
there are at least two radically different binding 
sites available. The drugs can either bind externally 
to the phosphate residues or can intercalate into DNA 
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(Waring, 1981). The affinity constants (K) for 
interaction at the two sites usually vary considerably; 
K for external binding usually about 104 compared to 
106 for intercalation (Blake and Peacock, 1968). The 
two sites may be treated separately on the binding 
curve. Furthermore not all intercalating sites are 
available for intercalation (see chapter 1,1.6.1. ), 
due to "nearest neighbour exclusion". 
In order to use this method for the 
determination of affinity constant, it is first 
necessary to ensure that both the free and bound forms 
of the drug obey Beer-Lambert's Law. It was shown that 
dilute solutions of all compounds prepared in this work 
obeyed Beer-Lambert's law in the concentration range 
from 1 X10-4 to 2X 10-6M. Furthermore it was shown 
that the bound form of drug obeyed Beer-Lambert's law 
by dilution of the final solution, containing excess 
DNA, at the end of the spectrophotometric titration. 
The absorbance at the X max of the drug was monitored 
after addition of each aliquot of DNA solution. 
In all cases the drug was fully bound at a 
DNA: drug ratio of >10: 1, this enabled reliable 
estimates for cb to be determined. Scatchard plots 
were produced for each-drug (figures 28-29) and were of 
comparable shape to that obtained for doxorubicin under 
identical conditions. The estimated K and n values were 
of the same order as those for doxorubicin (ie K% 106, 
n aa0.2). The values of K and n for the substituted 
anthraquinones, obtained, by Scatchard plots are shown 
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a1 
/1 1\ 
s4 
Compound K_la10-6 b substit8tion Mn pattern 
Doxo- 
-rubicin 4.42 (0.43)d 0.19 (0.002)d 
2'-(Diethylaminoethylamino)anthraquinones 
1A 1.48 (0.14) 
2A 3.97 (0.18) 
3A 1.71 (0.07) 
4A 3.17 (0.20) 
0.20 (0.004) 1- 
0.21 (0.002) 1,5- 
0.20 (0.001) 1,8- 
0.22 (0.006) 1,4- 
2' -(Hydroxye thylamino)e thylaminoanthraquinones 
1B 1.03 (0.09) 0.19 (0.001) 1- 
2B 3.20 (0.08) 0.22 (0.003) 1,5- 
3B 2.35 (0.11) 0.22 (0.002) 1,8- 
48 2.83 (0.10) 0.19 (0.004) 1,4- 
a. Affinity constant determined by Scatchard plots. 
b. Number of binding sites per DNA phosphate. 
c. Substitution pattern of anthraquinones. 
d. Standard deviation (n=3). 
Table 2: DNA binding properties of 
anthraquinones: determination 
constants. 
substituted 
of affinity 
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Figure 28 : Scatchard plots of 2'-(diethylamino)ethyl- 
amino substituted anthraquinones and 
doxorubicin. 
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Figure 29 : Scatchard plots of 2'-(hydroxyethyl- 
amino)ethylamino substituted anthraquin- 
ones. 
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. 
in table 2. These results are consistent with 
intercalation as a mode interaction of these 
anthraquinones with DNA. The pro-drugs did not show any 
significant binding to DNA, as evidenced by the lack of 
change in the spectral properties of these drugs. 
Therefore the affinity constants for these compounds 
could not be determined. From the results obtained it 
can clearly be seen that all the compounds (IA-4A, 
1B-4B), except the prodrugs, bind to DNA with the 
1-substituted anthraquinones (compounds 1A and 1B) 
having the least affinity for DNA, whilst the 
1,5-bis-substituted anthraquinones (compounds 2A and 
2B) have the highest affinity in each of the series. 
The order of affinity, for DNA, in both series of 
compounds is 1,5- > 1,4- > 1,8- > 1-substituted 
anthraquinones. The 2'-(diethylamino)ethylamino- 
anthraquinones have consistently higher affinities for 
DNA than the 2'-(hydroxyethylamino)ethylamino- 
anthraquinones, except in the case of 1,8-bis- 
substituted anthraquinones. 
Computer graphics modelling studies (performed 
by S. Islam and S. Neidle, King's College, London. ) of 
the interaction of 2'-(diethylamino)ethylamino- 
substituted anthraquinones with DNA, showed that these 
anthraquinones could intercalate into d(CpG) in one of 
two orientations, either parallel or perpendicular to 
the long axes of the base pairs. The 1-substituted 
compound (1A) can intercalate into d(CpG) from either 
the major or the minor groove (figure 30-32). The more 
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stable major-groove complex shows binding in the 
parallel orientation. The 1,8-substituted compound (3A) 
was shown to only intercalate from the major groove, 
due to steric hindrance in the minor groove. In this 
case the compound binds parallel to the long axes of 
the base pairs (figure 33). 
The 1,5-substituted anthraquinone (2A), was 
shown to bind to DNA by "straddling" across the 
intercalation site (figure 34). The disubstituted 
anthraquinone cannot simply be inserted into the 
intercalation site of d(CpG), since its thickness 
dimension is about 5.5L. This would require an initial 
base pair separation of at least 9X (5.5 + 3.4A). In 
order for compound (2A) to intercalate, DNA-breathing 
(transient base pair unstacking) has to occur to allow 
the docking of drug molecule into the receptor site. 
The anthraquinone must first interact with 
non-base-paired DNA residues, which subsequently 
hydrogen-bond together. Hence once the anthraquinone 
has intercalated into DNA, DNA-breathing is required 
before dissociation can take place. It was shown that 
prior disruption of base pairs is required not only 
immediately at, but also adjacent to, the binding site. 
The 1,4-substituted anthraquinone (4A) was shown 
to bind to DNA in a perpendicular orientation with the 
side chains in the major groove (figure 35). However 
the compound can also bind to DNA by "straddling" 
across the intercalation site (figure 36); in this case 
this is only possible after full geometric minimisation 
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of the dinucleoside geometry. 
To date, computer graphics modelling studies by 
Neidle and Islam, have been completed for the first 
series of anthraquinones (compounds (l'-(441). Modelling 
studies for the interaction of the second series of 
anthraquinones (compounds (1B)-(4B)) are currently in 
progress. 
Figures 30-36: Computer drawn views of the 
intercalation model of compounds 1A-4A. In all cases 
the top view is perpendicular to the base-pair plane, 
and the other two are perpendicular to this plane. The 
compounds are shown in dashed lines. The bottom plot is 
a space-filling representation. 
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Figure 30 : Intercalation of compound lA via the major 
groove of DNA. 
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Figure 31 : Intercalation of compound 1A via the minor 
groove of DNA. 
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Figure 32 : Intercalation of compound 1A perpendicular 
to the base pairs. 
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Figure 33 : Intercalation model for compound 3A. 
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Figure 34 : Intercalation model for compound 2A. 
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Figures 35 : Major grove intercalation for compound 4A. 
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Figure 36 : "Straddle" intercalation model for compound 
4A. 
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These computer graphics modelling studies have 
shown that the 1,5- and 1,4-disubstituted 
anthraquinones, (2A) and (4A), would be expected -to 
dissociate less readily from DNA than the 1- or 1,8- 
disubstituted anthraquinones. In order for compound 
(2A) (and (4A)) to dissociate from DNA, DNA breathing 
is required. 
The spectrophotometric titration method only 
gives the affinity constant (K) (the ratio of 
association (k1) and dissociation (k_1) constants), for 
the binding reaction. It would therefore be 
informative to use a method which gives information on 
the rate of dissociation of drug from (or association 
of drug with) the receptor, since this would further 
validate computer graphics modelling studies. In this 
work the dissociation of the anthraquinones, 1A-4A and 
1B-4B, and the a nthracyclines doxorubicin and 
daunorubicin from DNA were examined. 
2.2.1.3. Determination of dissociation rate constants 
of DNA-anthracyclines and DNA-anthraquinones 
by stopped-flow spectrophotometry. 
Both the anthracyclines and the substituted 
anthraquinones are ionised at physiological pH so that 
in addition to the intercalative mode of binding there 
will be a secondary mode of external binding to the 
helix, as occurs with other basic intercalating agents, 
(see 1.6). The equilibrium can thus be represented as: 
I, extern. kz intercal. 
DNA + Drug r DNA--boundDRUG DNA-Drug. 
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In support of this, T-jump and stopped flow studies 
with daunorubicin and polynucleotides and nucleic acids 
show a biexponential decay pattern (Grant and Phillips, 
1979; Forster et al., 1980). In this study all solutions 
were prepared in tris (0.015M) NaCl (0.2M) buffer pH 
7.4, since at this ionic strength only the 
intercalation mode of binding should be present. 
The dissociation rate constant for a particular 
DNA/drug complex with was determined at 20°, 25° and 
37°C using sodium dodecyl sulphate (SDS) to disrupt the 
DNA-drug complex. This agent has been used previously 
to disrupt DNA/drug intercalated systems, (Grant & 
Phillips, 1979; Muller & Crothers, 1968; and Wilson 
et al., 1976) including daunorubicin/DNA complexes 
(Grant & Phillips, 1979 and Wilson et al., 1976). In 
one study it was confirmed that alteration of the SDS 
concentration had minimal effect (±3%) on dissociation 
rate constant (Wilson et al., 1976). The reaction can 
be represented as: 
DNA-Drug 
k= 
DNA + Drug 
SDS+DRUG 
k-- 
*SDS-Drug 
where kd is the first order dissociation rate constant. 
The DNA-drug dissociation is the rate controlling step 
since the sequestering of drug with SDS is a diffusion 
controlled process. It is not possible, by analogy with 
the rate constants for other intercalating systems, to 
unambiguously determine whether the measured rate 
constant, kd, is identical to k-2 of the two-step 
mechanism. 
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Drug dissociation from DNA was monitored by 
recording the increase in extinction at the % max of 
free drug, over a period of about 6 half lives. In each 
case at least eight data points were collected and 
fitted to both a single exponential, and a 
biexponential equation using a microcomputer programme. 
In all cases the data conformed to a single exponential 
curve with a correlation coefficient >0.99; the data 
did conform to a biexponential model (R< 0.8). Hence 
this confirms the suitability of the ionic strength of 
the solution. 
The dissociation of anthracyclines and 
anthraquinones from DNA was shown to conform to first 
order kinetics for more than four half-lives for all 
complexes under these conditions. The first-order rate 
plots for the dissociation of DNA-daunorubicin, 
DNA-doxorubicin and DNA-anthraquinone (1A-4A and 1B-4B) 
complexes at 20°C, are shown in figures 37 and 38. The 
results have also been summarised for this and other 
temperatures (25 and 37°C) in table 3. In all cases 
there was an increase in the rate constant with 
temperature. The ranking order for the dissociation 
rate constants, of the substituted anthraquinone-DNA 
complexes was the same at 20,25, and 37°C. 
Measurements were taken at 37°C to ensure that the 
order is not changed at physiological temperatures. All 
reactions were studied at 20°C because this enabled a 
better reproducibility of the data than at higher 
temperatures. Dissociation rate constants were also 
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Figure 37 : First order " dissociation plots of 2'-(diethylamino)ethylamino anthraquinones 
and anthracyclines from calf thymus DNA. 
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Figure 38 : First order dissociation plots of 
2'-(hydroxyethylamino)ethylamino anthra- 
quinones from calf thymus DNA. 
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Dissociation rate constant S1 DRUG CONCN. 
1 
DRUG 20°C 25°C 37°C Inc 105 
Daun. 2 1.43 (0.17) 3 2.17 (0.2) 10.93 (0.76) 3.43 
Dcao. 2 1.84 (0.19) 2.07 (0.87) 9.87 (1.02) 3.45 
1A >150 --3.42 
2A 0.91 (0.12) 1.8 (0.05) 7.50 (0.3) 3.05 
3A 6.99 (0.52) 17.26 (1.2) 47.97 (5.6) 3.741 
4A 3.73 (0.14) 7.5 (0.38) 35.66 (3.30) 3.198 
1B )127 --3.332 
2B 1.39 (0.13) 1.93 (0.7) 19.61 (2.74) 3.874 
3B 3.69 (0.42) 7.08 (0.46) 24.28 (1.41) 3.663 
4B 3.82 (0.34) 6.02 (0.7) 19.61 (2.74) 3.874 
1 Final drug concn. after mixing with SDS =0.5 X stated concn. 
Final SDS concn in all cases 0.1X. 
2 
The values for daunorubicin (I) and daxorubicin (II) are not 
significantly different (p>0.99, n'5). 
3 Standard deviation (n-5) 
Table 3: Dissociation rate constants for DNA complexes of 
anthracyclines and substituted anthraquinones. 
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measured at 25°C as this is standard temperature for 
physicochemical studies. 
The dissociation rate constants for 
daunorubicin/DNA complexes are of the same order as 
those obtained by previous workers for 
polydeoxynucleotide-daunorubicin (3.3 S-1 at 20 and 
27.0 S-1 at 37°C) and for salmon sperm DNA-daunorubicin 
complexes (2.88 S-1 at 15°C) (Grant & Phillips, 1979; 
and Wilson et al., 1976). 
The dissociation rate constants for DNA 
complexes with disubstituted anthraquinones were' of the 
same order as for anthracycline complexes. In the case 
of the monosubstituted anthraquinones, (1A) and (1B) 
the dissociation rate constants were greater than 120 
S-1 at 20°C and could not be measured accurately at 
higher temperatures. The dissociation rate constants 
for the 1,8-disubstituted compounds (3A & 3B) were 
significantly lower than for the 1- substituted 
derivatives (1A & 1B) but were greater than for the 
1,4-bis-substituted a nthraquinones (4A & 4B). The 
1,5-bis-substituted anthraquinones had the lowest 
dissociation rate constants, 0.91 and 1.39 S-1 
respectively for 2A and 2B compared to 3.73 and 3.82 
S-1 for the 1,4-disubstituted anthraquinones, (compounds 
4A and 4B respectively) even though the affinity 
constants for these compounds were shown to be similar. 
It is not possible to calculate the association rate 
constants (k2) from the determined affinity constants 
as the buffer used here was of a higher ionic strength 
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than that used in the determination of the affinity 
constants (0.2M NaCl compared to 0.05M NaCl). 
As seen earlier it was shown from computer 
graphics modelling, (performed by S. A. Islam and 
S. Neidle), of the interaction of anthraquinones with 
the self-complementary d(CpG) dinucleotide, that in 
order to accomodate the 1,5-disubstituted anthraquinone 
(2A), DNA-breathing (transient base pair unstacking) 
has to occur to allow the docking of drug molecule into 
the receptor site. Hence once the anthraquinone has 
intercalated into DNA,. DNA-breathing is required before 
dissociation can take place. This is not necessary with 
the other compounds, though compound 4A can also bind 
in this manner as well, so explaining the very slow 
dissociation of the DNA/(2A) complex compared to the 
DNA complexes with 1-; 1,8-; or 1,4-bis-substituted 
anthraquinones and the anthracyclines. 
As mentioned earlier the effect of DNA on the 
fluorescence properties of the drug can be examined to 
show that a particular drug intercalates into DNA. The 
compounds synthesised in this work were found to 
exhibit insufficient fluorescence for DNA-drug binding 
studies. -However by using a compound which is known to 
intercalate into DNA and which has a large change in 
quantum yield on release from DNA (such as ethidium 
bromide), it was possible to examine the DNA binding of 
the compounds synthesised in this work, by fluorescence 
spectroscopy by competitive displacement of ethidium 
from DNA. This type of competitive study gives 
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information on both the nature of interaction of drugs 
with DNA and the relative affinity of the drugs to DNA. 
The effect of compounds, 1A-4A, 1B-4B, 2C-3C and 
2Ci-3Ci, on the binding of ethidium to DNA will now be 
discussed. 
2.2.2. Effect of drug on the binding of ethidium to 
DNA. 
The interaction of ethidium bromide with DNA has 
been extensively reviewed, (Waring, 1981, Yielding 
et al., 1983). Ethidium bromide has been shown to bind 
to DNA by intercalation. When binding to DNA the 
quantum yield of fluorescence of ethidium is enhanced 
(Paoletti, and Le Pe-cq, 1971). Hence if a compound binds 
to the same site in the DNA helix as ethidium the drug 
will compete with ethidium for that site. Providing the 
compound, in the absence of DNA, has no effect on the 
fluorescence of ethidium it is possible to monitor the 
effect of that compound on fluorescence enhancement. 
If ethidium (or another intercalating agent) 
bound to DNA is irradiatiated with polarised light, the 
fluorescence emitted will be polarised. This 
fluorescence polarisation is due to a reduced 
rotational movement of the drug, however in the absence 
of DNA the fluorescence will be depolarised. If another 
drug also binds to the same intercalation site, it will 
displace ethidium and therefore the polarisation of 
fluorescence will be reduced. This property can be used 
to quantify the relative differences in the affinities 
- 156 - 
of drugs for DNA, and also to show that an 
intercalative mode of binding occurs. 
The effect of compounds (lA-4A, 1B-4B, 2C-3C and 
2Ci-3Ci) on the fluorescence enhancement of ethidium 
bound to DNA will be discussed first. Then the effect 
of these compounds on the polarisation of fluorescence 
of ethidium bound to DNA will be examined. 
2.2.2.1. The effect of drug on the fluorescence 
enhancement of ethidium bromide due to binding 
to DNA. 
The ability of the substituted anthraquinones 
(compounds 1A-4A, 1B-4B, 2C-3C and 2Ci-3Ci) to displace 
intercalated ethidium bromide was investigated. 
Aliquots of ethidium bromide solution were added 
sequentially to a 2. Oml volume of, each of the 
following solutions; calf thymus DNA in buffer; calf 
thymus DIA and drug in buffer (10: 1 DNAp: drug ratio); 
drug in buffer; and buffer (for details of 
experimental conditions see 3.2.2.1). The fluorescence 
of each solution was recorded after each addition, at 
596nm (excitation 476nm) at 25°C. 
For each compound investigated fluorescence 
reading vs ethidium: DNA ratio was plotted (figures 
39-41). These plots show that fluorescence enhancement, 
and hence DNA-binding, of ethidium is reduced when 
compounds (1A-4A, 1B-4B and 2Ci-3Ci) are also bound to 
DNA. However in the case of pro-drugs (compounds 2C-3C) 
there was no significant change in the fluorescence 
enhancement due to ethidium binding to DNA, indicating 
- 157 - 
200 
180 
160 
140 
120 
., 4 
C 
0) 
. 0100 c 
H 
a) 
U 
v 80 U) 
a, 
0 
60 
40 
20 
0 
70.0 
Figure 39 : Effect of doxorubicin and 2'-(diethyl- 
amino)ethylamin6-substituted anthraquinones 
(1A-4A) on the fluorescence enhancement of 
ethidium binding to DNA. 
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Figure 40 : Effect of doxorubicin and 2'-(hydroxy- 
ethylamino)ethylamino-substituted anthra- 
quinones (1B-4B) on the fluorescence 
enhancement of ethidium binding to DNA. 
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Figure 41 : Effect of prodrugs (2C & 3C) and their 
"metabolites" (2Ci & 3Ci) on the 
fluorescence enhancement of ethidium 
binding to DNA. 
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that the pro-drugs do not bind to DNA. 
The monosubstituted anthraquinones (lA & 1B) had, 
the least effect on the fluorescence enhancement, 
whilst the 1,5-substituted anthraquinones (2A & 2B) 
caused a maximal change. These results show that 
substituted anthraquinones are able to displace 
ethidium from its binding (intercalation) site. 
It has recently been shown that certain 
intercalating agents (for example m-AMSA), reduce the 
fluorescence of ethidium bound to DNA without 
physically displacing it (Baguley & Le Bret, 1984). 
This reduction in fluorescence intensity may be as a 
result of reversible formation of electron-transfer 
complexes between the intercalating drug and the 
excited state of ethidium. Therefore in order to 
distinguish between ethidium displacement and formation 
of' electron-transfer complexes a more selective method 
was also used in this work. 
When a molecule binds to DNA, by intercalation, 
the molecule is constrained in its orientation in the 
time between exitation and fluorescence. If a solution 
of DNA-drug complex is irradiated with plane polarised 
light, fluorescence emmitted by the drug molecule will 
also be polarised. Therefore the effect of varying DNA 
concentrations on the polarisation of ethidium was 
investigated. 
Aliquots of DNA solution were sequentially added 
to each of three separate cuvettes containing ethidium 
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"bromide and also to one cuvette containing buffer. 
After each addition the polarisation, P, of 
fluorescence was measured, (see 3.2.2.2 for details). A 
graph of polarisation (P) vs DNA: ethidium ratio was 
plotted (figure 42). From this graph it can be seen 
that the polarisation increases with increasing 
DNA: ethidium ratio up to a maximal value (P=0.26), at a 
DNA: ethidium ratio of 6: 1. At DNA: ethidium ratios of 
greater than 6: 1 all the ethidium will be bound to DNA 
and the DNA will therefore have some unoccupied sites. 
However, at low DNA: ethidium ratio (less than 4.5: 1) 
all the binding sites are occupied by ethidium, 
therefore if another intercalating agent is added some 
of the ethidium will be displaced by the drug. This 
property may be utilised in quantifying the relative 
differences in the affinity of drugs to DNA. 
2.2.2.2. The effect of drug on the fluorescence 
polarisation of ethidium bound to DNA. 
Aliquots of drug solution were added, to each of 
eleven flasks containing DNA: ethidium (4: 1) solution, 
to give a range of concentrations. Aliquots of drug 
solution were similarly added to controls containing 
ethidium only. Fluorescence polarisation of solution in 
each of the flasks was determined and the % of ethidium 
bound to DNA calculated from: 
%binding 
Psamele_____Pcontrol 
X 100 
p 
max 
where Psample is the polarisation of DNA+ethidium+drug, 
Pcontrol is the polarisation of drug+ethidium and Pmax 
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substitution Concentration 
pattern required to displace 
Compound 50% of gthidium 
(M x 10 ) 
Doxorubicin - 0.70 (0.02)1 
2'- (Diethylamino)ethylaminoanthraquinones 
1A 1- 7.50 (0.05) 
2A 1,5- 0.85 (0.01) 
3A 1,8- 3.50 (0.04) 
4A 1,4- 0.35 (0.02) 
2'-(Hydroxyethylamino)ethylaminoanthraquinones 
1B 1- 5.00 (0.08) 
2B 1,5- 0.90 (0.02) 
3B 1,8- 0.90 (0.03) 
4B 1,4- 0.50"(0.01) 
Prodrugs and "metabolites" 
2Ci "metabolite" 2.60 (0.05) 
2C prodrug >40.0 (-) 
3Ci "metabolite" 2.50 
. 
(0.04) 
3C prodrug >40.0 (-) 
1 Standard deviation (n = 9). 
Table 4: Displacement of ethidium bromide by 
doxorubicin, substituted anthraquinones, and prodrugs. 
is the polarisation of DNA+ethidium (4: 1 ratio). 
The experiment was repeated at least nine times 
for each compound in order to ensure that the results 
were statistically reliable. A graph of %Binding of 
ethidium vs drug concentration was plotted for each of 
the compounds prepared in this work (figures 43-45). 
From these binding isotherms it can be seen that the 
displacement of ethidium from its binding site, by 
doxorubicin and the substituted anthraquinones (1A-4A, 
1B-4B, and 2Ci-3Ci), is qualitatively similar. However 
the prodrugs (2C & 3C) do not have any significant 
effect on the displacement of ethidium. The 
concentrations of drug required to displace 50% of 
ethidium are given in table 4. 
It was shown that significantly (P < 0.02, n=9) 
lower concentrations of 1,4-substituted anthraquinones 
(4A & 4B, 0.35 and 0.50 x 10-6M respectively) are 
required to displace ethidium from DNA than is required 
for doxorubicin (0.70 X 10-6M) or 1,5-substituted 
anthraquinones (2A & 2B, 0.85 and 0.90 x 10-6M 
respectively). However doxorubicin and the 
1,5-disubstituted anthraquinones have higher affinity 
constants and, as shall be seen later, higher A Tms. 
This may be because the 1,5-substituted anthraquinones 
can only bind to DNA by "straddling" (see 2.2.1.3), 
whilst the 1,4-substituted anthraquinones may bind to 
DNA without the requirement for DNA breathing. In the 
previous experiment, when ethidium was added to a 
DNA-drug complex, it was shown that 1,5-substituted 
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anthraquinones had a maximal effect on the inhibition 
of fluorescence enhancement of ethidium binding to DNA. 
This apparent anomaly may be due to the 1,5-substituted 
anthraquinones dissociating less readily from DNA than 
do the 1,4- derivatives. 
Higher concentrations of monosubstituted 
anthraquinones, (7.5 and 5.0 x 10-6M for 1A & 1B 
respectively), and 1-8-substituted anthraquinones, (3.5 
and 0.8 x 10-6M for 3A & 3B respectively), are required 
to displace ethidium from its binding site. These 
values correlate with the relative affinity constants 
for each compound tested. 
In the case of the prodrugs these compounds did 
not displace ethidium to any significant extent at 
concentrations of 4x 10-5M, this concentration is 
twenty fold greater than that at which the metabolites 
give displacement of ethidium. 
It has so far been shown both qualitatively and 
quantitatively that the anthraquinones synthesised in 
this work do indeed bind to DNA by intercalation, 
whilst their azo derivatives (prodrugs) do not. In 
order to further investigate the interaction of these 
anthraquinones with DNA, further studies were designed 
to show whether the DNA helix is stabilised to heat 
denaturation by these compounds and also whether on 
binding, these compounds cause unwinding of the DNA in 
order to accomodate the drug. 
- 16q - 
2.2.3. Effect of drug on the physical properties of 
DNA. 
2.2.3.1. Effect of drug on thermal denaturation 
properties of DNA. 
When double-stranded DNA molecules are subjected 
to increase in temperature or extremes of pH, the DNA 
denatures to give two single-stranded molecules as a 
result of rupturing of the hydrogen bonds in the double 
helix. On denaturation there is an increase in 
absorbance of the DNA solution, so the change in 
absorbance can be used to monitor denaturation (Marmur 
and Doty, 1962). The temperature at which half the 
total increase in absorbance has occurred is known as 
the melting (or transition) temperature (Tm). 
The intercalation of a drug molecule into the 
DNA helix stabilises the macromolecule such that more 
energy is required to separate the two strands. Thus 
the Tm of DNA is increased due to a change in enthalpy 
(Zunino et al., 1972). However if the drug binds 
externally to the helix then there is generally no 
significant change in the Tm. By measuring the change 
in the absorbance with temperature of the DNA solution 
at . the DNA X max (260nm), in the presence and absence 
of the drug, the A Tm (difference inTm's) can be 
determined. This is a measure of the stability of the 
drug/DNA complex. The increased stability imparted to 
the DNA helix by the drug is a measure of the affinity 
of binding. It should be noted however, that thermal 
stability of DNA is also influenced by changes in ionic 
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strength. As the ionic strength is increased, so is the 
stability of the helix, and hence the Tm. Furthermore 
the stability of the DNA helix is also affected by 
changes in the base composition; DNAs with high 
guanine-cytosine content have higher Tms than DNAs with 
high adenine-thymine content (Marmur and Doty, 1962). 
The Tm of calf thymus DNA in absence of drug was 
shown to be 71.2 ± 0.1°C in pH7.4, Tris (2.88mM), NaCl 
(18mM), buffer. The Tm values obtained for DNA, DNA and 
either substituted anthraquinones or doxorubicin (at 
10: 1 DNA/drug ratio) are shown in table 5. Typical 
melting curves for DNA and DNA+drug (compound 1A) are 
shown in figure 46. 
However in the case of DNA/anthraquinone 
complexes of (2A) and (4A) it was shown that the change 
in absorbance at 260nm was not an accurate measure of 
DNA melting. The increase in absorbance was 
significantly higher (80%) than that of DNA alone 
(50%). This was due to the bound drug having a lower 
extinction coefficient than the free drug at 260nm; 
both compound (2A) and (4A) have X max, in the uv 
region, close to the X max of DNA. At the isosbestic 
point there will be little (or no) change in the 
absorbance due to the release of drug as DNA denatures. 
In this way it was possible to monitor change in the 
absorbance of DNA at the isosbestic points, in the UV 
region (figure 47), of DNA+compound 2A (245nm) and 
DNA+compound 4A (268nm). The isosbestic points in the 
UV region of the spectrum were determined as follows. 
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Figure 46 : Melting curves of DNA (curve a) and 
DNA+anthraquinone (IA) (curve b), in the 
temperature range 58° - 94°C. 
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Figure 47 : Melting curves of DNA+anthraquinone (2A) at 
260 (curve a) and at isosbestic point, 
245nm, (curve b) in the temperature range 
700 - 1100. 
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Compound Tm(DNA)2 Tm(DNA+drug )2 ATm2 
Doxorubicin 71.2°C 87.5°C 16.3°C 
2'-(Diethylamino)ethylamino anthraquinones 
1A (1-) 1 71.2 80.0 8.8 
2ý (1,5-) 71.2 98.4 27.2 
2 71.2 96.3 25.1 
3A (1,8-) 71.2 80.7 9.5 
4j (1,4-) 71.2 92.5 21.3 
4 71.2 90.2 20.0 
2'-(Hydroxyethylamino)ethylamino anthraquinones 
1B (1-) 71.2 79.2 8.0 
2B (1,5-) 71.2 94.8 23.6 
3B (1,8-) 71.2 89.4 18.2 
4B (1,4-) 71.2 90.7 19.5 
Prodrugs and their potential metabolites 
2C 71.2 71.3 0.1 
2Ci 71.2 80.1 8.9 
3C 71.2 71.4 0.2 
3Ci 71.2 78.4 7.2 
'The 
numbers in brackets refer to substitution patern. 
2Mean 
Tm values 
± 0.1°C in all cases, (n=60, for DNA; 
n=4 for DNA+drug). 
3Tm 
at isosbestic point in the UV region. 
Table 5: ATm values for calf thymus DNA incubated 
with substituted anthraquinones (pH7.4, 
0.018M NaCl, 0.00288M Tris buffer). 
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The spectra of DNA+drug were recorded against DNA 
blanks (see 3.2.1.2); the concentrations of DNA in both 
reference and sample cuvette were identical and 
therefore only the effect of DNA on the absorbance 
spectrum of drug was recorded. Using this method, 
compounds (2A) and (4A) showed isosbestic points at 245 
and 268nm respectively. These wavelengths were used to 
determine the ATms of these anthraquinones. 
From these data it was shown that all 
aminoalkylamino substituted anthraquinones (lA-4A, 
1B-4B, and 2Ci-3Ci) stabilise DNA to thermal 
denaturation; however the azoanthraquinones (2C, 3C) 
were not shown stabilise DNA to any siginificant extent 
(A Tm < 0.2°C). The monosubstituted anthraquinones (lA 
and 1B) have ATm values (8.8 and 8.0°C respectively) 
less than that obtained with doxorubicin (16.3°C), and 
this is consistent with the lower affinity of these 
anthraquinones as shown by data already discussed (see 
2.2.1 and 2.2.2). The 1,5-substituted anthraquinones 
(2A and 2B) and the 1,4-substituted anthraquinones (4A 
and 4B) give significantly higher ATms than 
doxorubicin. This may be due to the 1,5- and 
1,4-substituted anthraquinones dissociating less 
readily, from DNA, than does doxorubicin as shown 
previously (2.2.1.3). 
The &Tm values obtained in this work gives some 
indication of binding ability of drug to DNA. Further 
evidence of the nature of the interaction of these 
anthraquinones with DNA can be obtained by examining 
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the effect of drug on covalently closed circular DNA 
(cccDNA). 
2.2.3.2. Effect of drug on covalently closed circular 
DNA (PM-2 DNA). 
The effect of substituted anthraquinones on the 
unwinding of bacteriophage PM-2 DNA was examined by gel 
electrophoresis. All cccDNAs share the following 
properties: they contain a covalently closed double 
stranded polydeoxynucleotide and, as shown elsewhere. by 
examination under an electron microscope, they are 
supercoiled (Adams et al., 1976). The supercoiling 
makes this type of DNA unusually compact and it 
therefore has an abnormally high sedimentation 
coefficient. When a drug intercalates into DNA, to 
accomodate the drug, local unwinding of the helix must 
occur, resulting in an increase in E, the average 
number of base-pairs per turn. Consequently, the 
number of supercoils must change as 
.2 
is varied. It 
has previously been shown that during the initial 
stages of intercalation of drug, the number of 
right-handed supercoils decrease (figure 48) and the 
sedimentation coefficient of closed circular DNA falls 
(Crawford and Waring, 1967). At a critical level of 
binding the initial deficiency of turns in the closed 
circular molecules is just balanced by the increase in 
p due to accumulated drug-induced unwinding and the 
molecules behave as relaxed open circles. As further 
drug binding occurs, the additional unwinding forces 
the open circles to supercoil in the opposite sense 
- 176 - 
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Figure 48: Effect of ethidium on the superhelical 
density of cccDNA (from Waring, 1981). 
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a 
resulting in an increase in the sedimentation 
coefficient. 
A major disadvantage of employing sedimentation 
velocity drug titrations is that the procedure requires 
large amounts of DNA and drug, furthermore only one 
concentration of drug may be use per centrifugation and 
therefore this method is also relatively time 
consuming. Alternatively, agarose gel electrophoresis 
can be used to separate covalently closed circular DNA 
from the relaxed covalently open circular DNA molecules 
of the same molecular weight (Keller et al., 1974). If 
the superhelical density of DNA is known then it is 
possible to determine the degree of DNA unwinding by 
the drug providing the affinity constant (K) and the 
number of drug molecules bound per base pair (n) is 
known. For the anthraquinones used in this work the K 
and n values were determined by means of 
spectrophotometric titration. 
Agarose gels containing differing concentrations 
of drug were prepared and the DNA+drug complex layered 
on top together with bromophenol blue. Bromophenol blue 
and cccDNA are negatively charged at pH 7.4 and 
therefore migrate towards the anode.. The 
anthraquinones, on the other hand, are positively 
charged at pH7.4 and migrate towards the cathode. It is 
possible to perform the titration with dye solely in 
agarose gels if the electrophoresis is stopped before 
the DNA band reaches the ascending boundary of the 
drug. In this way it is possible to run many gels 
- 178 - 
Figure 49: Gel electrophoresis of ccc-DNA (PM-2) in the 
presence of a range of concentrations of 
compound (3A), from left to right 0,0.1, 
0.2,0.3,0.4,0.5,0.8 and 1.0 pg/ml. 
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Figure 50: Gel electrophoresis of ccc-DNA (PM-2) in the 
presence of a range of concentrations of 
compound (1A), 0,1.0,2.0,3.0,4.0,5.0, 
8.0, and 10.0 ug/ml. 
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Critical 1 Unwinding angle2 Compound Concentration (Id) 
(M x 10 ) 
Ethidium 2.759 
Doxorubicin 2.759 
26.0 
14.3 
2'-(Diethylamino)ethylamino anthraquinones. 
1A (1-) 4 22.30 10.6 
2A (1,5-) 3.15 14.2 
3A (1,8-) 7.874 14.3 
4A (1,4-) 3.15 14.2 
4ý+ 
2'-(Hydroxyethyl)aminoethylamino anthraquinones 
1B (1-) 23.09 12.46 
2B (1,5-) 3.93 13.51 
3B (1,8-) 7.86 11.65 
4B (1,4-) 3.93 18.02 
Prodrugs and their "metabolites" 
2C3 »1000 - 
2C4 22.30 10.7 
3C »1000 - 
3Ci 22.30 10.7 
1 Concentration of drug at which the PM-2 DNA almost 
co-migrated with nicked DNA. 
2 The degree of local unwinding of the DNA helix due to 
each molecule of drug' bound to DNA. 
3 These azo anthraquinones did not have any effect on 
the migration of PM-2 D$1A in the concentration range 
used (1 x 10 M to 1x 10 M). 
4 The numbers in brackets refer to the substitution 
pattern. 
Table 6: "Critical concentrations" and calculated 
unwinding angles of cccDNA obtained with 
ethidium bromide doxorubicin, and substituted 
anthraquinones. 
I 0I 
containing differing concentrations of drug at the same 
time. This method has previously been used to determine 
the superhelical densities of a number of cccDNAs 
including PM-2 DNA (Espejo and Lebowitz 1976). Hence 
knowing the superhelical density it is possible to 
calculate, the degree of DNA unwinding caused by each 
molecule of drug. In this work a method based on that 
described by Espejo and Lebowitz (1976) was used. 
Electrophoresis of PM-2 DNA in the presence of 
aminoalkylamino anthraquinones showed that, as with 
ethidium and doxorubicin, the rate of migration of PM-2 
DNA decreased as drug' concentration increased (i. e. the 
DNA was unwound); this reached a minimal value when the 
DNA almost co-migrated with the nicked PM-2 present in 
the PM2 DNA sample. As the drug concentration was 
increased further, the rate of migration increased 
progressively (i. e. DNA was supercoiled in the opposite 
sense). Figures 49 and 50 show typical electrophoretic 
runs. The concentration of drugs at which the DNA 
almost co-migrated with nicked DNA, the critical 
concentrations, are shown in table 6. 
To calculate the degree of unwinding due to each 
bound molecule of drug, it is necessary to know the 
superhelical density of the PM-2 DNA and the number of 
drug molecules bound per DNA phosphate when the 
supercoils in the PM-2 DNA are totally unwound. The 
latter was calculated from the Scatchard equation: 
Kc n 
r= ------ (1) 
1+Kc 
, ems 
a 
K and n were determined for each drug (see 2.2.1.2. ), 
and substituting c' (for c), the critical concentration 
of drug, into equation (1) yields the value of r', the 
number of drug molecules/DNA phosphate which gives full 
relaxation 'of the supercoiled DNÄ. The method of 
calculating unwinding angle was that used by Espejo and 
Lebowitz (1976) and DeLeys and Jackson (1976), and is 
as follows: 
-10, Or' 
0-0= (2) 
180 
where a-0 is the superhelical density of PM-2 DNA and rd 
is the unwinding angle. The superhelical density for 
PM-2 DNA quoted by Espejo and Lebowitz is 0.042 based 
on an unwinding angle of 12° for ethidium; this has now 
been corrected and the currently accepted value for the 
unwinding angle for ethidium is 26° (Waring, 1981): the 
amended value for the unwinding angle produces a 
recalculated value of 0.0911 as the superhelical 
density for PM-2 DNA. Equation (2) thus becomes: 
1.638 
-0= ------ (3) 
r' 
The critical concentrations of drug required to relax 
cccDNA are shown in table 6. Using the K and n values 
from the Scatchard plots (table 2), the unwinding 
angles were calculated (table 6). From these results it 
can be seen that all substituted anthraquinones unwind 
cccDNA whilst the prodrugs have no significant effect 
on the migration of cccDNA. The local unwinding of the 
helix will only occur if the drug intercalates. These 
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results again show that the substituted anthraquinones 
interact with DNA by intercalation. 
To summarise the results so far; it has been 
shown that the substituted anthraquinones (lA-4A, 
1B-4B, and 2Ci-3Ci) a) unwind cccDNA, b) stabilise DNA 
to thermal denaturation, c) displace ethidium bromide 
from it intercalation site, d) have dissociation and 
affinity constants of the same order as doxorubicin, 
and e) exhibit isosbestic points on binding to DNA. 
These observations prove the hypothesis that these 
compounds interact with DNA by intercalation. 
Furthermore the prodrugs which were designed not to 
intercalate into DNA do not exhibit any of the above 
mentioned properties, and therefore do not intercalate 
into DNA. 
" 2.2.4. Additional methods used previously in DNA-drug interaction studies. 
Several literature methods have previously been 
described in the study of DNA-drug interactions 
(Waring, 1981; Wilson & Jones, 1981; Reinert, 1983; 
Patel, 1979). In recent years extensive use has been 
made of high resolution NMR to study the interaction of 
drugs with DNA (Patel, 1979), including studies of the 
interaction of daunorubicin with synthetic 
polynucleotides (Patel and Canuel, 1978; see 1.8.1). It 
has been recently shown elsewhere by NMR studies that 
1,5-bis[2'-(diethylamino)ethylamino]anthraquinone, 
compound (2A), has some preference for A-T sites on 
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DNA, (Feigon, et al., 1984); this is consistent with 
the "straddle" mode of binding of this compound to DNA, 
proposed from this work, since A-T regions have a 
higher population of transient base-pair disruptions. 
Circular dichroism studies have shown that the 
interaction of daunorubicin with DNA produces 
characteristic alteration in the CD spectrum of the 
drug, which vary with DNA-drug ratios (Krug & Young, 
1977). 
In order to monitor changes in the properties of 
drug on binding to DNA, electrochemical and physical 
methods have been utilised in addition to spectroscopic 
methods. Furthermore polarography was used to determine 
whether quinone-containing drugs intercalate into DNA, 
since there is a reduction in the wave height at the 
half-wave potential on binding of the drug to DNA 
(Calendi et a-l., 1965; Berg et al., 1981). 
When a drug intercalates into DNA there is a 
stiffening of the DNA molecule together with an 
increase in length. This results in an increase in 
viscosity of the DNA solution (Lerman, 1961). Therefore 
by monitoring this change in viscosity of a DNA 
solution on addition of drug, it is possible to 
determine if the drug intercalates (Berg & Echart, 
1970). In addition to changes in viscosity, there is a 
characteristic change in the sedimentation coefficient 
of DNA (Zunino et al., 1972, Waring, 1981). 
Equilibrium dialysis has been used previously to 
determine binding constants for DNA-drug interactions 
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(Zunino et al., 1972). In this method, the unbound drug 
molecules are allowed to equilibrate with DNA across a 
semipermeable membrane. After equilibration, the drug 
concentration is measured on both sides of the membrane 
and, knowing the total drug and macromolecule 
concentrations, the concentration of bound and free 
drug may be determined. Other methods where the free 
drug is physically separated from DNA-drug complex 
include ultracentrifugation, ültrafiltration, and 
partition methods. 
None of the above methods were used in this work 
since the use of spectrophotometric and electrophoretic 
methods have shown conclusively that the 
aminoalkylamino-substituted anthraquinones intercalate 
into DNA and allowed determination of the affinity 
constants and dissociation rate constants. 
It was shown in this work (see 2.2.1 - 2.2.3) 
that prodrugs of anthraquinones do not interact with 
DNA. However these prodrugs were designed such that 
active anthraquinones would be liberated in the target 
tissue (in this case liver). It was therefore important 
to determine whether the target tissue was capable of 
metabolising these prodrugs to release the 
corresponding aminoanthraquinones. 
2.3. PRELIMINARY STUDIES OF AZOANTHRAQUINONE 
METABOLISM BY LIVER FRACTIONS in vitro. 
One of the functions of the liver is to 
eliminate lipophylic compounds via metabolism to more 
polar metabolites. Therefore liver cells contain 
1QG 
several hundred types of enzymes capable of a number of 
biochemical reactions including conjugation, 
hydroxylation, oxidation and reduction of foreign 
compounds. Azo dyes have been widely used as colour 
additives in food and cosmetics. Reductive clevage of 
azo compounds by liver yields the corresponding amines 
(Miller and Miller, 1948, Muellier and Miller, 1950). 
It has previously been shown that mammalian 
azoreductase activity is mainly localised in the liver 
microsomes (Miller and Miller, 1948; Walker, 1976; 
Fujita and Peisach, 1982). It has also been shown that 
azobenzenes may be reduced to the corresponding 
aminobenzenes by rat liver microsomes in vitro under 
anaerobic conditions in the presence of NADPH (Mueller 
and Miller, 1950). Subsequently it has been shown that 
purified NADPH-cytochrome c reductase catalyses the 
reduction of azo dyes to primary amines (Hernandez 
et al., 1967; Fujita and Peisach, 1982). However, not 
all of the liver microsomal azoreductase activity could 
be attributed to this flavoprotein; some of the 
azoreductase activity was inhibited by carbonmonoxide, 
suggesting the possible involvement of cytochrome P-450 
(Fujita and Peisach, 1976). Furtheremore cytochrome b5 
was also reported to function as an electron carrier in 
the metabolism of azo compounds (Fuijita and Peisach, 
1977). Thus microsomal azoreductase system may consist 
of several different enzymes. Azoreductase activity has 
also been reported in the hepatic cytosol (Huang 
et al., 1979) in this case either NADH or NADPH may 
function as electron donors (Daniel, 1969). 
- 187 - 
The azoanthraquinones (compounds 1C-3C) were 
designed to be metabolised by liver to the 
corresponding aminoanthraquinones (1-aminoanthra- 
quinone, compounds 2Ci & 3Ci). Therefore the metabolism 
of these compounds was " examined in vitro using 
microsomal and cytosolic fractions from rat liver. The 
methods for preparing these subcellular fractions are 
described in chapter 3. 
The azoanthraquinones were not very soluble in 
aqueous media and therefore concentrated solutions 
(lmg/ml) of each drug in ethanol were prepared. A 
solution of the appropriate drug (O. lml) was added to 
each of five tubes containing either microsomal or 
cytosolic fraction, buffer, and NADPH regenerating 
system, or NADH in the case of cytosolic fraction (see 
chapter 3) at 0°C. Controls were set up so that any 
non-specific azo reduction could also be determined. 
The following controls were used: 
Drug + 
1. Buffer 
2. NADPH regenerating system (or NADH) + buffer. 
3. Micromosomal (or cytosolic) fraction + buffer 
4. Heat denatured microsomal (or cytosolic) fraction + 
NADPH regenerating system (or NADH) + buffer. 
Nitrogen (02 free) was bubbled through all the mixtures 
to attain near anaerobic conditions and the tubes 
sealed, since the azoreductase activity of microsomal 
preparation is reduced in the presence of oxygen. 
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Preliminary work showed that the metabolism of 
these prodrugs was essentially complete after four 
hours under the conditions described. The tubes were 
incubated at 37°C for 0,0.5,1.0,2.0 and 4.0 hours 
and the mixture extracted with dichloromethane after 
addition of sodium hydroxide. The organic layer was 
carefully removed and an aliquot (20i1) spotted onto a 
TLC sheet, using the appropriate aminoanthraquinone and 
azoanthraquinone as standards. 
Since there is a difference in the Rfs of 
azoanthraquinone and aminoanthraquinones, TLC was 
chosen as a method to show if metabolism of 
azoanthraquinones had taken place. This method has the 
advantage over spectrophotometric assay, in that other 
metabolites which may be formed can also be detected. 
It was shown that all azoanthraquinones could be 
reduced by both microsomal and cytosolic fractions. In 
the case of cytosolic reduction, the azoreduction 
proceeded without the addition of NADH, this could 
possibly be due to the presence of some NADH in the 
cytosolic fraction. However the amount of 
aminoanthraquinone formed was considerably less than in 
the presence of NADH. None of the other controls showed 
any metabolism of the azoanthraquinones. 
During the incubation period two spots were 
formed for each of the pro-drugs, the first spot had 
the same colour and Rf as the pro-drug (0.5,0.3, and 
0.3 respectively for compounds 1C, 2C and 3C). The 
intensity of this spot decreased as the incubation 
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progressed. The second spot had the same colour and Rf 
as the corresponding amino anthraquinones (0.8,0.5, 
0.55 respectively for 1-aminoanthraquinone, compounds 
2Ci and 3Ci), the intensity of this spot increased in 
parallel to the decreasing intensity of the spot 
corresponding to the pro-drug. In all cases the prodrug 
spot could not be detected, (neither by visible 
inspection nor under UV light) within one hour, in the 
microsome incubates, and one and half hours in cytosol 
incubates. 
These preliminary studies showed that it is 
possible to design prodrugs of anthraquinones, which 
yield anthraquinones capable of interacting with DNA 
when metabolised by liver. 
All anthraquinones prepared in this work were 
screened for antitumour activity in vitro and in vivo; 
the results obtained will be described briefly in the 
following section. 
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2.4. ANTITUMOUR ACTIVITY 
The compounds prepared in this work were 
designed to be potential antitumour agents and 
therefore the antitumour properties of these drugs 
in vitro and in vivo were investigated. The substituted 
anthraquinones (1A-4A and 1B-4B), anthraquinone 
prodrugs (2C & 3C) and their metabolites (2Ci & 3Ci) 
have been evaluated for their antiproliferative 
activity in vitro using CCRF-CEM human leukaemia cells 
by Lilly Research Centre, Windlesham, Surrey. The 
substituted anthraquinones (lA-4A and 1B-4B) have also 
been screened for their antiproliferative. activity 
in vitro against HeLa cells, essentially by a similar 
method to that described by Uyeki et al., (1981), 
(performed by M. Partridge, Leicester Polytechnic, 
Leicester). The first series of anthraquinones (lA-4A) 
have been evaluated for their activity against P-388 
leukaemia in vivo by the Cancer Research Campaign 
Experimental' Cancer Chemotherapy Unit, University of 
Aston, Birmingham. The testing procedures have not 'yet 
been completed but the results obtained to date are 
shown in Tables 7-9. 
From the results obtained to date, compounds 
1A-4A do not show any significant activity (table 9) 
against mice bearing P-388 leukaemia in vivo. However 
all compounds showed antiproliferative activity 
in vitro: compound (4B) was shown to be the most potent 
(IC500.2jiM) against CCRF-CEM human leukaemia. Compound 
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Compound Substitution 
pattern 
IC5001m) IC50(µg/ml) 
( 2'-Diethylamino)ethylamino anthraquinones 
1A 1- 5.02 1.8 
2A 1,5- 1.77 0.9 
3A 1,8- 2.55 1.3 
4A 1,4- 3.34 1.7 
(2'-H ydroxyethylamino)ethylamino anthraquinones 
1B 1- 5.48 1.9 
2B 1,5- 1.44 0.7 
3B 1,8- 1.23 0.6 
4B 1,4- 0.21 0.1 
"Pro drugs" and their metabolites 
2Ci - 4.82 1.8 
2C - 10.48 4.8 
3Ci - 4.82 1.8 
3C - 23.58 10.8 
Table 7: Antiproliferative activity of anthraquinones 
in vitro (CCRF-CEM human leukaemia assay). 
Performed by Lilly Research Centre, 
Windlesham, Surrey. 
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Compound Substitution IC50(jiM) 
pattern" 
Mitoxantrone 1,4-1 1.0 
(2'-Diethylamino)ethylamino anthraquinones 
1A 1- 51.0 
2A 1,5- 9.0 
3A 1,8- 27.0 
4A 1,4- 25.0 
(2'-Hydroxyethylamino)ethylamino anthraquinones 
1B 1- 17.0 
2B 1,5- 2.6 
3B 1,8- 5.7 
4B 1,4- 1.0 
1Mitoxantrone is a 5,8-dihydroxy substituted analogue 
of compound 4B. 
Table 8: Antiproleferative activity of anthraquinones 
in vitro against HeLa cells. Performed by 
M. Partridge, Leicester Polytechnic, 
Leicester. 
6 
- 1012 
0 
Compound Dose 
_l 
Schedule T/C 
mg. kg 
1A 16 QO1DX01 95 
8 100 
4 100 
2 98 
1 105 
2A 128 QO1DXO1 92 
64 105 
32 100 
16 105 
8 98 
4 107 
2 98 
1 102 
3A 8 QO1DXO1 107 
4 105 
2 104 
16 Q04DXO3 102 
8 98 
4 91 
4A 128 0O1DXO1 111 
64 97 
. 
32 103 
16 112 
8 107 
4 100 
2 95 
1 117 
T/C= % survial of drug treated mice/controls. T/C 
values <120 are not significant. 
Daunorubicin at 16mg. kg on a QO1DX01 schedule gave T/C 
143 and at 4mg. kg on a Q04DX03 schedule gave T/C 128. 
Table 9: In vivo activity of 2'(diethylamino)ethyl- 
amino-substituted anthraquinones (IA-4A) 
against leukaemia P-388. Performed by by the 
Cancer Research Campaign Experimental Cancer 
Chemotherapy Unit, University of Aston, 
Birmingham 
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(4B), ametantrone, was originally synthesised by 
Murdock et al., (1979) and Zee Cheng and Cheng (1978) 
and is currently in Phase II clinical trials. 
The (2'-hydroxyethyl)aminoethyl anthraquinones 
show a greater antiproliferative activity in vitro than 
do the corresponding (2'-diethylamino)ethylamino 
analogues against HeLa and CCRF leukaemia cells. The 
monosubstituted anthraquinones (lA & 1B) are 
significantly less active than the disubstituted 
anthraquinones. 
The 1,5-bis-substituted anthraquinone (2A) was 
the most potent of the (2'diethylamino)ethylamino- 
substituted anthraquinones (A series) (IC50 1.7711M and 
8.2µM vs CCRF human leukaemia and HeLa cells 
respectively) in vitro. The 1,8-bis-substituted 
anthraquinone (3A) showed higher antitumour activity 
than the 1,4-bis-substituted anthraquinone (4A), 
against CCRF human leukaemia (IC50 2.55 and 3.34µM 
respectively for compounds 3A and 4A). However 
compounds (3A) and (4A) are almost equipotent (IC50 
27.0 and 25. OpM respectively) against HeLa cells. 
The 1,4-bis- substituted anthraquinone (4B) was 
the most potent of the (2'-hydroxyethylamino)ethyl- 
amino-substituted anthraquinones (B series), (IC50, 
0.21 and 0. lilM respectively against CCRF human 
leukaemia and and HeLa cells) in vitro. The 1,8-bis- 
substituted anthraquinone (3B) (IC50 1.23pM) was more 
effective than the 1,5-bissubstituted anthraquinone 
(2B) (IC50 1.44; 1M) against CCRF human leukaemia. 
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However compound (2B) was more potent than compound 
(3B) (IC50 2.6 and 5.7jM respectively) against HeLa 
cells. 
These data are not exactly as predicted from the 
DNA binding studies and this could be due to several 
factors. For example, the compounds may bind 
differentially to components, such as proteins, present 
in the growth medium. However it can clearly be seen 
from the results presented in this work that the 
disubstituted anthraquinones have a greater 
antiproliferative activity in vitro than the 
monosubstituted analogues. Furthermore the presence of 
the hydroxyethylaminoethylamino side chain further 
enhances the potency of these compounds. This is 
supported by recent reports on the clinical 
effectiveness of mitoxantrone and ametantrone in the 
treatment of cancer (Estay et al., 1983; Loesch et al., 
19 83 ) 
The prodrugs (compounds 2C and 3C) and their 
metabolites have been tested only against CCRF human 
leukaemia in vitro. The metabolites were found to be 
significantly more active than the prodrugs, as 
predicted by the DNA binding studies. Metabolites of 
these prodrugs (2Ci and 3Ci) were equipotent (IC 50 
4.82pM) and only marginally more active than compound 
(lA; IC 50 5.02NM), showing that the presence of an 
aromatic amino group at position 4 or 5 of the 
anthraquinone chromophore does not significantly alter 
the activity of monosubstituted anthraquinones. 
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Compound 2C (IC 50 10.48. M) was more potent than 
compound 3C (IC 50 23.58pM). This reduction in potency 
of the pro-drugs may be due to the fact that the 
compounds need to be metabolised in vivo by the liver 
to the parent amino anthraquinone before they can 
interact with DNA; in accordance with their design. 
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3. EXPERIMENTAL 
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3.1. SYNTHESIS OF SUBSTITUTED ANTHRACENE-9,1O-DIONES. 
All chemicals were purchased from the Aldrich 
Chemical Company, Gillingham. Kodak Chromagram sheets 
(No. 13181) were used for all TLC work. Unless 
otherwise stated, potassium bromide (KBr) discs were 
used for all infra-red spectroscopy, CDC13 was used as 
a solvent for 
1H NMR, and phosphate buffer (0.2M, pH 
7.0) was used for U. V. /Vis spectroscopy. Elemental 
analyses were carried out by CHN Analysis Ltd., 
Wigston, Leics. The following instruments were used in 
this work, 
Perkin-Elmer 552-S UV/Vis spectrophotometer, 
Perkin-Elmer 298 Infra-Red spectrophotometer, 
Hitachi Perkin-Elmer R 600 (60MHz) NMR 
spectrometer, 
V. C. Micromass 16F mass spectrometer. 
3.1.1. Synthesis of 2'-(diethlamino)ethylamino 
anthracene-9,10-diones (A series). 
3.1.1.1. Synthesis of 1-[2'-(diethylamino)ethylaminoi- 
anthracene-9,1O-dione (1A). 
1-Chloroanthracene-9,10-dione was purified by 
recrystallisation from nitrobenzene. 2-(Diethylamino)- 
ethylamine (98%+) was used without further 
purification. 
1-Chloroanthracene-9,10-dione (12.1g, 0.05mol) 
was dissolved in 2-(diethylamino)ethylamine (58g, 
0.5mol) and the solution heated under reflux for 2 
IAA 
hours. ' The reaction mixture was cooled in an ice bath 
and excess hydrochloric acid (10M, 100ml) added slowly 
whilst maintaining the temperature below 15°C. 
The acidic mixture was extracted sequentially 
with ether (3 X 200m1) and chloroform (3 X 200ml). The 
ethereal layers were discarded and the bulked 
chloroform extracts were dried and evaporated in vacuo. 
The residue was dissolved in deionised water, made 
alkaline (pH13), with sodium hydroxide and extracted 
with chloroform (3 X 200m1). The bulked extracts were 
evaporated in vacuo and washed several times with 
water. Finally the solid was suspended in absolute 
ethanol and the solvent evaporated in vacuo . The 
solid was dried over P205 in vacuo and recrystallised 
from absolute ethanol to yield the free base (9.67g, 
60%), Mp 156-158°C. 
" TLC Rf 0.7 (MeOH/CHC13 1/1). 
Elemental analysis: found, C 74.77, H 7.11, N 8.46%. 
Calc. for C20 H22 N2 02, C 74.51, H 6.83, N 8.69%. 
IR cm-1 ; 3285 (NH), 3000-2800 (CH2 CH3), 1660 (quinone 
carbonyl), 1585 (aromatic C=C). 
1Hnmr: 9.7 (NH, 1H); 7.2-8.3(m) (aromatic, 7H); 3.3(q) 
(CH2,2H); 2.6(m) (CH2,6H); 1.1(t) (CH3,6H). 
m/e (EI) 322 (M+), other major fragments; 250 (M-72), 
236 (M-86), 151, (M-171), 86, (M-236). 
UV % max. (e X 10-3) (HC1 salt) 495 (3.22), 315 (2.99), 
279 (5.64), 248 (16.16). 
The hydrochloride salt was prepared by 
dissolving the base in ether (sodium dried) and 
inn _ 
bubbling dry HC1 gas for 2 minutes whilst stirring the 
solution. The resultant precipitate was filtered and 
dried over P205 in vacuo. 
3.1.1.2. Synthesis of 1,5-bis-[21-(diethylamino)ethyl- 
amino]-anthracene-9,10-dione (2A). 
1,5-Dichloroanthracene-9,10-dione was purified 
by recrystallisation from toluene. 2-(Diethylamino)- 
ethylamine (98%+) was used without further 
purification. 
1,5-Dichloroanthracene-9,10-dione (5.52g, 
0.02mol) was dissolved in 2-(diethylamino)ethylamine 
(23,2g, 0.2mol) and refluxed for 4 hours. The reaction 
mixture was cooled in an ice bath and excess 
hydrochloric acid (10M, 100ml) slowly added whilst 
maintaining the temperature below 15°C using an ice 
bath. 
The acidic mixture was extracted sequentially 
with ether (3 X 200m1) and chloroform (3 X 200m1). The 
aqueous layer was made alkaline (pH 13-14) with sodium 
hydroxide, extracted with chloroform (3 X 200m1), and 
the bulked extracts dried and evaporated in vacuo. The 
solid residue was washed several times with deionised 
water, the last traces of water removed by adding 
absolute ethanol and evaporation in vacuo. The solid 
was dried over P205 in vacuo and recrystallised from 
absolute ethanol to yield the free base (4.19g, 48%), 
Mp >300°C. 
TLC Rf 0.50 (MeOH/CHC13 1/1). 
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Elemental analysis: found, C 71.31, H 8.31, N 12.60%. 
Calc. for C26 H36 N4 02, C 71.52, H 8.31, N 12.83%. 
IR cm-1 ; 3420 (NH), 3000-2800 (CH2 CH3), 1660 (quinone 
carbonyl), 1585 (aromatic C=C). 
1Hnmr: 9.7 (NH, 2H); 6.8-7.6(m), (aromatic, 6H); 
3.4(t), (CH2,4H); 2.7(m), (CH2,12H); 1.1(t), (CH31 
12H). 
m/e (EI) 435 (M-1), other major fragments; 363 (M-73), 
349, (M-87), 264, (M-172), 235, (M-201), 86, (M-350), 
58, (M-378). 
UV % max. (e X 10-3) (HC1 salt) 515 (9.50), 282 (10.72), 
231 (31.46), 201 (20.17). 
The hydrochloride salt was prepared as described 
for (IA). 
3.1.1.3. Synthesis of 1,8-bis-[2'-(diethylamino)ethyl- 
amino]-anthracene-9,10-dione (3A). 
This was prepared by the 
(2A) using 1,8-dichl 
(recrystallised from toluene, 
diethylaminoethylamine (23.2g, 
under ref lux for 3 hours. 
Yield 2.62g, (30%) of free base 
same method as compound 
oroanthracene-9,10-dione 
5.52g, 0.02mol) and 
0.2mol), with heating 
Mpt. >300°C. 
TLC Rf 0.55 (MeOH/CHC13 1/1). 
Elemental analysis: found, C 71.31, H 8.32, N 12.50%. 
Calc. for C26 H36 N4 02, C 71.52, H 8.31, N 12.83%. 
IR cm-1 ; 3280 (NH), 2790-2980 (CH2 CH3), 1670 (quinone 
carbonyl), 1585 (aromatic C=C). 
1Hnmr: 9.7 (NH, 2H); 7.1-7.5(m), (aromatic, 6H); 
)n, ) 
0 
3.25(q), (CH2,4H); 2.5(m), (CH2,12H); 1.2(t), (CH3, 
12H). 
m/e (EI) 436 (M+) other major fragments; 363 (M-73), 
350, (M-86), 235, (M-201), 100, (M-336), 86, (M-350), 
58, (M-378). 
UV X max. (E X 10-3) (HC1 salt) 536 (7.90), 316 (5.37), 
250 (9.07), 236 (33.05), 201 (23.55) 
3.1.1.4. Synthesis of 1,4-bis-[2-(diethylamino)ethyl- 
amino]-anthracene-9,10-dione (4A). 
1,4,9,10-Te trahydroxyanthracene (leucoquinizarin), 
was purified by repeated recrystallisation from 
acetone: water mixture (9: 1). 2-(Diethylamino)ethylamine 
(98%+), was used without further purification. 
1,4,9,10-Tetrahydroxyanthracene (4.84g, 0.02mol) 
was suspended in butan-l-ol (100ml) then 
2-(diethylamino)ethylamine (23.2g, 0.2mol) added 
dropwise with stirring under nitrogen (oxygen free, and 
dried). The suspension was then heated to 50-55°C for 2 
hours, using an oil bath, and allowed to stand overnight 
at room temperature. The mixture was then aerated for a 
period of 8 hours at 50-55°C and the resultant mixture 
evaporated in vacuo. The residue was dissolved in 
hydrochloric acid (2N, 200m1). The solution was then 
extracted sequentially with ether (3 X 200m1) And 
chloroform (3 X 200m1) . 
The aqueous layer was then made alkaline (pH 
13-14), extracted with chloroform (3 X 200ml), and the 
bulked extracts dried and evaporated in vacuo. The solid 
-n-4 
residue was washed several times with deionised water 
and the last traces of water removed by adding absolute 
ethanol followed by evaporation in vacuo. The solid was 
dried over P205 in vacuo and recrystallised from 
absolute ethanol to yield the free base (4.88g, 56%), Mp 
175-177°C. 
TLC Rf 0.5 (MeOH/CHC13 1/1). 
Elemental analysis: found, C 71.51, H 8.33, N 12.82%. 
Calc. for C26 H36 N4 02, C 71.52, H 8.31, N 12.83%. 
IR cm-1 ; 3420 (NH), 3000-2800 (CH2 CH3), 1660 (quinone 
carbonyl), 1585 (aromatic C=C). 
1Hnmr: 9.7 (NH, 2H); 7.2-8.4(m), (aromatic, 6H); 3.5(t), 
(CH2,4H); 2.7(m), (CH2,12H); 1.1(t), (CH3,12H). 
m/e (EI) 436 (M+), other major fragments; 236 (M-173), 
151, (M-285), 86, (M-350), 69, (M-367), 58, (M-378). 
UV %max. (e X 10-3) (HC1 salt) 626 (10.12), 582 (9.55), 
256 (24.72), 207 (17.99). 
The hydrochloride salt was prepared as described 
for (1A). 
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3.1.2. Synthesis of 2'-(h droa eth lamino)eth lamino- 
anthraquinones (B series). 
3.1.2.1. Synthesis of 1-[2'-(2-hydroxyethyl)aminoethyl- 
amino]-anthracene-9,10-dione (1B). 
1-Chloroanthraquinone was purified by 
recrystallisation from nitrobenzene. 2-Aminoethylamino- 
ethanol (97%) was used without further purification. 
1-Chloroanthraquinone (9.7g, 0.04mol) was 
suspended in 2-aminoethylaminoethanol (83.2g, 0.8mol) 
by mechanical stirring and heated to 90°C in an oil 
bath for two hours. 
The reaction mixture was cooled in an ice bath, 
and poured into deionised water (500m1). The resulting 
solid was f iltered and dried in vacuo at room 
temperature for 48 hours. The solid was suspended in 
hydrochloric acid (10N, 200m1) and stirred for 24 
hours. The mixture was centrifuged, the supernatant 
decanted, diluted with deionised water (300m1) and 
sequentially extracted with ether (4x200m1) and 
chloroform (4x200m1). The aqueous layer was made 
alkaline (pH 13-14) with sodium hydroxide and extracted 
with chloroform. The bulked organic extracts were dried 
and evaporated to dryness in vacuo and the solid 
recrystallised from chloroform: hexane (1: 1), to yield 
the free base (5.5g, 44%), Mp 106-108°C. 
TLC Rf 0.7 (MeOH/EtAc 1/1). 
Elemental analysis: found, C 67.95 H 5.96, N 8.78%. 
Calc. for C18 H18 N2 03 . 0.5H20 :C 67.96, H 5.96, N 
8.77%. 
IR Cm-1 (KBr Disc); 3400 (OH), 3260 (NH), 3000-2800 
(CH2 CH3), 1670 (quinone carbonyl), 1580 (aromatic 
C=C). 
1Hnmr: 9.9 (NH, 1H); 7.2-8.4(m), (aromatic, 7H); 
4.1(s), (OH); 3.5(m), (CH2,8H); 2.4(s), (NH-aliphatic 
side chain). 
m/e (EI) 311 (M+1), other major fragments; 237 (M-73), 
222, (M-87), 74, (M-236). 
UV % max. (E X 10E 
3) in phosphate buffer (0.2M, pH7.0) 
(HC1 salt) 498 (6.23), 313 (5.82), 278 (10.6), 247 
(32.29). 
The hydrochloride salt was prepared by 
dissolving the base in 2-methoxyethanol and bubbling 
dry HC1 gas for 2 minutes whilst stirring the solution. 
Diethylether was then added to the solution, the 
resultant precipitate filtered and dried over P205 in 
vacuo. 
3.1.2.2. Synthesis of 1,5-bis-[2'-(2-hydrozyethyl)aoino- 
ethylawino]anthracene-9,10-dione (2B). 
1,5-Dichloroanthraquinone, was purified by 
recrystallisation from toluene. 2-Aminoethylamino- 
ethanol (97%) was used without further purification. 
1,5-Dichloroanthraquinone (11.04g, 0.04mol) was 
suspended in 2-aminoethylaminoethanol (83.2g, 0.8mol) 
by mechanical stirring and heated to 90°C in an oil 
bath for four hours. The reaction mixture was cooled in 
an ice bath and excess hydrochloric acid (10M, 100ml) 
was added slowly whilst maintaining the temperature 
below 15°C, using an ice bath. 
The acidic mixture was extracted sequentially 
with ether (3 X 200m1) and chloroform (3 X 200ml). The 
aqueous layer was made alkaline (pH 13-14) and the 
resulting suspension filtered. The solid was washed 
several times with cold deionised water and 
recrystal li sed twice from 2-me thoxye thanol/ethyl 
acetate (2/1), to yield the free base (5.2g, 31.5%), Mp 
125-127°C. 
TLC Rf 0.2 (MeOH/EtAc 1/1). 
Elemental analysis: found, C 61.32 H 7.01, N 13.00%. 
Calc. for C22 H28 N4 04 . 1.0H20 :C 61.40, H 6.98, N 
13.02%. 
IR Cm-1 ; 3410 (OH), 3260 (NH), 2920-2830 (CH2 CH3), 
1660 (quinone carbonyl), 1590 (aromatic C=C). 
1Hnmr: (HC1 salt) (D20) 6.8-7.5(m) (aromatic, 6H); 
4.0(m) (CH2,12H); 3.5(m) (CH2,4H). 
m/e (EI) 412 (M+), major fragments; 264 (M-148), 236, 
(M-176), 74, (M-338). 
UV X max. (e X 10E-4) in phosphate buffer (0.2M, pH7.0) 
(HC1 salt) 518 (1.15), 281 (1.24), 230 (4.00). 
The hydrochloride salt was prepared as described 
for (1B). 
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3.1.2.3. Synthesis of 1,8-bis-[2'-(2-hydroxyethyl)- 
aminoethylamino]anthracene-9,10-dione (3B). 
1,8-Dichloroanthraquinone, was purified by 
recrystallisation from toluene. 2-Aminoethylamino- 
ethanol (97%) was used without further purification. 
1,8-Dichloroanthraquinone (5.52g, 0.02mol) was 
suspended in 2-aminoethylaminoethanol (41.6g, 0.4mol) 
by mechanical stirring and heated to 90°C in an oil 
bath for three hours. The reaction mixture was cooled 
to room temperature and a mixture of ethanol (200m1) 
and de ionised water (400m1) added. The solution was 
evaporated in vacuo and the residue washed several 
times with dionised water. The last traces of water 
were removed by the addition of absolute ethanol 
(100ml) followed by evaporation in vacuo. The solid was 
then dried in vacuo at room temperature overnight. 
The compound was purified by "flash" column 
chromatography using the following solvent mixtures: 
EtAc/MeOH 10/0 300ml 
EtAc/MeOH 9/1 300m1 
EtAc/MeOH 8/2 300m1 
EtAc/MeOH 6/4 300m1 
EtAc/MeOH 4/6 300m1 
EtAc/MeOH 2/8 300m1 
EtAc/MeOH 0/10 300ml 
50m1 fractions were collected and chromatographed on 
TLC plates. Fractions containing a single component 
were pooled and evaporated in vacuo. Only one of the 
components (most polar) was fully characterised: and it 
")nQ 
was shown to be the desired compound. This component 
was recrystallised from ethanol to yield the free base 
(0.6g, 7*. 3%), Mp 130-132°C. 
TLC Rf 0.15 (MeOH/EtAc 1/1). 
Elemental analysis: found, C 63.30, H 6.46, N 13.56%. 
Calc. for C22 H28 N4 04: C 64.08, H 6.80, N 13.59%. 
IR Cm-1 ; 3420 (OH), 3260 (NH), 2920-2830 (CH2 CH3), 
1660 (quinone carbonyl), 1590 (aromatic C=C). 
1Hnmr (DMSOd6), 9.7 (NH, 1H); 7.1-7.6(m), (aromatic, 
6H); 4.0(m), (CH21 12H); 3.5(m), (CH2,4H). 
m/e (EI) 411 (M-1), other major fragments; 322 (M-90), 
266, (M-146)', 74, (M-338), 44, (M-368). 
UV Amax. (s X 10E-3) in phosphate buffer (0.2M, pH7.0) 
(HC1 salt) 540 (8.45), 318 (5.12), 280 (10.87), 236 
(35.27). 
3.1.2.4. Synthesis of 1,4-bis-[2'-(2-hydroxyethyl)amino- 
ethylamino)anthracene-9,10-dione (4B). 
1,4,9,10-Tetrahydroxyanthracene (leucoquinizarin), 
was purified by repeated recrystallisation from 
acetone: water mixture (9: 1). 2-Aminoethylaminoethanol 
(97%) from Aldrich Chemical Company, was used without 
further purification. 
Compound (4B) was prepared by the same method as 
compound (4A) using 1,4,9,10-tetrahydroxyanthracene 
(4.84g, 0.02mol) and 2-aminoethylaminoethanol (20.8g, 
0.2mol). After aeration the mixture was filtered 
through a sintered glass funnel and the solid washed 
with hexane/ethanol (1/1,2x , 
200ml) mixture. The 
compound was recrystallised from ethanol/water mixture 
)no 
(1/4), to yield the free base (5.3g, 64.3%), Mp 
156-158°C. 
TLC Rf 0.2 (MeOH/EtAc 1/1). 
Elemental analysis: found, C 63.96, H 6.91, N 13.56%. 
Calc. for C22 H28 N4 04: C 64.08, H 6.80, N 13.59%. 
IR Cm-1 ; 3420. (0H), 3280 (NH), 2920-2830 (CH2 CH3)1 
1610 (quinone carbonyl), 1580 (aromatic C=C). 
1Hnmr (CD3000D): 7.2-8.1(m) (aromatic, 6H); 4.0(m) 
(CH21 12H); 3.5(M) (CH2,4H). 
m/e (EI) 411 (M-1), other major fragments; 264 (M-148), 
236, (M-176), 74, (M-338). 
UV x max. (E X 10E 
4) in phosphate buffer (0.2M, pH7.0) 
(HC1 salt) 628 (1.49), 583 (1.50), 256 (3.35), 204 
(2.62). 
The hydrochloride salt was prepared by 
dissolving the base in absolute ethanol and bubbling 
dry HCl gas for 2 minutes whilst stirring the solution. 
The resultant precipitate was filtered and dried over 
P205 in vacuo. 
3.1.3. Synthesis of Azoanthraquinones. 
These azoanthraquinones were synthesised from 
their corresponding amino anthraquinones and therefore 
the synthesis of aminoanthraquinone intermediates will 
be described here first. 
^1n 
3.1.3.1. Synthesis of 1-amino-4-[2'(diethylamino)ethyl- 
amino]-anthracene-9,10-dione (2Ci). 
1-Amino-4-bromoanthracene-9,10-dione (a gift 
from I. C. I) was purified by recrystallisation from 
glacial acetic acid. 2-(Diethylamino)ethylamine (98%+) 
was used without further purification. 
1-Amino-4-bromoanthracene-9,10-dione (2.92g, 0.01 
mol) was dissolved in 2-(diethylamino)ethylamine (11.6g, 
O. lmol) and the solution heated under reflux for 30 
minutes. The reaction mixture was cooled in an ice 
bath, and de ionised water (50m1) added. The solution 
was evaporated in vacuo and the residue washed several 
times with deionised water. The last traces of water 
were removed by the addition of absolute ethanol (5 0m1) 
followed by evaporation in vacuo. The solid was then 
dried in vacuo at room temperature overnight. 
The solid was redissolved in hexane/ethyl 
acetate (1/1) mixture and purified by "flash" column 
chromatography using the following solvent mixtures: 
Hexane/EtAc 1/1 150ml 
Hexane/EtAc 0/1 150m1 
EtAc/MeOH 9/1 150m1 
EtAc/MeOH 8/2 150m1 
EtAc/MeOH 6/4 150m1 
25m1 fractions were collected and chromatographed on 
TLC sheets (solvent EtAc/MeOH, 8/2). Fractions 
containing a single component were pooled and 
evaporated in vacuo. Only one of the components (Rf 
0.5) was fully characterised, and found to be the 
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desired product. This component was recrystallised from 
a mixture of hexane and ethyl acetate (2/1) to yield 
the free base (1.5g, 44.5%), Mp 112-113°C. 
TLC Rf 0.5 (EtAc/MeOH 1/1) 
Elemental analysis: found, C 70.97, H 6.90, N 12.42%. 
Calc. for C20 H23 N3 02, C 71.19, H 6.87, N 12.45%. 
IR cm-1 ; 3400 (NH2), 3260 (NH), 3000-2800 (CH2 CH3)1 
1645 (quinone carbonyl), 1585 (aromatic C=C). 
1Hnmr: 10.8 (NH, 1H); 7.4-8.3(m) (aromatic, 7H); 3.4(q) 
(CH2,2H); 2.6(m) (CH2,6H); 1.1(t) (CH3,6H). 
m/e ('EI) 337 (M+), other major fragments; 265 (M-72), 
251 (M-86), 86, (M-251). 
UV % max. (e X 10-3) (HCl salt) 606 (9.59), 565 (1.01), 
254 (2.69), 205 (21.00). 
The hydrochloride salt was prepared as described 
for (IA). 
3.1.3.2. Synthesis of 1-amino-5-[2'-(diethylamino)- 
ethylamino]-anthracene-9,1O-dione (3Ci). 
Compound (3Ci) was prepared and purified by the 
same method as for compound (2Ci) using 
1-amino-5-chloroanthracene-9,10-dione (2.56g, O. Olmol) 
and 2-(diethylamino)ethylamine (11.6g, 0.1mol), with 
heating under reflux for 50 minutes, to yield the free 
base (1.42g, 42%), Mp 137-139°C. 
TLC Rf 0.55 (EtAc/MeOH 1/1) 
Elemental analysis: found, C 71.12, H 6.89, N 12.36%. 
Calc. for C20 H23 N3 02, C 71.19, H 6.87, N 12.45%. 
IR cm-1 ; 3480 (NH2), 3325 (NH), 3000-2800 (CH2 CH3)1 
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1630 (quinone carbonyl), 1565 (aromatic C=C). 
1Hnmr: 9.8 (NH, 1H); 6.9-7.6(m) (aromatic, 7H); 3.4(q) 
(CH2,2H); 2.6(m) (CH2,6H); 1.1(t) (CH3,6H). 
m/e (EI) 337 (M+), other major fragments; 265 (M-72), 
251 (M-86), 86, (M-251). 
UV Xmax. (c X 10-4) (HC1 salt) 507 (1.12), 280 (1.15), 
230 (3.77). 
The hydrochloride salt was prepared as described 
for (1). 
3.1.3.3. Synthesis of 1-amino-5,8-bis-(2'-(diethyl- 
amino)ethylamino]-4-hydroxy-anthracene-9,10- 
dione (4Ci). 
1,5-Diamino-4,8-dihydroxyanthracene-9,10-dione 
(a gift from I. C. I) and 2-(diethylamino)ethylamine 
(98%+) were used without further purification. 
1,5-Diamino-4,8-dihydroxyanthracene-9,10-dione 
(2.70g, 0.01mol) and 2-(diethylamino)ethylamine (11.69, 
O. lmol) were suspended in aqueous methanol (50%, 60m1), 
and nitrogen (02 free) was bubbled through the mixture 
for a period of 15 minutes at 60-65°C. Sodium 
dithionite (4.2g, 0.02mol) was added to the mixture and 
heated for a further period of 22 hours under nitrogen 
(02 free). 
Butan-l-ol (50m1) was then added and the mixture 
aerated for a period of 4-5 hours and evaporated 
in vacuo. The solid residue was suspended in a mixture 
of ethyl acetate: water (5: 3,800ml) and allowed to 
separate. The aqueous layer was discarded and the 
organic layer extracted with deionised water (3 x 
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300m1). The ethyl acetate layer was then dried with 
sodium sulphate (anhydrous), filtered and evaporated 
in vacuo. 
The compound was purified by redissolving the 
residue in ethyl acetate (25m1) followed by "flash" 
column chromatography. The following solvent mixtures 
were used: 
EtAc - 250m1 
EtAc/MeOH 9.5/0.5 250ml 
EtAc/MeOH 9/1 250ml 
EtAc/MeOH 8/2 250ml 
EtAc/MeOH 6/4 500m1 
EtAc/MeOH 2/8 500ml 
MeOH - 500m1 
50m1 fractions were collected and chromatographed on 
TLC sheets (solvent EtAc/MeOH, 1/1). Fractions 
containing a single component were pooled and 
evaporated in vacuo. Using the above system two 
components were separated but only one of these was 
fully characterised and found to be the desired 
product. This component was recrystallised from 
absolute ethanol to yield the free base (1.2g, 25.7%). 
Mp 180-182°C. 
TLC Rf 0.3 (EtAc/MeOH 1/1). 
Elemental analysis: found, C 66.73, H 8.02, N 14.98%. 
Calc. for C26 H37 N5 03, C 66.78, H 7.91, N 14.98%. 
IR cm-1 ; 3460 (NH, OH bonded), 3000-2800 (CH2 CH3), 
1620 (quinone carbonyl), 1575 (aromatic C=C). 
1Hnmr: 9.7 (NH, 2H); 7.2-8.4(m), (aromatic, 4H); 
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3.6(q), (CH2, 
12H). 
m/e (EI) 467 
(M-86), 295, 
UV x max. (E 
256 (24.72), 
4H); 2.8(m), (CH2,12H); 1.1(t), (CH3, 
(M+), other major fragments; 468 (M+1) 381 
(M-172), 86, (M-381). 
X 10-3) (HC1 salt) 630 (9.52), 585 (8.95), 
210 (16.99). 
The hydrochloride salt was prepared as described 
for (iA). 
3.1.3.4 Synthesis of 1-(4'-hydroayphenyl)azoanthracene- 
9,10-dione (1C). 
Fast red AL salt (a nthraquinone-l-diazonium 
chloride, from Aldrich) and phenol were used without 
further purification. 
Anthraquinone-l-diazonium chloride (zinc 
complex, 4g) was added to a solution of phenol (3.0g), 
in sodium hydroxide (2M, 30m1), with mechanical 
stirring. The resultant mixture was stirred for a 
further 30 minutes and allowed to stand overnight at 
room temperature. The resultant precipitate was 
filtered and sequentialy washed with sodium bicarbonate 
solution (2%, 3x300ml), and deionised water (6x300m1). 
The solid was dried in vacuo for 12 hours at 50-55°C 
and recrystallised from absolute ethanol to yield 
1-(4'-hydroxyphenyl)azoanthracene-9,10-dione (3g), Mp 
146-147°C. In this case it is not possible to calculate 
the percentage yield since the molecular weight of the 
anthraquinone-l-diazonium zinc complex is 
indeterminate. 
TLC Rf 0.5 (CHC13). 
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Elemental analysis: found, C 73.56, H 3.61, N 8.52%. 
Calc. for C20 H12 N2 03: C 73.16, H 3.66, N 8.53%. 
IR Cm-1 ; 3400 (OH), 1620 (quinone carbonyl), 1580 
(aromatic C=C). 
iHnmr (DMSOd6), 7.1-7.6(m), '(aromatic, 11H); 5.2(s), 
(OH, 1H). 
m/e (EI) 328 (M+), other major fragments; 329 (M+1), 
221, (M-107), 221, (M-107), 151, (M-177), 93, (M-235). 
UVX max. -(e X 10E-3) in methanol 495 (5.50), 430 
(6.12), 250 (6.87). 
3.1.3.5. Synthesis of 1-[2'-(diethylamino)ethylavino]- 
4-(2"4"-dihydrozyphenyl)azoanthracene-9,10- 
dione (2C). 
1-Amino-4-(N', N'diethylaminoethylamino)anthraqu- 
inone (0.1g, 0.296mmol) was dissolved in hydrochloric 
acid (5M, 2. Oml) and cooled in a NaCl/ice bath. A 
solution of sodium nitrite (0.304M, 1.0ml) was also 
cooled and added to the amine with stirring. The 
resultant mixture was added to a solution of resorcinol 
(0.091 M) in sodium hydroxide (2M, 5ml), also at 0-5°C 
and stirred by shaking. 
The mixture was extracted twice with 
dichloromethane (20m1) and the solvent discarded. The 
aqueous layer was then evaporated in vacuo and the last 
traces of water were removed by adding absolute ethanol 
followed by evaporation in vacuo. The residue was then 
suspended in chloroform (100ml), filtered to remove 
inorganic material, and the solution evaporated 
in vacuo. The resultant green solid was dissolved in 
0.5m1 of methanol and purified by "flash" column 
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. 
chroma tograpy using ethyl acetate/methanol (8/2) as 
eluent. Fractions (25m1) were collected and 
chromatographed on TLC plates; those containing a 
single component were pooled and evaporated in vacuo. 
In this case only three components were present; 
resorcinol, the starting amine, and the desired azo 
derivative. Fractions containing the azo derivative 
were evaporated in vacuo and the solid recrystallised 
from ethanol/chloroform (2/1) mixture to yield the free 
base (0.09g, 66%), Mp 137-138°C. 
The reaction was repeated twice using 0.2g of 
amine to yield 0.18g, 66% and 0.20g, 73% respectively. 
TLC Rf 0.3 (MeOH/EtAc 2/8) 
Elemental analysis: found, C 68.15, H 5.63, N 12.22%. 
Calc. for C20 H12 N2 03: C 68.12, H 5.68, N 12.23%. 
IR Cm-1 ; 3430 (OH), 3260 (NH), 2920-2830 (CH2 CH3)1 
1640 (quinone carbonyl), 1580 (aromatic C=C). 
1Hnmr (DMSOd6), 9.7 (NH, 1H); 7.2-8.3(m) (aromatic, 
9H); 4.4 (OH, 2H) 3.3(q) (CH2,2H); 2.6(m) (CH2,6H); 
1.1(t) (CH3,6H). 
m/e (EI) 458 (M+), other major fragments; 235 (M-223), 
109 (M-349), 86, (M-372). 
UV % max. (E X 10-3) , in chloroform 626 (3.22), 480 
(4.00), 280 (5.64). 
The hydrochloride salt of this compound could 
not be prepared as it was found that the azo compound 
degraded to the parent amine in the presence of HC1. 
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3.1.3.6. Synthesis of 1-[2'-(diethylamino)ethylamino]- 
5-(2"4"-dihydroayphenyl)azoanthracene-9,10- 
dione (3C). 
Compound (3C) was prepared by a similar method 
as that for compound (2C) using 1-amino-5- 
(N', N'diethylaminoethylamino)anthraquinone (0.1g, 
0.296mmo1). After coupling the diazonium chloride to 
resorcinol the resulting precipitate was centrifuged 
and the supernatant discarded. The solid was washed 
several times with deionised water, resuspended in cold 
ethanol (at 0°) and centrifuged. Ethanol was discarded 
and the solid dried in vacuo at 60°C for 8 hours. 
Compound (3C) was purified by the same method as 
compound (2C) to yield the free base (0.093g, 68%), Mp 
138-140"C. 
The reaction was repeated once using 0.4g of 
amine to yield 0.37g, 68% of the product. 
TLC Rf 0.3 (MeOH/EtAc 2/8) 
Elemental analysis: found, C 68.09, H 5.68, N 12.25%. 
Calc. for C20 H12 N2 03: C 68.12, H 5.68, N 12.23%. 
IR Cm-1 ; 3420 (OH), 3280 (NH), 2920-2830 (CH2 CH3), 
1620 (quinone carbonyl), 1560 (aromatic C=C). 
1Hnmr (DMSOd6), 9.7 (NH, 1H); 7.4-8.3(m) (aromatic, 
9H); 4.6 (OH, 2H) 3.3(q) (CH2,2H); 2.6(m) (CH2,6H); 
1.1(t) (CH3,6H). 
m/e (EI) 458 (M+), other major fragments; 235 (M-223), 
109 (M-349), 86, (M-372). 
UV X max. (E X 10-3), in chloroform 520 (3.20), 390 
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(2.90), 280 (3.55). 
The hydrochloride salt of this compound could 
not be prepared as it was found that the azo compound 
degraded to the parent amine in the presence of HC1. 
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3.2 INTERACTION OF SUBSTITUTED ANTHRAQUINONES WITH DNA. 
Calf thymus DNA (Type 1) was obtained from 
Sigma Chemical Company, London; pM2 DNA (cccDNA) was 
obtained from Boehringher Mannheim, Lewes, E. Sussex. 
All reagents were of Analar grade. All glass apparatus 
used in this work was silanised with Repelcote (Hopkins 
and Williams), washed twice with methanol (Fisons, 
H. P. L. C. grade) and dried overnight at room temperature 
before use. All volumetric glassware was of grade A 
specification. Volumes less than 0.50m1 were measured 
using Hamilton precision glass syringes. All drugs were 
stored over phosphorous pentoxide under vacuume. All 
drug solutions were protected from light and stored at 
4°C prior to use. Concentrations of all drug solutions 
were determined spectrophotometrically immediately 
before use. DNA has a variable molecular weight, and 
therefore the concentration of DNA in solution was 
expressed in terms of molarity of DNA phosphate; this 
was determined using an extinction value of 6600 at 
260nm for DNA (phosphate). The term 'water' denotes 
freshly prepared water, double distilled in all glass 
apparatus. Unless otherwise stated Tris buffer (pH 
7.40, Tris Cl 0.008M, NaCl, 0.05M) was used throughout 
this part of the work. 
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3.. 2.1. Effect of DNA on the spectral properties 
of drug. 
3.2.1.1. Effect of DNA on absorbance of light by drug 
in the visible region of the spectrum. 
A 5x1075 M solution of the drug was prepared in 
Tris buffer and 5. Oml of this solution was added to 
each of six 10ml volumetric flasks. DNA solution (about 
2.5x10-3 M) in the same buffer was added to give a 
range of DNA: drug ratios from 0 to 15: 1. The solutions 
were then made to volume with Tris buffer. 
The spectra of the solutions were recorded 
sequentially against a buffer blank, between 150nm 
below and 150nm above the X max of the drug in the 
visible region of the spectrum, and were superimposed 
on each other. 
3.2.1.2. Effect of DNA on absorbance of light by drug 
in the UV region of the spectrum. 
A solution of drug (lx10-4 M), and a range of 
DNA solutions were prepared in tris buffer (ranging 
from 5x10-5M to 5x10-4M). Appropriate DNA solution 
(precisely 2. Oml) was placed in both sample and 
reference cuvette, thus ensuring that the concentration 
of DNA in sample and reference beam were identical. 
Drug solution (precisely 1.0ml) and buffer (precisely 
1.0ml) were added to the sample and reference cuvette 
respectively, and the solutions mixed carefully. The 
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spectra were recorded sequentially from 150nm above the 
X max in the visible region to 190nm and were 
superimposed as before. The spectrum of free drug was 
recorded by replacing DNA solution with buffer. 
3.2.1.3. Spectrophotometric titration studies. 
Spectrophotometric titrations were performed at 
25°C using a Perkin Elmer 552S spectrophotometer fitted 
with a thermostatted 5-cell holder and cell programmer. 
Fixed volumes (3.00ml) of the drug solution 
(approximately 5x 10-5M) were trans fe red to each of 
three matched quartz cuvettes and buffer was (3.00ml) 
placed in the reference cell as a blank. The cuvettes 
were protected from light to minimise 
photodecomposition of the drug. 
Aliquots (12 x 20,4 x 40, and 7x 10091) of DNA 
solution (2.5 x 10-3M) were added sequentially to each 
of the cuvettes (drug and blank) using a Hamilton l00µ1 
syringe. After each addition the mixture was carefully 
stirred and left to stand for 5 minutes to allow 
DNA/drug complex to equilibrate. After equilibration, 
the absorbance of the mixture was measured at the X max 
of the free drug. Aliquots of DNA solution were added 
until there was no significant change in the observed 
extinction coefficient (e obs 
). The data for each cell 
were treated separately to allow for minor variations 
in the pathlengths. The values for the extinction of 
the free drug (e f) were calculated by dividing the 
initial absorbance of each cell by the free drug 
concentration. The binding parameters K and n were 
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0 
determined from a Scatchard plot of 
[(bound drug concn. /DNA concn. ) /free drug conch. ] vs 
(bound drug concn. /DNA concn. ); the free and bound drug 
concentrations for each point being determined from the 
fractional decrease in extinction at that point. 
3.2.1.4 Dissociation kinetics study of DNA-drug 
complexes by stopped-flow spectrophotometry. 
Solutions of daunorubicin (a gift from 
Farmitalia Carlo Erba, Milan, Italy), doxorubicin 
(Sigma Chemical Company, Poole, Dorset, UK) and each of 
the anthraquinones (compounds 1A-4A, and compounds 
1B-4B) were prepared in tris (0.015M) NaCl (0.2M) 
buffer pH 7.4, containing calf-thymus DNA (Type I) at a 
drug to DNAp ratio of exactly 0.10. DNAp is the 
concentration of DNAp calculated as DNA phosphate from 
the absorbance of the solution at 260nm (E260=6,600). 
The dissociation rate constant for a particular 
DNA/drug complex was determined at 20°, 25° and 37°C 
as follows. The appropriate solution was placed in one 
reservoir of a SF3 series Stopped Flow spectrometer 
(Hi-Tech Scientific Limited, Salisbury, UK). Sodium 
dodecyl sulphate (SDS), 0.2, %, in the same buffer was 
placed in the other reservoir. The reservoirs were 
connected to two separate syringes and to the mixing 
chamber via a three way tap (figure 51). Both syringes 
were driven at the same rate, using compressed air, to 
deliver each solution to the mixing chamber; on 
stopping the flow, the absorbance, at the X max of the 
free drug, was monitored and the output recorded on a 
Tectronix storage oscilloscope. 
- 223 - 
ýýýTý 
.' 
11ý 
'l 
V 
"ý- 
ot 
-0 
C cc 
WW 
J 
Oi 
c 
HJ20. 
O2 
Ua 
IL 2 
oeou r-oEa-0 
{L . ýýýr 
IOCL--u 
JýOG- 
\ý ,_ r 
Figure 51: Schematic diagram of stopped flow apparatus. 
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The increase in extinction was monitored over a 
period of about 6 half lives. In each case at least 
eight data points were collected and fitted to a single 
exponential and to a biexponential equation using a 
microcomputer programme. In all cases the data could be 
fit to a single exponential with a correlation 
coefficient of 0.99 or better: the data did not fit a 
biexponential model (correlation coefficient less than 
0.89). 
I 
3.2.2. Effect of drug on the binding of ethidium to 
DNA. 
3.2.2.1. The effect of drug on the fluorescence 
enhancement of ethidium bromide due to binding 
to DNA. 
A solution of drug (2.0x10-6M) in Tris buffer 
was prepared, two further solutions containing DNA 
(2. Ox10-5M) and DNA and drug (2. Ox10-5M and 2.0x10-6M 
respectively) were prepared. 
Buffer (precisely 2. Oml) was placed in one 
cuvette and the same volume of each of the above 
solutions were placed in three separate cuvettes; 
buffer and drug solutions acting as controls. The 
cuvettes were placed in a jacketted cell holder of a 
Perkin Elmer LS5 spectrofluorimeter and fluorescence 
intensities, (% excitation, 476nm, ? emission, 596nm), 
of the solutions were determined at 25°C. 
Aliquots, (6 x 10u1,5 x 20p1,6 x 40u1, and 6x 
l00)11), of ethidium solution (2. OxlO-5M) were 
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sequentially added to each of the four cuvettes and 
readings taken after mixing and allowing to stand for 1 
minute. Fluorescence intensities were corrected for 
changes in volume. 
3.2.2.2. Determination of fluorescence polarisation of 
ethidium bromide when bound to DNA and 
irradiated with polarised light. 
A solution of ethidium bromide (2.0x10-6M) was 
prepared in tris buffer. Tris buffer (2.00ml) was 
placed in one cuvette and ethidium bromide solution 
(2.00ml) in each of 3 cuvettes. The cuvettes were 
placed in a jacketted cell holder of a Perkin Elmer LS5 
spectrofluorimeter fitted with a manual polarisation 
accessory and fluorescence intensities, (% excitation, 
476nm, X emission, 596nm), of the solutions were 
determined at 25°C. 
The fluorescence readings were converted into 
polarisation values using the equation: 
FI Iý. 
vZ____FLý. vZx(FI 
IM/FLýHL) 
corrected FII (v) + FL (v) x (FII (H) /FL (H)) 
Where pcorrected is the corrected polarisation, F 
represents fluorescence intensity, II denotes that the 
emission polariser is parallel to to the vertical 
component of the polarised light, L denotes that the 
emission polariser is perpendicular to the vertical 
component of the polarised light (v) indicates the 
direction of polarisation (vertical) of the light 
incident on the sample, and (H) indicates the direction 
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of polarisation (horizontal) of the light incident on 
the sample. 
The above equation may be rewritten as: 
F(0ý0) 
___Fý. 
EHIx_(F(90ýQlIF(90ý90) ) Pcorrected 
F(0/0) + F(0/90)x (F (90/0) IF (90/90)) 
Where F represents the fluorescence intensity, and the 
subscripted values in brackets represent the position 
in ° of excitation and emission filters respectively. 
Aliquots, (6 x 10Nl, 5x 20p1,6 x 40; 11, and 6x 
100µl), of DNA solution (2.0 x 10-4M) were sequentially 
added to the cuvettes and the polarisation of 
fluorescence determined. The readings were corrected 
for changes in volume. 
3.2.2.3. The effect of drug on the fluorescence 
polarisation of ethidium bound to DNA. 
A solution of ethidium bromide (2xlO-5M) was 
prepared in tris buffer and 1.00ml of this solution 
placed in each of twenty two, 10ml volumetric flasks. A 
solution of DNA (2xlO-3M) was prepared and sufficient 
volume added to each of the eleven flasks, to give a 
DNA: ethidium ratio of 4: 1 precisely. 
A solution of drug (2xl0-4M) was prepared and 
added to the eleven flasks containing DNA and ethidium, 
to give a range of concentrations of the drug from 0 to 
8.0x10-6M. Similar volumes were added to the rest of 
the flasks; the latter acting as controls. The 
polarisation of fluoresence, for each of the solutions 
was determined three times and the above experiment 
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repeated three times. 
The % of ethidium bound to DNA was determined 
using the following equation: 
PsamD1e-_-p 
control % binding= -X 100 
Amax 
where Psample is the polarisation of DNA+ethidium+drug, 
Pcontrol is the polarisation of drug+ethidium and Pmax 
is the polarisation of DNA+ethidium (4: 1). 
3.2.3. Effect of drug on the physical properties of 
DNA. 
3.2.3.1. Effect of the drug on thermal denaturation 
properties of DNA. 
A solution (precisely 3. Oml) of an appropriate 
concentration of drug in buffer, and water (6. Oml) were 
added to a 10ml volumetric flask and the solution 
sonicated for 15 minutes to remove dissolved air. 
DNA solution (Calf thymus), approximately 2.5 x 
10-3M in buffer, (precisely 0.60m1), was added to the 
contents of the flask, the solution made to volume with 
water, and mixed gently (final buffer concentration; 
0.018M NaCl, 0.00288 M Tris Cl; DNA: drug ratio of 
exactly 10: 1). The solution (2. Oml) was placed in a 
quartz cuvette with a ground glass stopper. The cuvette 
was placed in an electrically thermostatted cell holder 
of a Perkin Elmer 552S Spectrophotometer fitted with a 
temperature programmer. The absorbance of the solution 
at 260nm was recorded as the temperature was raised 
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from 58 to 110°C (0.5°C/min) except for compound (2A) 
and compound (4A) where the absorbance was monitored at 
the isosbestic point (268nm and 245nm respectively). 
This was repeated for three further samples and the 
mean Tm calculated. 
The mean Tm of DNA in the absence of drug from 4 
similar determinations in the same buffer was 
subtracted to give the &Tm value. 
3.2.3.2. Effect of drug on covalently closed circular 
DNA (PE-2). 
PM-2 DNA was dissolved in tris buffer, pH 7.4, 
(0.05M tris-C1 buffer containing 0.002M EDTA, 0.018M 
NaCl and 0.02M sodium acetate) to give a solution of 
approximately 100iig ml-1. Appropriate volumes of drug 
solution (100ig ml-1) were added to each of eight 5ml 
volumes of 1% Agarose Type I (Sigma) in the same 
buffer, at 45°C, such as to give final concentration 
range of drug from 0.00 to 1.00pg ml-1. Each solution 
was poured into a 125mm x 5.8mm glass tube with one end 
sealed with nescofilm, and the ends of the resultant 
gels trimmed when cool, the nescofilm being replaced 
with cotton gauze. An aliquot (20pl) of PM-2 DNA 
solution containing drug at 5: 1 molar ratio of 
DNA(P)/drug was layered onto the top of the gel 
followed by 20311 of 20% sucrose and bromophenol blue. 
Electrophoresis was performed at 45V (5 milliamps per 
tube) at 20-25°C for 3-4 hours until the bromophenol 
blue had migrated to about half the length of the gel. 
The gels were removed, stained with ethidium bromide 
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(4. Oug ml-1) in the same buffer, destained overnight 
with the same buffer and photographed. The critical 
concentration was determined, this being the 
concentration at which the ccc-DNA virtually 
co-migrates with nicked PM-2 DNA in the sample. 
3.3. METABOLISM OF AZOANTHRAQUINONES USING RAT LIVER 
FRACTIONS IN VITRO. 
3.3.1. Subcellular fractionation of rat liver. 
A male rat was killed by decapitation, the 
abdomen was cut open and the liver quickly excised and 
rinsed free of excess blood by immersion in a beaker of 
ice cold 0.15M NaCl 0.05M phosphate pH7.4 buffer. All 
subsequent stages were carried out at a temperature of 
0-4°C. 
After gently blotting, to remove fluid, the 
liver was weighed and cut into small pieces and placed 
into a glass Potter Elveljehm homogeniser tube (30m1) 
containing approximately 15-20m1 of the above buffer. 
The pestle was attached to an electric motor and the 
liver homogenised by repeated passings of the pestle 
through the homogenate, while the pestle was driven at 
a suitable speed (800-1000 rpm). The final 
concentration of the homogenate was adjusted so that 
the liver was suspended at a final concentration of 20% 
w/v. The homogenate was centrifuged at 10,000 xg for 
30 minutes, the supernatant was decanted and 
centrifuged at 100,000 xg for 60 minutes. The 
resultant supernatant was cleared of the fatty surface 
layer and termed c ty osol. The pellet was resuspended in 
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the same buffer (0.15M NaCl 0.05M phosphate pH 7.4) and 
termed microsomal fraction (final protein content 
2.0mg/ml determined by the method of Lowry et al., 
1951). 
3.3.2. Metabolism of azoanthra uinones b rat 
liver fractions to vitro. 
The metabolism of the azoanthraquinones (1C-3C) 
was examined in vitro by the following method. 
A solution of the appropriate azoanthraquinone 
(lmg/ml, O. lml), in ethanol was added to each of five 
tubes containing 1.0ml of microsomal (or cytosolic) 
fraction, NADPH regenerating system (0.5m1, see 
appendix 1), and 0.4m1 of buffer at 0°C. Appropriate 
controls (five of each) were also set up containing 
drug (0.1m1,1mg/ml) and either: 
heat denatured microsomes (or cytosol), 1.0ml + NADPH 
regenerating system (0.5m1) + Buffer 0.4m1 or, 
microsomes (or cytosol), 1.0m1 + Buffer (0.9m1), or, 
NADPH regenerating system (0.5m1) + Buffer (-1.4m1). 
Nitrogen (O2free) was bubbled through the mixtures for 
15 minutes and the tubes sealed. 
The tubes were incubated in a water bath (37°C) 
for 0,0.5,1.0,2.0, and 4.0 hours. Sodium hydroxide 
solution (2. Oml, 5M) and dichloromethane (1. Oml) were 
added at the end of incubation period and centrifuged. 
In the case of cytosolic fraction NADH (100mg/ml, 
0.5m1) was used instead of NADPH regenerating system. 
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Dichloromethane was then carefully removed and an 
aliquot (10ul) spotted onto a TLC sheet together with a 
solution of appropriate azoanthraquinone and 
aminoathraquinone. In all cases the solvent system was 
same as that used for synthetic work (see section 
3.1.3). 
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4. SUMMARY AND CONCLUSIONS 
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Cancer is a leading cause of death in Western 
countries. To date, complete cure for the majority of 
tumours has not been attained, despite the introduction 
of a number of treatments, including surgery, 
radiotherapy and chemotherapy. A major problem in the 
treatment of cancer has been a failure to selectively 
eradicate all tumour cells. Surgery, in combination 
with radiotherapy and (or) chemotherapy, has proved to 
be useful in the treatment of solid tumours; however 
the treatment of metastases and leukaemia is only 
possible by the use of radiotherapy and chemotherapy. A 
major problem with the currently available 
chemotherapeutic agents is their severe toxicity and 
rapid development of tumour resistance to these agents. 
Since the late 1940's, many antitumour agents 
have been discovered; mainly by large scale empirical 
screening programmes. An alternative approach to 
develop more effective antitumour agents is to study 
the mechanisms by which the existing drugs act and to 
attempt to improve the cytotoxic activity by 
modification of the structure. This work has been 
concerned with the design of potential antitumour drugs 
based on the mode of action of the anthracycline 
antibiotics doxorubicin and daunorubicin. Both 
doxorubicin and daunorubicin are potent antileukaemic 
agents. Doxorubicin also shows activity against a broad 
spectrum of solid tumours (Weirnik, 1980). These 
anthracyclines are known to intercalate between the 
base-pairs of double-stranded DNA (Neidle, 1980), and 
this is currently believed to be the principal 
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mechanism by which they exert their cytotoxic action. 
A considerable amount of information has been 
accumulated on the nature of intercalation of drug 
molecules into DNA since Lerman first described the 
intercalation model in 1963. The intercalation site is 
now well defined and the structural features necessary 
for a molecule to intercalate into DNA are also known. 
These requirements -include a planar tri- or tetra- 
cyclic ring system with a positively charged group 
(such as 
+NH3), 
either in the ring system or in a side 
chain, to attract the drug to the anionic helix 
(Waring, 1981). The side chain may be orientated in 
such a way as to stabilise the interaction once the 
drug has intercalated, by binding electrostatically to 
the phosphate residues on the helix, or by other 
bonding interactions. 
In an attempt to mimic the planar unit of 
doxorubicin, the anthraquinone chromophore present in 
this antibiotic was selected as the chromophore for the 
compounds prepared in this work. Several aminoalkyl- 
substituted anthraquinones have been previously 
synthesised (Müller, et al., 1971; Double and Brown, 
1975; Zee-Cheng and Cheng, 1978; Murdock, et al., 
1979). However only a limited variation of substitution 
pattern has been incorporated in these studies. 
Furthermore there is a lack of a systematic study of 
the nature of interaction of anthraquinones with DNA. 
This work has investigated these issues. 
In this work three series of substituted 
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anthraquinones were prepared. The first series 
consisted of four compounds (lA-4A) substituted with a 
2'-(diethylamino)ethylamino side chain in the 1-, 1,4-, 
1,5-, and 1,8- positions of the anthraquinone 
chromophore. The second series consisted of four 
compounds (1B-4B) substituted with a 2'-(hydroxy- 
ethylamino)ethylamino side chain in the 1-, 1,4-, 1,5-, 
and 1,8- positions of the anthraquinone chromophore. 
The third series of anthraquinones consisted of 
azoanthraquinone prodrugs (1C-3C) and their potential 
aminoanthraquinone metabolites (2Ci-4Ci). 
The effect of substitution pattern on the nature 
and affinity of binding of the two series of 1-, 1,4-, 
1,5-, and 1,8- substituted anthraquinones to DNA was 
examined in detail (summarised in table 10) and 
correlated with computer graphics modelling studies 
(performed by S. Islam and S. Neidle) which examined 
interaction of these synthesised anthraquinones with 
DNA. The methods used to evaluate the DNA binding of 
the anthraquinones " were selected to allow both 
quantitation and characterisation of the DNA/drug 
interaction. Doxorubicin was also used as a reference 
intercalating agent. 
All compounds prepared in this work (except the 
pro-drugs 2C & 3C), were shown to intercalate into DNA 
since they all showed the following properties: 
1. significant hypochromic and bathochromic shifts 
of the absorbance maxima of the drug, and the 
presence of an isosbestic point, on binding to 
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DNA; 
2. competitive displacement of a known 
intercalating agent (ethidium bromide) from DNA, 
by the compound under test, analysed by 
competitive fluorescence polarisation assay; 
3. a significant stabilisation of the DNA helix to 
thermal denaturation in the presence of drug, 
4. unwinding of covalently closed circular DNA 
(pM2) caused by drug, analysed by gel 
electrophoresis. 
Taken individually, none of these results alone is 
sufficient to unequivocally prove intercalation of drug 
occurs, but all these effects are typical of those seen 
with other proven intercalating agents, including 
anthracyclines (Plumbridge and Brown, 1979). When 
considered together, the data (table 10) provide strong 
evidence of an intercalative interaction of the 
anthraquinones (excluding the pro-drugs) with DNA. 
All compouds, with the exception of the 
pro-drugs (2C & 3C), were found to intercalate into 
DNA, and in addition they showed qualitatively similar 
effects to those observed with doxorubicin. Having 
shown that intercalation occurs, the affinity of the 
drug for DNA was then quantified by spectrophotometric 
titration with Scatchard plots (table 10). The compound 
with greatest affinity for DNA was shown to be, 
1,5-bis-[2'(Diethylamino)ethylamino]anthraquinone (2A), 
as evidenced by spectrophotometric titration (K=3.97 X 
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On binding to DNA 
Conc. to 
Z dec. ATma Kx 10' 
give 50% 
ethidiinn 1 Compound in c (°C) M-b c 
binding de (k 1) IC(50) (n) 0 (PM) (20 C) Hela CCRF 
Daxoru- 
-bicin 35.0 16.3 4.42 14.3 0.70 1.84 1.0 - 
(0.19) 
1A (1-)f 37.0 8.8 1.48 
(0.20) 
2A (1,5-) 27.0 25.1 3.97 
(0.21) 
3A (1,8-) 32.0 9.5 1.71 
(0.20) 
4A (1,4-) 42.0 20.0 3.17 
(0.22) 
10.6 7.50 >150 51.0 5.02 
14.2 0.85 0.91 9.0 1.77 
14.3 3.50 6.99 27.0 2.55 
14.2 0.35 3.73 25.0 3.34 
1B (1-) 32.0 8.0 1.03 12.46 5.00 >127 17.0 5.48 
(0.19) 
2B (1,5-) 32.0 23.6 3.20 13.51 0.90 1.39 2.6 1.44 
(0.22) 
3B (1,8-) 33.0 18.2 2.35 11.65 0.90 3.69 5.7 1.23 
(0.22) 
4B (1,4-) 38.0 19.5 2.83 18.02 0.50 3.82 1.0 0.21 
(0.19) 
2Ci 25.0 8.9 ND 10.7 2.60 ND ND 4.82 
2C 0.0 0.1 ND 0 X40.0 ND ND 10.48 
3Ci 33.0 7.2 ND 10.7 2.50 ND ND 4.82 
3C 0.0 0.2 ND 0 > 40.0 ND ND 23.58 
a The difference between the melting temperature of DNA in presence 
and absence of drug at a 10: 1 DNA/drug ratio. 
b Affinity constant (K), and the number of binding sites per DNA 
phosphate group (n). 
c Unwinding of ccc DNA per bound drug molecule in °. 
d First order dissociation rate constant (k 1S 
1). 
e Concentration of drug (pM) required to inhibit cell proliferation by 
50%. 
f Substitution pattern. 
ND Not determined. 
Table 10 : SLnnmary of INA binding and in vitro antiproliferative 
properties of substituted anthraquinones aal their potential 
pro-drugs. 
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106 M-1) , and A Tm value (25.111). - indeed the e Tm 
value is considerably greater than that obtained for 
doxorubicin (16.3? ). However the affinity of compound 
2A for DNA is lower than that obtained for doxorubicin 
(K=4. '42 X 106 M 1). Compounds 1A (1-substited, K=1.48 X 
106 M-1) and 3A (1,8-bis- substituted, K=1.71 X 106 
M-1) show a significantly lower affinity for DNA than 
compound 2A; however the corresponding 1,4-bis- 
substituted analogue (4A, K=3.17 X 106 M-1) shows 
similar affinity for DNA as compound 2A. Similar 
differences in the DNA binding of 2'-(hydroxy- 
ethylamino)ethylamino-substituted anthraquinones (B 
series) were shown. 
From computer graphics modelling studies of the 
interaction of anthraquinones (A series) with DNA 
(performed by S. A. Islam and S. Neidle), it was shown 
that compound 1A (1-substituted) can be intercalated 
into DNA from either the major or minor groove 
direction. The low energy state of the anthraquinone 
intercalated into the d(CpG) model for DNA was 
calculated to be between -305 and -312.1 Kcal mole-1. 
The 1,8-bis-substituted anthraquinone (3A) can only 
intercalate from the major groove side, with the 
chromophore arranged parallel to the base pairs. The 
low energy state of the anthraquinone intercalated into 
DNA was -338.2 Kcal mole-1. Compound 2A has an enhanced 
energy of interaction, due to favourable dispersion 
factors. One side-chain resides in the major groove, 
and the other is in the minor groove. Compound 2A could 
only bind to DNA by this "straddling". In order to 
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accomodate the 1,5-substituted compound (2A), 
DNA-breathing (transient base pair unstacking) has to 
occur to allow the docking of the drug molecule into 
the receptor site. In this case the low energy state of 
the anthraquinone intercalated into DNA was calculated 
to be -353.6 Kcal mole-1; of which at least 20-25 Kcal 
mole-1 is needed, in addition to the total 
intermolecular energy of the DNA-drug complex. The 
dissociation of compound 2A from its intercalation site 
would involve prior disruption of the base base pairs 
not only immediately at, but also adjacent to, the 
site. Therefore it would be expected that compound 2A 
would dissociate less readily than compounds 1A and U. 
Furthermore compound 2A would be, expected to have some 
preference for A-T regions, since these have a higher 
population of transient base-pair disruption. The 
latter has recently been confirmed experimentally by 
other workers using NMR techniques (Feigon et al., 
1984). The 1,4-bis-substituted derivative (4A) was 
found to only bind satisfactorily in a perpendicular 
orientation with the side chains in the major groove. 
The low energy state of the anthraquinone intercalated 
into DNA was calculated to be -345.5 Kcal mole-l. 
However compound 4A can also intercalate into. DNA by 
"straddling"; this type of binding is only possible 
after full geometric optimisation with the low energy 
state of the anthraquinone on interaction being -373.4 
Kcal mole-l. f 
Results from stopped-flow spectrophotometry were 
consistent with these findings. The dissociation rate 
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constants of both series of anthraquinones from DNA, 
(table 10) were in the order 1- (lA & 1B); >> 1,8- (3A & 
3B); > 1,4- (4A & 4B); > daunorubicin and doxorubicin > 
1,5- (2A & 2B) substituted anthraquinones. The 
1,5-disubstituted anthraquinones (2A & 2B) thus showed 
the slowest rate of dissociation from DNA; the 
DNA-anthraquinone complexes dissociating more slowly 
than the DNA complexes of the anthracyclines 
daunorubicin and doxorubicin. This would be expected 
considering the computer graphics modelling studies 
which show DNA breathing is necessary to allow the 
subsequent release of drug (2A) from DNA. 
The 2'-(diethylamino)ethylamino-substituted 
anthraquinones (A series) showed a greater affinity for 
DNA than the corresponding 2'-(hydroxyethylamino)- 
ethylamino substituted anthraquinones (B series), with 
the exception of the 1,8-disubstituted compounds (3A 
and 3B). However the 2'-(hydroxyethylamino)ethylamino 
substituted anthraquinones were more cytotoxic against 
HeLa and CCRF human leukaemia cells in vitro (tested by 
M. Partridge, Leicester Polytechnic and by Lilly 
Research Centre, Windlesham) than the 2'-(diethyl- 
amino)ethylamino-substituted anthraquinones. For 
example, IC50 values of 1.0 and 25.0jiM respectively 
were obtained for compounds 4B and 4A against HeLa 
cells; however the affinity constants (K) were 2.83 and 
3.17 X 106M-1 respectively. This apparent lack of 
correlation between DNA binding and in vitro biological 
activity, of the two series of anthraquinones, may be 
due to differences in cellular uptake of the drug. 
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However, if the DNA binding data for compounds within 
each of the two series of anthraquinones are compared, 
then there is a correlation between IC50 and DNA 
binding ability. Both the affinity for DNA, and 
antiproliferative activity, of the first series of 
compounds (1A-4A) is in the order 1,5-> 1,4-> 1,8-> 1- 
substituted anthraquinone. In the case of the second 
series (1B-4B) the affinity for DNA is in the same 
order as for the first series but the antiproliferative 
activity of the compounds is 1,4-> 1,5-> 1,8-> 1- 
substituted anthraquinone, this may probably be due to 
differences in the protein binding of these drugs. 
From the compounds prepared in this work, the 
1,5-bis-[2'(diethylamino)ethylamino]anthraquinone (2A) 
has the highest affinity for DNA but is not the most 
potent cytotoxic compound in the in vitro screens 
employed here. This may be due to insufficient uptake 
of drug by the cells, as previously described. The 
in vitro antiproliferative activity of substituted 
anthraquinones against HeLa cells are in the order 4B> 
2B> 3B> 2A> 1B> 4A> 3A> 1A. It is apparent from these 
preliminary results, that the 2'-(hydroxyethyl- 
amino)ethylamino anthraquinones (1B-4B) are 
significantly more cytotoxic than the corresponding 
2'-(diethylamino)ethylamino anthraquinones (1A-4A). To 
date only the first series compounds prepared have been 
evaluated for antitumour properties against P-388 
leukaemia in mice in vivo; they were shown to lack 
cytotoxic activity. These results show that the 
substituted anthraquinones (A series) would be 
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cytotoxic if sufficient drug concentrations were 
attained at the tumour site. 
It has so far been shown that it is possible to 
design compounds which have significantly high affinity 
for DNA, and that these compounds can also be cytotoxic 
providing the drug can be delivered to the site of 
action; the next logical step was to target the drug to 
specific tumour cells. This approach also should allow 
reduction of the toxicity of the drugs. In this work, 
model anthraquinone pro-drugs were prepared which were 
anticipated to be selectively activated by a target 
organ. The target organ chosen, in this case, was the 
liver since at present only a limited number of 
chemotherapeutic agents have shown to be effective 
against liver tumours; furthermore the single most 
effective agent against hepatocellular carcinoma is 
doxorubicin, a known intercalating agent. The pro-drugs 
(2C-3C) were so designed that they would not 
intercalate into DNA but, when metabolised by 
intracellular enzymes, they would yield the 
intercalating anthraquinones (Xi-Xi). It was found 
that azotization of 1-amino-4(or5)-[2'(diethylamino)- 
ethylamino]anthraquinone with subsequent coupling to 
resorcinol yielded a compound which did not intercalate 
into DNA, in accord with its design. The pro-drugs (2C 
& 3C) were unable to stabilise DNA to thermal 
denaturation, to displace ethidium from DNA, or to 
unwind cccDNA. Since the anthraquinone pro-drugs did 
not show significant DNA binding, the affinity of the 
drugs for DNA, could not be satisfactorily determined. 
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However, the potential "metabolites" (2Ci & 3Ci) of 
compounds 2C and 3C were shown to intercalate into DNA. 
To determine if the design was valid, the effect of 
cytosolic and microsomal preparations from rat liver, 
on the pro-drugs was investigated. The pro-drugs were 
indeed shown to be metabolised by rat liver microsomes 
and cytosol to the aminoanthraquinones confirming the 
validity of the approach. Preliminary in vitro 
antiproliferative studies against CCRF human leukaemia 
show that the pro-drugs are significantly less 
cytotoxic than the corresponding aminoanthraquinones. 
The aminoanthraquinones (2Ci & 3Ci) are as active as 
the 1-substituted anthraquinones (1A & 1B). This was as 
predicted from DNA binding studies since the 
anthraquinone pro-drugs did not bind to DNA. The low 
activity shown by the pro-drugs may be due to the 
reduction . of the azoanthraquinone moieties to the 
corresponding amines. 
From the above results, the following 
suggestions for the future development of compounds of 
this type may be made. It would be of interest to see 
if there are any differences in uptake and 
intracellular distribution of the substituted 
anthraquinones, and to relate these properties to lipid 
solubility, and cytotoxic action of the compounds 
in vitro and in vivo. It is clear from this work that 
1,5-disubstituted anthraquinones have a greater 
affinity for DNA (and also dissociate less readily), 
than the corresponding 1,4- (and 1,8)-disubstituted 
anthraquinones. By analogy with the 1,4-disubstituted 
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anthraquinones where it was shown that 5,8-dihydroxy 
derivatives have a greater antitumour activity than the 
parent compounds (Murdock et al., 1979); the 
4,8-dihydroxy analogues of compounds 2A & 2B would be 
expected to have a greater activity than the parent 
compounds. 
H0 HNR 
cx x RNH 0 HO From computer graphics studies of the interaction of 
the A series of anthraquinones it was observed that the 
terminal methyl group could lie in the vicinity of the 
edges of the base pairs. Appropriate substitution at 
these methyl positions could result in participation in 
specific interactions. 
In this work, azo derivatives of 1-amino-4(or 
5)-[2'(diethylamino)ethylamino]anthraquinones have been 
prepared which do not intercalate. It was shown that 
these anthraquinones may be metabolised to the parent 
amino anthraquinones, which are capable of binding to 
DNA. In order to show if these the compounds have 
selective activity, further studies of the distribution 
and metabolism of these anthraquinones in vivo are 
needed. The monosubstituted anthraquinones have 
insufficiently high affinity for DNA when compared to 
the disubstituted anthraquinones. It would therefore be 
advantageous to prepare azo derivatives of 
1-amino-disubstituted anthraquinones in order to 
- 245 - 
0 
exploit this enhanced affinity for DNA. This work has 
thus shown significant differences in DNA binding 
properties of substituted anthraquinones, and has 
identified structural requirements for optimum DNA 
binding in' the series. The feasibility of 
azoanthraquinones as pro-drugs has been demonstrated. 
The work can therefore form a basis for a more rational 
design of such compounds. 
All the compounds prepared in this work were 
designed as potential antitumour agents. However it may 
also be of interest to screen these anthraquinones for 
activity against other organisms; for example the 
anthracycline antibiotic daunorubicin, has been shown 
to possess trypanocidal action (Williamson et al., 
1981). Furthermore, anthraquinones similar to those 
prepared here have been shown to possess antiviral, 
(Stringfellow et al., 1979), antileishmanial, (Schnur 
et al., 1983), and antiamoebic properties (Fabio 
et al., 1978; Winkelmann and Raether, 1979). In 
addition they have been shown to have activity against 
some Trichomonas species (Winkelmann & Raeter, 1979). 
Ametantrone (Compound 4B) has been shown to 
inhibit lipid peroxidation and, since a free radical 
mechanism has been postulated for the initiation of 
lipid peroxidation and inflammatory processes, it would 
be of interest to examine whether simple anthraquinones 
may be useful as antiinflammatory agents. 
- 246 - 
BIBLIOGRAPHY 
ACTON, E. M., and TONG, G. L., (1981), J. Med. Chem., 24, 
669. 
ACTON, E. M., TONG, G. L., MOSHER, C. W., and WOLGEMUTH, 
R. L., (1984), J. Med. Chem., 27,638. 
ADAMS, R. L. P, BURDON, R. H., CAMPBELL, A. M., and SMELLIE 
R. M. S. (1976) in Davidson's The Biochemistry 
of Nucleic Acids. Eigth edition, published by 
Chapman and Hall, London. 
ALBERTS, D. S., GRIFFITH, K. S., GOODMAN, G. E., HERMAN, 
G. E., and MURRAY, E., (1980), Cancer 
Chemother. Pharmacol., S. 11. 
ALMOND, P., CUTBUSH, S. D., ISLAM, S. A., KURODA, R., 
NEIDLE, S., GANDECHA, B. M., and BROWN, J. R., 
(1983), Acta Cryst., C39,627. 
ANTON, R., and HAAG-BERRURIER, M., (1980), 
Pharmacology, 20,104. 
ARCAMONE, F., FRANCESCHI, G., PENCO, S., and SILVA, A. 
(1969), Tetrahedron Lett. , 1007. 
ARCAMONE, F. (1981), Doxorubicin- Anticancer Antibio- 
tics. Medicinal Chemistry- a series of 
monographs 17, Academic Press. 
ARNOTT, S., (1970), Prog. Biophys. Mol. Biol., 21,267. 
ARNOTT, S., (1979), Nature, 278,780. 
ARNOTT, S., CHONDRUSEKARAN, R., BIRDSALL, D. L., LESLIE, 
A. G. W., and RATCLIFF, R. L., (1980), Nature, 
283,743. 
ATWELL, G. J., LEUPIN, W., TWIGDEN, S. J., and DENNEY, 
W. A., (1983), J. Am. Chem. Soc., 105,2913. 
AU, W. W., BUTLER, M. A., MATNEY, T. S., and LOO, T. L. 
(1981), Cancer Res., 41,376. 
AUR, R. J. A., SIMON, J. V., and PRATT, C. B., (1971), 
Cancer, 27,1332. 
BACHUR, N. R., GORDON, S. L., and GEE. M. V. (1977), Mol. 
Pharmacol. 13,901. 
BACHUR, N. m., GORDON, S. R., GEE, M. V., and KON, H., 
(1979), Proc. Nat. Acad. Sci. U. S. A., 76,954. 
BACHUR, N. R., (1982a), in New Approaches to the design 
of antineoplaRaic agents, Proc. Annu. Med. 
Chem. Symp, 22 P. 39. Ed., Barados, T. J., 
and Kalaman, T. I.. Published by Elsevier, New 
York. 
- 247 - 
0 
BACHUR, N. R., (1982b), in, Proc. Int. Symp. on 
anthracyclines antibiotics in cancer therapy, 
1981 P. 97. Ed. Muggia, F. M., Young, C., and 
Carter, S. K.. Published by Martinus Nijhoff, 
the Hague. 
BACHUR, N. R., GEE, M. V., and FRIEDMAN, R. D., (1982c), 
Cancer Res., 42,1078. 
BAGULE, B. C., and Le BRET, M., (1984), Biochem. USA., 
23,937. 
BATES, D. A., and WINTERBOURN, C. C., (1982), FEBS Lett., 
145,137. 
BEHE, M., and FELSENFELD, G., (1981), 
Proc. Natl. Acad. Sci. USA., 78,1619. 
BENDER, R. A., ZWELLING. L. A., DOROSHOW. J. H., LOCKER. G. Y., 
HANDE. K. R., MURINSON. D. S., COHEN. M., 
MYERS. C. E. and CHABNER. B. A., (1978), Drugs, 
16,46. 
BENJAMIN, R. S., WIERNIK, P. H., and BACHUR, N. R., 
(1975), Med. Paed. Oncol., 1,63. 
BENNETT, S., SHARPLES, D., and BROWN, J. R., (1982), 
J. Med. Chem., 25,369. 
BERG, H., and ECKART, K., (1970), Z. Naturforsch., 256, 
362. 
BERG, H., HORN, G., LUTHARDT, U., and IHN, W., (1981), 
Bioelectrochemistry and Bioenergetics, 8, 
537. 
BERLIN, V., and HASELTINE, W. A., (1981)p J. Biol. Chem. , 
256,4747. 
BLAKE, A., and PEACOCK, A. R., (1968), Biopolymers, 6, 
1225. 
BLOOM, S. M., and 'HUTTON, R. F., (1963), Tetrahedron 
Lett.,, 1993. 
BLUM, R. H., and CARTER, S. K., (1974), Ann. Intern. Med., 
80,249. 
BONNADONNA, G., BERETTA, G., TANCINI, G., BROMBILLA, C., 
BAYETTA, E., De PALO, G. M., De LENA, M., 
FOSSATI-BELLANI, F., et al., (1975), Cancer 
Chemother. Rep., 6,231. 
BONADONNA, G., BRUSOMOLINO, E., VALAGUSSA, P., ROSSI. A, 
BURGNATELLI, L., BRAMBILLA, C., DELENA, G., 
TANCINI, E., MUSUMECI, R., and VERONESI, U., 
(1976), New Eng. J. Med., 294,405. 
- 248 - 
BONADONNA, G., MONFARDINI, S., De LENA, M., 
FOSSATI-BELLANI, F., and BERRETTA, G., (1970) 
Cancer Res., 30,2522. 
BROWN, J. P., and BROWN, R. J., (1976), Mutat. Res., 40, 
203. 
BROWN, 'J. P., and DIETRICH, P. S., (1979), Mutat. Res., 
66,9. 
BROWN, J. R., (1978), in, Progress in Medicinal 
Chemistry, 15,125. Ed. ELLIS, G. P., and 
WEST, G. B. Published by North-Holland 
Publishing Company, Amsterdam. 
BROWN, J. R., (1983), in, Molecular Aspects of 
Anti-Cancer Drug Action. Topics in Molecular 
and Structural Biology, 3,57. Ed. Neidle, 
S., and Waring, M. J.. Published by Macmillan 
Press, London. 
BROWN, J. R., and IMAM, S. H., (1984), in, Progress in 
Medicinal Chemistry, in Press. 
BUKHARI, A., CONNORS, T. A., GILSENAH, A. M., ROSS, 
W. C. J., TISDALE, M. J., WARWICK, G. P., and 
WILMAN, D. E. V., (1973), J. Natn. Cancer. I., 50, 
243. 
CAIN, B. F., (1974), J. Med. Chem., 17,922. 
CAIN, B. F., and ATWELL, G. J., (1974), Europ. J. Cancer, 
10,539. 
CAIRNS, J., (1962), Cold Spring Harbor Symp. quant. 
Biol., 27,311. 
CAIRNS, J., (1978), in Cancer: Science and Society, 
Published by W. H. FREEMAN, San Francisco. 
CALENDI, E., DiMARCO, A., REGGIANI, M., SCARPINATO, B., 
and VALENTINI, L., (1965), Biochim. Biophys. 
Acta., 103,25. 
CARTER, S. K., (1975),. J. Natl. Cancer. Inst., 55,1265. 
CARTER, S. K. and MATHý. G., (1980), in, Drug treatment- 
Principles and practice of clinical 
pharmacology and therapeutics, 951. Ed. 
Ave ry, S. , Published by Adis Press, Sidney. 
CARTER, S. K. , (1980), Cancer Chemother. Pharmac., 4,5. 
CARTER, S. K., (1982), in, Anthracycline Antibiotics in 
Cancer Therapy, P. 471. Ed. Muggia, F. M., 
Young, C. W., Carter, S. K.. Published by 
Martinus Nijhoff, The hague. 
CHABNER. B. A., MYERS. C. E., COLEMAN. C. H. and JONES. D. G., 
(1975), New England Jnl. of Medicine, 292, 
1107. 
- 249 - 
CHARGRAFF, E., (1950), Expe rimentia, 6,201. 
CHEN, T. K., FICO, R., and CANELLAKIS, E. S., (1978), 
J. Med. Chem, 21,868. 
CHENG, C. C., ZIBNDEN, G., ZEE-CHENG, R. K-Y., (1979) J. 
Pharm. Sci., 68,393. 
CIAK, J., and HAHN, F. E., (1967), Science; 156,655. 
COHEN, J. L., KRAND, T., SHRIDER, B., MATIAS, P., NORTON, J. 
and BAKTER, D., (1971), Cancer Chemother. 
Rep., 55,253. 
COHEN, L. F., GLAUBINGER, D. L., KANN, H. E., and KOHN, 
K. W., (1980), Proc. Am. Ass. Cancer Res., 21, 
277. 
CONNORS, T. A., (1975), in, Antineoplastic and Immuno- 
-suppresive Agents (II), 18. Ed. 
SARTORELLI. A. C. and JONES. D. G. Published by 
Springer-Verlag New York. 
CONNORS, T. A., (1980), Chem. Ind., P. 447. 
CORBETT, T. H., ROBERTS, B. J., TRADER, M. W., LASTER, 
W. R., GRISWOLD, D. P., and SCHABEL, F. M., 
(1982), Cancer Treat. Rep., 66,1187. 
CORTES, E. P., TAKITA, H., and HOLLAND, J. F., (1974), 
Cancer, 34,518. 
COWAN, J. D., VON HOFF, D. D., and CLARK, G. M., (1983), 
Invest. New. Drugs, 1,139. 
CRAWFORD, L. V., and WARING M. J., (1967), J. Mol. Biol. , 
25,23. 
, 
CRICK, F. H. C., WANG, J. C., and Bauer, W. R., (1979), 
J. Mol. Biol. , 129,449. 
CROOKE, S. T., DU VERNAY, V. H., and MO NG, S., (1981), in 
Molecular Actions and Targets for Cancer 
Chemotherapeutic Agents. P. 137, Ed., 
Sartorelli, A. C., LAZO, J. S., and BERTINO, 
J. R.. Published by Academic Press, New York. 
DALGLEISH, D. G., PEACOCKE, A. R., FEY, G., and HARVEY, 
C., (1971), Biopolymers, 10,1853. 
DANIEL, J. W., (1969), Biochem. J., 111,19P 
DAVIES, D. R., and ZIMMERMAN, S., (1980), Nature, 283, 
11. 
DeLEYS, R. J., and JACKSON D. A., (1976), 
Biochem. biophys. Res. commun., 69,446. 
- : sn - 
DENNY, W. A., BAGULEY, B. C., CAIN, B. F., and WARING, 
M. J., (1983), in, Molecular aspects of 
anti-cancer drug action. Topics in molecular 
biology 3 P. 1. Ed. Neidle, S., and Waring, 
M. J.. PuElished by Macmillan Press, London. 
DERVAN, P. B., and BECKER, M. M., (1978), 
J. Am. Chem. Soc., 100,1968. 
DiMARCO, A, GOETANI, M., and SCORPINATO, B., (1969), 
Cancer Chemotherapy Rep., 53,33. 
DiMARCO, A., (1975), Cancer Chemotherapy Reports, 6, 
91. 
DiMARCO, A., CASAZZA, A. M., GANBETTA, R., SUPINO, R. 
and ZUNINO, F., (1976), Cancer Res., 36, 
1962. 
DiMARCO, A., CASAZZA, A. M., DASDIA, T., NECCO, A., 
PRATESI, G., RIVOLTA, P. j VELCHI,, A. j ZACCARA, A., and ZUNINO, F., (1977), 
Chem. -Biol. Interact., 19,291. 
DiMARCO, A., (1981), Chemoterapia. Oncol., 4,5. 
DOLL, R., (1977a), Nature, 256,589. 
DOLL, R., (1977b), in, Origins of Human Cancer, 1. Ed. 
HIATT, H. H., WATSON, J. D. and WINSTEN, J. A.. 
Published by Cold Spring Harbor Laboratory. 
DOROSHOW, J. H., and REEVES, J., (1981), 
, 
Biochem. Pharmacol., 30,259. 
DOUBLE, J. C. and BROWN, J. R., (1975), J. Pharm. 
Pharmacol., 27,502. 
DOUBLE, J. C., and BROWN, J. R., (1976), 
J. Pharm. Pharmacol., 28,166. 
DREWINKO, B., YANG, L-Y., BARLOGIE, B., and TRUJILLO, 
J. M., (1983), Cancer Res., 43,2648. 
DOWNWARD, J., YARDEN, Y., MAYES, E., SCRACE, G., TOTTY, 
N., STOCKWELL, P., ULLRICH, A., SCHLESSINGER, 
J., and WATERFIELD, M. D., (1984), Nature, 
307,521. 
DULBECCO, R., (1982), Endeavour, New Series, 6,59. 
DU VERNAY, V. H., in Cancer Chemotherapy, III 
Antineoplastic Agents. P233, Ed., Crooke, 
S. T., and Prestayko, A. W.. Published by 
Academic Press, New York. 
ESPEJO, R. T., and LEBOWITZ, J., (1976), Analytical 
Biochem., 72,95. 
- 251 - 
ESTEY, E. H., KEATING, M. J., McCREDIE, K. B., BODEY, 
G. P., and FREIREICH, E. J., (1983), Cancer 
Treat. Rep., 67,389. 
EVENSON, D. P., DARZYNKIEWICZ, Z., STAIANO-COICO, L., 
TRAGANOS, F., and MELAMED, M. R., (1979), 
Cancer Res., 39,2574. 
EVENSON, D. P., TRAGANOS, F., DARZYNKIEWICZ, Z., 
STAIANO-COICO, L., and MELAMED, M. R., (1980), 
J. natn. Cancer Inst. , 64,857. 
FABIO, P. F., FIELDS, T. L., LIN, Y-I., BURDEN, E. J., 
CARVAJAL, S., MURDOCK, K. C., and LANG, S. A., 
(1978), J. Med. Chem., 21,273. 
FALKSON, G., MOERTEL, C. G., LAVIN, P., PRETORIUS, F. J. , 
CARBONE, P. P., (1978), Cancer, 42,2149. 
FEIGON, J, DENNY, W. A., LEUPIN, W., and KEARNS, D. R., 
(1984), J. Med. Chem., 27,450. 
FORSTER, W., STUTTER, E., and BAUR, E., (1980), Studia 
Biophys., 79,101. 
FRIEDMAN, C. A., (1980), Pharmacology, 20,113. 
FREIFEILDER, D., (1971), J. Mol. Biol., 60,401. 
FRIDOVICH, I., (1977), in, Biochemical and Medical 
aspects of active oxygen. p. 171. Ed. 
Hayaishi, 0., and Asada, K.. Published by 
University Park Press, Baltimore. 
FRIDOVICH, I. , (1979), in, Advances 
in Inorganic 
Biochem. p. 67. Ed. Eichhorn, G. L., and 
Manilli, L. G.. Published by Elsevier, 
Amsterdam. 
FUJIMOTO, S. and OGAWA, M., (1982), Cancer. Chem. 
Pharmacol., 8,157. 
FUJITA, S., and PEISACH, J., (1976), Pharmacologist, 
18,206. 
FUJITA, S., and PEISACH, J., (1977), Biochem. Biophys 
Res. Commun., 79,328. 
FUJITA, S., and PEISACH, J., (1982), Biochim Biophys 
Acta., 719,178. 
FULLER, W., and WARING, M. J., (1964), Ber. Bunsenges. 
Physik. Chem., 68,805. 
GILLADOGA, A. C., MANUEL, C., TAN, C. T. C., WOLLNER, N., 
STERNBERG, S. S., and MURPHY, M. L., (1976), 
Cancer, 37,1070. 
- 252 - 
GOLDMAN, R., FACCHINETTI, T., BACH, D., RAZ, A., and 
SCHINITZKY, M., (1978), Biochim. Biophys. 
Acta. 512,254. 
GOODMAN, J., and HOCHSTEIN, P. r (1977), Biochem. Biophys. Res. Commun., 77,797. 
GOORMAGHTIGH, E., CHATELAIN, P., CASPERS, J., and 
RUYSSCHAERT, J. M., (1980), Biochem. Biochim. 
Biophys. Acta, 597,1. 
GRANT, M., and PHILLIPS, D. R., (1979), Mol. 
Pharmacol., 16,357. 
GRAVES, D. E., and KRUGH, T. R., (1983), Biochem. U. S. A., 
22,3941. 
GREENHALGH, C. W., and HUGHES, N., (1968), 
J. Chem. Soc. (C), 1284. 
GRISAR, J. M., HICKEY, K. R., FLEMING, R. W., and MYER, 
G. D., (1974), J. Med. Chem., 17,890. 
GUTTERMAN, J. U., (1978)#, Cancer Immunol. Immunother. , 3,153. 
GUTTERIDGE, J. M. C. , and TOGG, D., (1982), FEBS le tt. , 149,228. 
HAMILTON, L. D., FULLER, W., and REICH, E., (1963), 
Nature, 198,538. 
HARTWELL, i. '? and ABBOTT, B., (1969), 
Adv. Chemother. Pharmacol., 7,117. 
HENDERSON, B. M., DOUGHERTY, W. J., JAMES, V. C., TILLEY, 
L. P., and NOBLE, J. F., (1982), Cancer Treat. 
Rep., 66,1139. 
HENRY, D. W. , (1976), in, Cancer Chemotherapy, p. 15. 
Ed. Sartorelli, A. C.. Published by Amer. 
Chem. Soc. , Washington. 
HENRY, D. W., (1979), Cancer Treat. Rep., 63,845. 
HERNANDEZ, P. H., GILLETTE, J. R., and MAZEL, P., (1967), 
Biochem. Pharmacol., 16,1877. 
HERZOG, V., and FAHIMI, H. D., (1974), Science 185,271. 
HIRSCHBERG, E. j, WEINSTEIN, I. B. , GESTEN, N. j, HORNER, E., FINKELSTEIN, T., and CARCHMAN, R., (1968)l 
Cancer Res., 28,601. 
HIRSCHBERG, E., (1974), in Antibiotics III. Mechanism 
of action of antimicrobial and antitumour 
agents, p. 274. Ed. Corcoran, Y. W., and Hahn, 
F. E.. Published by Springer-Verlag, Berlin. 
- 253 - 
HORI, S., SHIRAI, M., HIRANO, S., OKI, T. , INUI, T. , TSUKAGOSHI, S., ISHIZUKA, M., TAKEUCHI, T., 
and UMEZAWA, H., (1977), Gann, 68,685 
HORTON, J., BEGG, C. B., ARSENAULT, J., BRUCKNER, H., 
CREECH, R., and HANN, R. G., (1978), Cancer 
Treat. Rep., 62,159. 
HORWITZ, B., MADRAS, B. K., MEISTER, A., OLD, L. J., 
BOYSE, E. A. and STOCKERT, E., (1968), Science, 
160,533. 
HUANG, M. T., MWIA, G. T., and LU, A. Y. H. (1979), 
J. Biol. Chem., 254,3930. 
ISLAM, S. A., NEIDLE, S., GANDECHA, B. M., and BROWN, 
J. R., (1983), Biochem. Pharmacol., 33,2801. 
JOHNSON, R. K., ZEE-CHENG, R. K-Y., LEE, W. W., ACTON, 
E. M., HENRY, D. W., and CHENG, C. C., (1979), 
Cancer Treat. Rep., 63,425. 
JONES, A., and NEIDLE, S., (1975), Acta Cryst., B31, 
1324. 
KAPUSCINSKI, J., DARZYNKIEWICZ, Z., TRAGANOS, F., and 
MELAMED, M. R., (1981), Biochem. Pharmacol., 
30,231. 
KARCZMAR, G. S., and TRITTOR, T. R., (1979), Biochim. 
Biophys. Acta. 557,306. 
KELLER, W., and WENDEL, I. (1974), Cold Spring Harbor 
Symposium on Quantitative Biology, 39,199. 
KENNEALEY, G. T. and MITCHELL, M. S. , (1977), in, Cancer, a 
comprehensive treatise, 5, P. 3. Ed. 
BECKER, F. F., published by Pelenum Press, New 
York. 
KENNEALY, G. T., BOSTON, B., MITCHELL, M. S., KNOBF, 
M. K., BOBROW, S. N., PEZZIMENTI, J. F., 
LAWRENCE, R., and BERTINO, J. R., (1978), 
Cancer, 42,27. 
KHARASCH, E. D., and NOVAK, R. F., (1981), Biochem 
Pharmacol., 30,2881. 
KHARASCH, E. D., and NOVAK, R. F., (1982a), Biochem. 
Biophys. Res. Commun., 108,1346. 
KHARASCH, E. D., and NOVAK, R. F., (1982b), Molecular 
Pharmacol., 22,471. 
KHARASCH, E. D., and NOVAK, R. F., (1983), Archives of 
Biochem. Biophys., 224,682. 
KIMLER, B. F., (1980), Cancer Res., 40,42. 
- 254 - 
KIMLER, B. F., and HACKER, M. P., (1981), Cancer Clin. 
Trials., 4,173. 
KOMIYAMA, T. -, OKI, T., and INUI, T., (1979), J. 
Antibiot., 32,1219. 
KRUGH, T. R., and YOUNG, M. A., (1977), Nature, 267,627. 
Le PECQ, J. B., and PAOLETTI, C., (1967), J. Mol. Biol., 
27,87. 
LERMAN, L. S., (1961), J. Mo1. Biol., 3,18. 
LERMAN, L. S., (1963), Proc. Natl. Acad. Sci. USA., 49,94. 
LERMAN, L. S., (1964a), J. Cell. Comp. Physiol., 64 
Suppl. 1,1. 
LERMAN, L. S., (1964b), J. Mol. Biol., 10,367. 
LIN, A. J., COSBY, L. A., and SARTORELLI, A. C., (1976), 
in Cancer Chemotherapy, P. 71-86, Ed. 
Sartorelli, A. C., (A. C. S., Washington). 
LOESCH, D. M., VON HOFF, D. D., KUHN, J., COLTMAN, C. A., 
TIO, F.,, CHAUDHURI, T. K., BENDER, J. F., and 
GRILLO-LOPEZ, A. J., (1983), Cancer Treat. 
Rep., 67,987. 
LOWN, 'J. W., CHEN, H-H., and PLAMBECK, J. A., (1979), 
Biochem. Pharmacol., 28,2563. 
LOWN, J. W., HANSTOCK, C. C., BRADLEY, R. D., and SCRABA, 
D. G., (1984), Mol. Pharmacol., 25,178. 
LOWRY, O. H., ROSEBOROUGH, N. J., FARR, A. L., and 
RANDALL, R. J., (1951) , J. Biol. Chem. , 193, 256. 
LUZATI, V., MASSON, F., and LERMAN, L. S., (1961), 
J. Mol. Biol., 3,634. 
MARMUR, J. and DOTY, P., (1962), J. Mol. Biol., 5,109. 
MILLER, J. A., and MILLER, E. C., (1948), J. Exp. Med., 87, 
139. 
MIMNAUGH, E. G., SIDDIK, A. H., DREW, R., SIKIC, B. I., and 
GRAM, T. E., (1979), Toxic. Appl. Pharmacol., 
49,119. 
MIMNAUGH, E. G., TRUSH, M. A., and GRAM, T. E., (1981), 
Biochem. Pharmacol., 30,2797. 
MIMNAUGH, E. G., TRUSH, M. A., GINSBURG, E., and GRAM, 
T. E., (1982), Cancer Res., 42,3574. 
MINOW, R. A., BENJAMIN, R. S., LEE, E. T., and GOTTLIEB, 
J. A., (1977), Cancer, 39,1397. 
- 255 - 
MOORE, H. W., (1977), Science, 197,527. 
MOREHOUSE, L. A., TIEN, M., BUCHER, J. R., and AUST, 
S. D., (1983) Biochem. Pharmacol., 32,123. 
MORTON, D. L. and GOODNIGHT, J. E., (1978), Cancer, 42, 
2224. 
MUELLER, G. G., and MILLER, J. A., (1950), J. Biol. Chem., 
185,145. 
MULLER, W., and CROTHERS, D. M., (1968), J. Mol. Biol., 
35,251. 
MÜLLER, W., FUGEL, R., and STEIN, C., (1971), Libeigs 
Ann. Chem., 754,15. 
MURDOCK, K. C., CHILD, R. G., FABIO, P. F., ANGIER, R. B., 
WALLACE, R. E., DURR, F. E., CITARELLA, R. V., 
(1979), J. Med. Chem., 22,1024. 
MURRAY, E. F., and WALLACE, R. E., (1980), In, 
Anthracyclines: Current status and new 
developments. Ed., Crooke, S. T., and Reich, 
S. D.. Publi shed by Academic Press, New York. 
149,228. 
NAKATA, Y., and HOPFINGER, A. J., (1980), Biochem. 
biophys. Res. Commun., 98,317. 
NEIDLE, S., (1976), Bioch im. Biophys. Acta. , 454,207. 
NEIDLE, S., (1978), in, Topics in Antibiotic Chemistry, 
2, P. 240. Ed. Sammes, P. G., Published by 
Ellis Horwood, 
. 
Chichester. 
NEIDLE, S., (1979), in, Progress in Medicinal Chemistry 
16,151. Ed. Ellis, G. P. , and West, G. B. 
NEIDLE, S., (Ed. ) (1980) Advances in Nucleic acid 
structure, Published by Macmillan Press, 
London. 
NEIDLE, S., and SANDERSON, M. R., (1983), in, Molecular 
Aspects of Anti-Cencer Drug Action. Topics in 
Molecular and Structural Biology, 3,35. Ed. 
Neidle, S. , and Waring, M. J.. Published by Macmillan Press, London. 
NEIDLE, S., and TAYLOR, G., (1979), FEBS Lett., 107, 
348. 
NERSTAD, N. P., (1978), Mutat. Res., 57,253. 
NEVILLE, D., and DAVIES, D., (1966), J. Mol. Biol. , 17, 57. 
NIPPON KAYAKU CO., Japan, (1982), JP. 57,193,430. 
(Chem. Abs. 98,197810). 
- 256 - 
HOHL, H., and JORDAN, W.., (1983), Biochem. Biophys. 
Res. Commun., 114,197. 
O'BRYAN, R.. M., LUCE, J. K., TALLEY, R. W., GOTTLIEB, 
J. A., BAKER, L. H. , and BONADONNA, G., (1973), 
Cancer, 32,1. 
OKI, T., (1977), J. Antibiot., 30 (Suppl. ), 70. 
OON, C-J, FRIEDMAN, M. A., (1982), Cancer Chemother. 
Pharmacol., 8,231. 
PAOLETTI, J., and Le PECQ, J. B., (1971), J. Mol. Biol. , 
59,43. 
PATEL, D. J., (1979), Accounts of Chem. Res., 12,118. 
PATEL, D. J., (1979), Biopolymers, 18,553. 
PATEL, D. J., (1980), in, Nucleic Acid Geometry and 
Dynamics, P. 185. Ed. Sarma, R. H.. Published 
by Pergamon, Oxford. 
PATEL, D. J., " KOZLOWSKI, S. A., and RICE, J. A., (1981), 
Proc. Natn. Acad. Sci. U. S. A., 78,3333. 
PATEL, D. J., and CANUEL, L. L., (1978), Eur. J. Biochem., 
90; 247. 
PEACOCKS, A. R., and SKERRET, J. H. N., (1956), 
Trans. Farady Soc. , 67,261. 
PECK, L. J., NORDHEIM, A., RICH, A., and WANG, J. C., 
(1982), Proc. Natl. Acad. Sci. USA., 79,4560. 
PHILLIPS, D. R., DiMARCO, A., and ZUNINO, F., (1978), 
Eur. J. Biochem. , 85,487. 
PIGRAM, W. J. , FULLER, W., and HAMILTON, L. D., 
(1972), 
Nature new Biol., 235,17. 
PLUMBRIDGE, T. W., and BROWN, J. R., (1977), 
Bioch im. Biophys. Acta, 479,441. 
PLUMBRIDGE, T. W., and BROWN, J. R., (1979)p 
Bioch im. Biophys. Acta. , 563,181. 
PLUMBRIDGE, T. W., AARONS, L. J., and BROWN, J. R., 
(1978), J. Pharm. Pharmacol. , 30,69. 
PLUMBRIDGE, T. W., KNIGHT, V., PATEL, K. L. and BROWN, 
J. R., (1980), J. Pharm. Pharmacol., 32,78. 
POHL, W. F., and ROBERTS, G. W., (1978), J. Math. Biol., 6, 
383. 
POVIRK, L. F., HOGAN, M., and DATTAGUPTA, N., (1979), 
Biochemistry, 18,96. 
- 257 - 
PRATT, W. B. and RUDDON, R. W., (1979), The anticancer 
drugs. Published by Oxford University Press. 
PRATT, C. B., CROM, D. B., WALLENBERG, J., SANYAL, S. K., 
MILIAUSKAS, J., and SOHLBERG, K., (1983), 
Cancer Treat. Rep., 67,85. 
PRICE. C. C., (1975), in, Antineoplastic and Immuno- 
-suppresive Agents (II), P. 1, Ed. 
SARTORELLI. A. C. and JONES. D. G. Published by 
Springer-Verlag New York. 
PRITCHARD, N. J., BLAKE, A., PEACOCKE, A. R., (1966), 
Nature, 212,1360. 
QUIGLEY, G. J., WANG, H-J., UGHETTO, B., Van der MAKEL, 
J. H., Van Boom and RICH, A., (1980), 
Proc. Natn. Acad. Sci. U. S. A., 77,7204. 
REDDY, E. P, REYNOLDS, R. K., SANTOS, E., and BARBACID, 
M., (1982), Nature, 300,149. 
REILLY, J. J., NEIFEILD, J. P. and ROSENBERG, S. A., 
(1977), Cancer, 40,2053. 
REMERS, W. A., (1979)., in, The Chemistry of Antitumour 
Antibiotics 1,63. Published by Wiley, New 
York. 
REINERT, K. E., (1983), Nucleic Acid Res., 11,3411. 
RICH, A., QUIGLEY, G. J., and WANG, A. H-J., (1981), in, 
Biomolecular stereodynamics, 1, P. 25. Ed. 
Sarma, R. H.. Published by Adenine Press, New 
York. 
RODLEY, G. A., SCOBIE, R. S., BATES, R. H. T., and LEWITT, 
R. M., (1976), Proc. Natl. Acad. Sci. U. S. A., 73, 
2959. 
ROGERS, K. E., and TOKES, Z. A., (1984) Biochem. 
Pharmacol. , 33,605. 
ROSS, W. E. , GLAUBIGER, D. L. , and KROHN, 
K. W., (1978), 
Biochim. Biophys. Acta. j, 519,23. 
ROSS, W. E., and SMITH, M. C., (1982), Biochem. 
Pharmacol. , 31 1931. 
SABEUR, G., GENERT, D., and AUBEL-SADRON, G., (1979), 
Biochem. Biophys. Res. Commun., 88,722. 
SARTIANO, G. P., LYNCH, W. E., and BULLINGTON, W. D., 
(1979), J. Antibiot. 32,1038. 
SASISEKHARAN, V., PATTABIRAMAN, N. p and GUPTA, G., 
(1977), Current Science, 46,763. 
- 258 - 
SAUNDERS, K. H., (1949), in, The aroma tic 
diazo-compounds and their technical 
applications. Published by Edward Arnold, 
London. 
SCATCHARD, G., (1949), Ann. N. Y. Acad. Sci., 51,660. 
SCHELL, F. C., YAP, H-Y, BLUMENSCHEIN, G., VALDIVIESCO, 
M., and BODEY, G., (1982), Cancer Treat. 
Rep., 66,1641. 
SCHNUR, L., BACHRACH, U., BAR-AD, G., HARAN, M., 
TASHMA, Z., TALMI, M. , , 
and KATZHENDLER, J., 
(1983), Biochem. Pharmacol., 32,1729. 
SHARGEL, L. , BANIJAMALI, A. R., and KUTTAB, S. H., (1984), J. Pharm. Sci., 73,161. 
SILL, A. D., ANDREWS, E. R., SWEET, F. W., HOFFMAN, J. W., 
TIERMAN, P. L., GRISAR, J. M., FLEMING, R. W., 
and MAYER, G. D., (1974) J. Med. Chem. , 17,965. 
SINHA, B. K., and CHIGNELL, C. F., (1979), Chem-Biol. 
Interact., 28,301. 
SINHA, B. K., and GERGORY, J. L., (1981), Biochem. 
Pharmacol. , 30,2626. 
SMITH, I. E., (1983), Cancer Treat. Reviews, 10,103. 
SOBELL, H. M., TSAI, C-C., JAIN, S. C. and GILBERT, S. G., 
(1977), J. Mol. Biol., 114,333. 
SOBELL, H. M., TSAI, C-C., JAIN, S. C. and SAKORE, T. D., 
(1978), Phil. Trans. R. Soc. London, 283,295. 
SOMEYA, A., and TANAKA, N., (1979) J. Antibiotics, 32, 
839. 
SPARANO, B. M., GORDON, G., HALL, C., IATROPOULOUS, 
M. J., and NOBLE, J. F., (1982), Cancer Treat. 
Rep., 66,1145. 
STEEL, G. G., (1973), in, Cancer Medicine P. 125. Ed. 
HOLLAND, J. F. and FREI, E. , III, published by 
Philadelphia Lea and Febiger. 
STRINGFELLOW, D. A., WEED, S. D., and UNDERWOOD, G. E., 
(1979), Antimicrob. Agents. Chemother. , 15, 
111. 
STONE, A. L., and BRADLEY, D. F., (1961), 
J. Amer. Chem. Soc., 83,3627. 
STUART-HARRIS, R. C., and SMITH, I. E., (1982), Cancer 
Chemother. Pharmacol., 8,179. 
STUART-HARRIS, R. C., BOZEK, T., PAVLIDIS, N. A., and 
SMITH, I. E., (1984), Cancer Chemother. 
Pharmacol., 12,1. 
- 259 - 
SWANBECK, G., (1966), Biochim. biophys. Acta., 123, 
630. 
SYKES, P., (1975),, in A guidebook to mechanism in 
organic chemistry (Fourth edition). Published 
by Longman, London. 
TABIN, C. J., BRADLEY, S. M., BARGMANN, C. I., WEINBERG, 
R. A., PAPAGEORGE, A. G., SCOLNICK, E. M., DHAR, 
R., LOWY, D. R, and CHANG, E. H., (1982), 
Nature, 300,143. 
THAYER, W. S., (1977), Chem. Biol. Interact. , 19,265. 
TOKES, Z. A., ROGERS, K. E., and REMBAUM, A., (1982), 
Proc. natn. Acad. Sci., 79,2026. 
TONG, G. L., HENRY, D. W., and ACTON, E. M., (1979)l 
J. Med. Chem., 22,36. 
TRITTON, T. R., and YEE, G., (1982), Science, 217,248. 
TRITTON, T. R., YEE, G., and WINGARD, (1983), Fed. Proc. , 
42,284. 
UNVERFERTH, D. V., UNVERFERTH, B. J., BALCERZAK, S. P., 
BASHORE, T. A., and NEIDHART, J. A., (1983), 
Cancer Treat. Rep. , 67,343. 
UYEKI, E. M., NISHI, A., WITTICK, P. J., CHENG, C. C., 
(1981), J. Pharm. Sci., 70,1011. 
VAN ECHO, D. A., WHITACRE, M. Y., AISNER, J., and 
WIERNIK, P. H., (1981), Cancer Treat. Rep., 
65,831. 
VALDIVIESCO, M., BEDIKIAN, A. Y., BURGESS, M. A., SAVRAJ, 
N., JEFFERS, W. B., and BODEY, G. P., (1981)f 
Cancer Treat. Rep., 65,841. 
VON HOFF, D. D. , POLLARD, E. , KUHN, J. , MURRAY, E. , and 
COLTMAN, C. A., (1980) Cancer Res., 40,1516. 
VON HOFF, D. D., COLTMAN, C. A., and FORSETH, B., (1981), 
Cancer Res. , 41,1853. 
WAKELIN, L. P. G., ROMONOS, M., CHEN, T. K., GLAUBIGER, 
D., CANELLAKIS, E. S. , and WARING, M. J. , (1978), Biochemistry, 17,5057. 
WAKELIN, L. P. G., ROMONOS, M., CANELLAKIS, E. S., and 
WARING, M. J., (1976), Studia Biophys., 60, 
111. " 
WALLACE, R. E. , MURDOCK, K. C., ANGIER, R. B., and DURR, 
F. E., (1979), Cancer Res., 39,1570. 
WALKER, R., (1976), Food Cosmet. Toxicol., 8,659. 
- 260 - 
WANG, A. H-J., QUIGLEY, G. J., KULPAK, F. J., CRAWFORD, 
J.. L. , VON BOOM, J. H., VAN DER MAREL, G., and 
RICH, A., (1979), Nature, 282,680. 
WANG, J. C. (1974), J. Mol. Biol., 89,783. 
WANG, J. C., and BAUER, W. R., (1979), J. Mol. Biol. , 129, 458. 
WANG, J. J., CHERVINSKY, D. S., and ROSEN, J. M., (1972), 
Cancer Res., 32,511. 
WARD, J. J., REICH, E., and GOLDBERG, I. H., (1965), 
Science, 149,1259. 
WARING, M. J., (1968) , Nature, 219,1320. 
WARING, M. J., (198AA, in, Molecular Basis of Drug 
Action. 2 edition, P. 258. Ed., Gale, E. F., 
Cundliffe, E., Reynolds, P. E., Richmond, 
M. H. R. , and Waring, M. J.. Published by John Wiley and Sons (London). 
WARING, M. J., and FOX, K. R., (1983), in Molecular 
Aspects of Anticancer Drug Action. Topic in 
Molecular and Structural Biology 3,127. Ed. 
Neidle, S., and Waring, M. J.. Published by 
Macmillan Press, London. 
WATERFIELD, M. D., SCRACE, G. T., WHITTLE, N., STROOBANT, 
P., JOHNSON, A., WASTESON, A, WESTMARK, B., 
HELDIN, C-H, HUANG, J. S., and DEVEL, T. F., 
(1983), Nature, 304,35. 
WATSON, J. D., and CRICK, F. H. C., (1953) Nature, 171, 
737. 
WILSON, D. W. and JONES, R. L., (1981), 
Adv. Pharmacol. Chemother., 18,177-222. 
WEIRNIK, P. H. and SERPIK, A. A., (1972), Cancer Res., 
32,2023. 
WEIRNIK, P. H., (1980), in, Anthracyclines Current 
Status and New Developments P. 273. Ed. 
CROOKE, S. T. and REICHpS. D. published by 
Academic Press, New York. 
WEISBERGER, J. H., (1973), in, Cancer Medicine P. 45. Ed. 
HOLLAND, J. F. and FRIE, E. I II. , published by 
Philadelphia Lea and Febiger. 
WEISS, H. D. , WALKER, M. D. , AND WEIRNIK, P., (1974)p New. 
Eng. J. Med., 291,127. 
WILKINS, M. H. F., STOKES, A. R., and WILSON, H. R., 
(1953), Nature, 171,738. 
- 261 - 
WILMAN, D. E. V., and CONNORS, T. A., (1983), in Molecular 
Aspects of Anticancer Drug Action. Topic in 
Molecular and Structural Biology 3,233. Ed. 
Ne idle, S., and Waring, M. J.. Published by 
Macmillan Press, London. 
WILLIAMSON, J., SCOTT-FINNIGAN, T. J., HARDMAN, M. A., 
BROWN, J. R., (1981), Nature, 292,466. 
WILSON, D. W., GRIEE, D., REIMER, R., BAUMAN, J. D., 
PRESTON, J. F., and GABBAY, E. J., (1976), 
J. Med. Chem., 19,381. 
WILSON, W. R., WHITMORE, G. F., and HILL, R. P., (1981), 
Cancer. Res. , 41,2817. 
WINKELMAN, E., and RAETER, W., (1979), 
Arzeneimitellforschung, 29,1504. 
WINTERBOURNE, C. C.,, (1981), FEBS le tt. , 136,89. 
WRIGHT, R. G. McR., WAKELIN, L. P. G., FIELDES, A., 
ACHESON, R. M., and WARING, M. J., (1980), 
Biochemistry, 19,5285. 
YAMAKI, H., SUZUKI, H., NISHIMURA, T., and TANAKA, N., 
(1978), J. Antibiot., 31,1149. 
YAP, H-Y., BLUMENSCHEIN, G. R., SCHELL, F. C., BUZDAR, 
A. U., VALDIVIESCO, M. j, and BODEY, G. P., 
(1981) Annals of Intern. Med., 95,694. 
YIELDING, L. W., YIELDING, K. L., and DONOGHUE, J. E., 
(1983), Bioploymers, 23,83. 
YOUNG, R. C., OZOLS, R. F., and MYERS, C. E., (1981), New 
Engl. J. Med., 305,139. 
ZEE-CHENG, R-K., Y. , and CHENG, C. C. , (1978), J. Med. Chem. , 
21,291. 
ZEE-CHENG, R. K-Y., PODREBARAC, E. G., MENON, C. S., and 
CHENG, C. C., (1979), J. Med. Chem., 22,501. 
ZUBROD. C. G., (1972), Proc. Natl. Acad. Sci., U. S. A., 
69,1042. 
ZUNINO, F., GAMBETTA, R., DiMARCO, A., and ZACCARA, A., 
(1972), Biochim. Biophys. Acta., 277,489. 
ZUNINO, F., DiMARCO, A., ZACCARA, A. p and LUONI, G., 
(1974),. Chem-biol Intercations, 9,25. 
ZUNINO, F., GAMBETTA, R., DiMARCO, A., VELCHICH, A., 
ZACCARA, A., QUADRIFOGLIO, F., and CRESENZI, 
V., (1977) Biochim. biophys. Acta, 476,38. 
ZUNINO, F., Di MARCO, A., ZACCARA, At and GAMBETTA, 
R. A., (1980), Biochim. biophys. Acta., 607, 
206. 
- 262 - 
ADVANCED STUDIES UNDERTAKEN IN CONNECTION WITH THE 
PROGRAMME OF RESEARCH IN PARTIAL FULFILMENT OF THE 
REQUIREMENT OF THE THE DEGREE OF DOCTOR OF PHILOSOPHY. 
The candidate has attended courses on design of 
experiments, and information retrieval during the first 
year, and ancillary lectures in computer programming, 
statistics and electronics during the second and third 
years of the research programme. The candidate has 
attended lectures and seminars on drug metabolism, 
spectroscopy, and the use of modern chromatographic 
techniques. 
The candidate has also attended and contributed 
to postgraduate seminars and colloquia held within the 
department, covering most aspects of the pharmaceutical 
sciences. The candidate has also delivered a lecture at 
the graduate symposium, Durham University (July, 1984) 
and has presented a poster at the Biochemical Society 
Meeting, (July, 1982). 
The candidate's directed reading has included 
advanced aspects of organic chemistry, biochemistry, 
and spe ctrop ho tome try. 
- 263 - 
APPENDIX 1 
Preparation of NADPH regenerating system 
NADP 16.2mg 
Glucose-6-Phosphate 26mg 
Glucose-6-Phosphate 
de hydroge nase 60units 
Magnesium Chloride Soln. 
(MgC12 . 6H20 1G/ml) 0.100ml 
Phosphate buffer to lUml 
The solution was prepared immediately prior to use and 
stored in an ice bath. 
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